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Prediction is difficult — especially o f the future
Neils Bohr
Hofstadter’s Law: It always takes longer than you expect, even when 
you take into account Hofstadter's Law
Douglas Hofstadter
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Summary
Chronic heart failure is a common condition with an adverse prognosis. Despite optimal 
treatment, ambulant patients with mild symptoms have an annual mortality of more than 
15%. Clinical, exercise, echocardiographic and haemodynamic variables are known to 
carry prognostic information, but accurate identification of those most likely to die 
remains difficult. This work assessed abnormalities of ventricular activation and 
repolarisation respectively using the signal-averaged electrocardiogram and interlead QT 
interval variability of the standard 12-lead electrocardiogram. Disordered autonomic 
function is common in cardiac failure. This was assessed by 24 hour heart rate variability 
and baroreflex sensitivity. Plasma noradrenaline and plasma atrial and brain natriuretic 
peptide levels were used to assess neuroendocrine activation, a hallmark of chronic heart 
failure. These measures were determined prospectively and compared with known 
prognostic variables in a chronic heart failure population.
Original Hypotheses
1. Sudden cardiac death in patients with heart failure is caused predominantly by 
malignant ventricular arrhythmias. These may be predicted by non-invasive 
markers of the arrhythmogenic substrate i.e. signal-averaged ECG, QT dispersion; 
triggers i.e. non-sustained ventricular tacycardia, and autonomic modulators i.e. 
heart rate variability and baroreflex sensitivity. This assessment will provide 
additional independent prognostic information on mortality risk in patients with 
chronic heart failure.
2. Markers of neuroendocrine activation and autonomic dysfunction would predict 
progression of chronic heart failure, and all-cause and progressive heart failure 
death.
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Patients
One hundred and ninety-five patients with stable chronic heart failure were recruited. 
Exclusion criteria included age >75 years; uncontrolled hypertension (BP >170/90 mmHg); 
recent (6 months) unstable angina or myocardial infarction; significant valvular heart 
disease; atrial fibrillation; insulin dependent diabetes mellitus; chronic renal failure 
(creatinine>200|Limol/l); autonomic neuropathy or any non-cardiac condition likely to 
prove fatal over the study period.
Methods
ECG tracings were manually digitised at standard paper speeds of 25mm/sec and gain 
of lOmm/mV. A signal averaged ECG was acquired in accordance with published 
guidelines. Patients with bundle branch block were prospectively analysed using 
published criteria. Subjects able to exercise underwent symptom limited 
cardiopulmonary treadmill exercise testing using a standardised exponential workload 
protocol. Twenty-four hour ambulatory ECG's were obtained on all subjects during 
unrestricted out of hospital activity. Time domain measures of heart rate variability 
were calculated using accepted standards. Ejection fraction was determined 
echocardiographically by Simpson’s biplane technique, or, in subjects with poor 
endocardial definition left ventricular ejection fraction was assessed semi- 
quantitatively, and by radionuclide ventriculography. Baroreflex sensitivity was 
measured using the bolus phenylephrine injection technique and non-invasive arterial 
pressure monitoring. Plasma BNP was measured by radioimmunoassay. 
Noradrenaline was measured by HPLC and electrochemical detection after prior 
extraction from plasma.
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Follow-up and Classification of Endpoints
Follow-up information was extracted annually from review of their hospital and/or GP 
case records. Follow-up was closed on 1st Sept 1998. Vital status was determined in 
all cases from information from the Death section of the General Register Office of 
Scotland. Prospectively defined endpoints were cardiovascular death, progressive 
heart failure death and sudden death.
Statistical Analysis
Kaplan-Meier curves and the log-rank test were used to determine the statistical 
association of co-variates with mortality. A multivariate Cox proportional hazards 
analysis was performed to determine the incremental prognostic power of 
investigational variables. To simplify this model, NYHA status was grouped as class 
II or below, or III and above. Maximal oxygen consumption was dichotomised at 
14ml/kg/min (as in previous studies), with patients unable to exercise (due to cardiac 
limitation) being assigned a value of <14ml/kg/min. Autonomic variables were 
dichotomised above and below the median values. Two types of Cox regression 
analyses were performed:
The incremental prognostic utility of each investigational variable was determined 
singly after adjustment by multivariate analysis of readily available parameters: age, 
aetiology of heart failure, NYHA class, left ventricular ejection fraction and presence 
of intra-ventricular conduction defect/bundle branch block on the 12 lead ECG.
In the second model, all investigational co-variates were analysed together using a 
forward conditional stepwise model after adjustment for baseline co-variates.
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Results
Clinical characteristics of the study population are shown in Table 1. One hundred 
and ninety nine patients were recruited. Clinical details and follow-up were available 
in the complete cohort.
Table 1: Patient demographics and baseline variables
Patient Demographics
Age, years* 6 1 .6 5 4 .2 -6 7 .5
NYHA class 2 .7 0 .8
Cause of CHF (n) Ischaemic 163
Non-ischaemic 36
Therapy (%) ACE Inhibitor 89
Diuretics 6 6
Digoxin 2 7
Other vasodilators 41
p blockers 2 0
LVEF (%) 2 3 9
Peak V02 (ml/kg/min) 16.9 4 .9
IVCD/BBB (n) Present 6 4
Absent 135
NYHA -  New York Heart association functional class; I VCD -  intraventricular 
conduction defect; BBB -  bundle branch block. Values given as mean ± SD, except 
where indicated *, median ± IQR
Mortality
Follow up was complete on all patients. Median duration of follow-up was 1086 days 
IQR 734-1259 days. In those surviving, median follow-up was 1173 days, IQR 1031- 
1289 days. There were 54 (27%) deaths in total, and 47 (24%) cardiovascular deaths. 
There were 23 (12%) progressive heart failure deaths and 24 (12%) sudden deaths.
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Univariate Analysis
Established clinical parameters (aetiology of heart failure, NYHA class, left 
ventricular ejection fraction and peak oxygen consumption) significantly predicted 
cardiovascular death (log rank test p<0.01). Age did not predict death, possibly 
because of the truncated upper limit. Intraventricular conduction defects/bundle 
branch block and a positive signal averaged ECG also predicted cardiovascular death 
(log rank test p<0.01). No electrocardiographic measure of QT dispersion (T wave 
end dispersion, T wave apex dispersion or the respective coefficients of variation) was 
prognostic. Plasma neurohormones, baroreflex sensitivity, and time domain measures 
of heart rate variability (Triangular Index, SDNN and SDNN-I) also predicted 
cardiovascular death (log rank test p<0.01).
Multivariate Analysis
After adjustment for baseline variables (age, NYHA status, presence/absence of 
I VCD, left ventricular ejection fraction and peak oxygen consumption), only a 
positive SAECG, the presence of non-sustained ventricular tachycardia, markers of 
autonomic dysfunction and plasma neurohormones retained prognostic power. When 
investigational variables were analysed concurrently, depressed heart rate variability 
and baroreflex sensitivity failed to predict cardiovascular mortality. However, plasma 
markers of neuroendocrine activation significantly predicted cardiovascular death: 
supramedian levels of plasma BNP or plasma Noradrenaline respectively conferred a 
5 fold and 3 fold increase in risk. Perhaps surprisingly, a positive SAECG provided 
similar prognostic power, but the utility of this measure would be more limited, as 
only a minority of patients had a positive SAECG (31 of 124, 25%).
When subject to the scrutiny of multivariate analysis, a positive SAECG, the presence of non­
sustained ventricular tachycardia on Ho Iter monitoring and depressed baroreflex sensitivity
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predicted sudden death significantly. Prognostic significance was retained even when the 
variables were analysed concurrently, rather than singly. All 3 variables were potent 
predictors of mortality, each conferring a 3 fold increased risk of sudden death.
Discussion
Chronic heart failure is a common, growing and major public health care burden. 
Identifying high-risk patients suitable for aggressive intervention, optimisation of 
treatment and prevention of death is of great importance. Despite extensive study by 
many investigators, identification of those patients who are most likely to deteriorate 
and die remains difficult.
In this well-characterised cohort of patients with chronic heart failure, neuroendocrine 
activation assessed by plasma BNP or plasma Noradrenaline predicted cardiovascular 
death. This information was additive to and independent of other powerful prognostic 
variables including NYHA class, age, left ventricular ejection fraction, peak VO2 and 
presence/absence of bundle branch block. Howevr, plasma BNP may be measured 
from a simple venous blood sample, and has been proven to be stable at room 
temperature over 72 hours. It is inexpensive, and requires no specialised equipment at 
the bedside. Direct assay kits are now available which both simplify and lessen the 
cost of its measurement. This has implication for its more widespread use. 
Interestingly, a positive SAECG, the presence of non-sustained ventricular 
tachycardia and depressed baroreflex sensitivity all identified a patient cohort at high 
risk of sudden death. Linking this data with the prognostic importance of depressed 
baroreflex sensitivity in the study cohort with recent data on “electrical storms” in 
patients with implantable cardioverter-defibrillators, it suggests that these markers 
might be used to identify patients who would benefit from these devices.
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1 INTRODUCTION
1.1 A Histo ry  o f  He a r t  Failure
1.1.1 Ancient Civilisations, Greeks and Romans
The earliest civilisations first appeared more than 4000 years ago in the Middle East, 
China, South America and India. The first recorded medical text is a Sumerian tablet 
from around 4000 BC, commenting on various medicinal cures, and suggesting the 
addition of potassium nitrate to a number of them. The Ancient Greeks are often 
credited with first describing and counting the pulse. The following quotation from 
the Edwin Smith Surgical Papyrus (circa 3000 BC) suggests that the Egyptians 
antedated them by twelve centuries:
“Now i f  the priests o f  Sekhmet or any physician pu t his hands...upon the two hands, upon the 
pulse, upon the two fee t he measures the heart, because its vessels are in the back o f  the head 
and in the pulse; and because its pulsation is in every vessel o f  every member”  ^
The most important ancient text is the Ebers Papyrus, dating from around 1600 BC, 
over three hundred years before Moses was found in the bullrushes [2\ It may contain 
the first recorded description of angina, along with a recognition of its ominous 
prognosis:
“when you examine a man fo r  illness in his cardia, he has pains in his arm, in his breast, on 
the side o f  the cardia...it is death which approaches him ”
Other passages state,
“The heart is tired; this means that the heart does not speak or the vessels o f  the heart are 
mute... When there is inundation o f  the heart, the saliva (sputum?) is in excess; therefore the 
body is weak. ”
It is tempting to speculate that this may be the first recorded description of the clinical 
syndrome of heart failure 131. These clinical descriptions of cardiac symptoms have
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been confirmed by the pathological examination of Egyptian mummies revealing 
coronary disease with evidence of myocardial infarction. The Egyptians did believe 
that dyspnoea was due to a blockage in the flow of blood, and employed bleeding as a 
treatment. It has been suggested that this was the first use of preload reduction by 
venesection in the treatment of heart failure.
More recently, it has become apparent that other civilisations also had first hand 
knowledge of the anatomy of the heart, possibly because of human sacrifice. A statue 
dating from 1000 B.C. pictures the heart with both ventricles and pulmonary artery 
and aorta l4’. However, there are no medical texts surviving from the Olmec 
civilisation.
Greek civilisation flourished from 2000 BC to 100 BC, making lasting contributions 
to medical knowledge. Hippocrates (460-377 BC) believed that human temperaments 
and physiques depended on the humours, being phlegmatic, sanguine, melancholic or 
choleric. Even today, some 23 centuries later, we still use these descriptions. 
Hippocrates’ commentaries are said to describe cardiac pain, along with recognition of 
its poor prognosis:
“frequent recurrence o f  cardialgia, in an elderly person, announces sudden death ”
Erasistratus (330-250 BC) carried out many systematic human dissections, and indeed 
was said to have dissected criminals alive. He recognised that the heart provided the 
motive power for the circulation. Praxagoras of Cos (circa 340 BC) is first credited 
with using the pulse in diagnosis, and his pupil Herophilus (circa 300 BC) with 
recognising that it was synchronous with the heartbeat and was the first to count the 
rate using a water-clock 151. Thus, although the ancient Greeks made great advances in
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organising medicine and in the method of clinical observation, they did not advance 
knowledge of heart failure beyond that of the Egyptians.
From 100 BC to 476 AD Roman civilisation dominated the Western World. Celsus 
(53 BC -7 AD), a Roman author but not physician, wrote the first published textbook 
of general medicine. In it he describes a condition he terms “Kardiakon”:
“...excessive weakness o f  the body... (which) wastes away through immoderate sweating...it 
may be recognised by the weak pulsation o f  the blood vessels, while sweat... breaks out... the 
fee t and legs remaining more dry and co ld ...” ^
Some authorities have taken this to represent myocardial infarction, but it may 
describe the cardiac cachexia, sympathetic over-activity and peripheral 
vasoconstriction characteristic of heart failure. A large pharmacopeia from this time 
suggested scylla (which contains cardioactive glycosides) and opium for the treatment 
of breathlessness, being particularly useful “...when the patient has a bloody 
sputum.” 131. Galen, a Roman physician to the gladiators lived from 138-201 AD. He 
stated that blood ebbed and flowed throughout the body, and that it passed from the 
right to left ventricle through interventricular septal pores. This erroneous belief 
exerted a profoundly negative influence on medical thinking for the next 1500 years, 
during which time to even doubt Galen’s beliefs was considered heretical.
1.1.2 The Middle Ages and Renaissance
During the Middle Ages the Arabic-speaking peoples of North Africa maintained and 
added to Greco-Roman medical knowledge. Avicenna (Ibn Sina, 980-1037 AD), a 
Persian called “the Prince of Physicians”, wrote a five-volume influential “Canon of 
Medicine”, which was reprinted over fifteen times and remained a standard medical 
text until the 17th century [6\ In the Third volume he describes dyspnoea and 
orthopnoea, although he ascribed this to imbalance of the humours. Another possible
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description of heart failure dates from this time, along with realisation of its grim 
prognosis:
"dyscrasia (i.e. heart disease) stops the circulation inside the arteries, helping retention o f  
fluids and leading to death ”
The first clear description of heart failure occurs in an account of the illness of
Alexius I, ruler of the Byzantine Empire from 1081-1118 AD I?l. His daughter
described his illness, along with the remedies proposed:
“the physicians...felt his pulse and found all sorts o f  irregularities...his heart, they said, was 
inflamed..every day it grew worse, attacking him no longer at intervals, but relentlessly, with 
no interruption. He was unable to lie on either side so weak that every breath involved great 
effort...his condition was serious, fo r  never fo r  one moment could he breath freely. He was 
forced  to sit upright to breathe at all...but when his stomach was visibly enlarged to a great 
size and his fee t also swelled up and fever laid him low, some o f  the doctors with scant regard 
fo r  the fever, had recourse to cauterisation. "
Human dissection was finally authorised by Pope Sixtus IV in the late 15th century
and gradually medical education passed from the Church to universities. This lead
directly to the rise of the great anatomists, so ultimately refuting Galenic teachings.
Andreus Vesalius (1514-1564), Professor of Anatomy at Padua, published the first
great anatomical work, De Humani Corporis Fabrica in 1543. Leonardo da Vinci had
produced similar illustrations decades earlier but these were in private collections
(now in Windsor Castle) and would not have been known to him. Vesalius could not
demonstrate Galen’s interventricular pores, although he was careful not to deny their
existence. The first discovery of the pulmonary circulation is attributed to the Arabic
physician Ibn an-Nafis (1210-1288) although his work remained undiscovered for
many centuries. The first European suggesting that blood flowed from the right to left
ventricles through the lungs was Michael Servetus, who published “Christianismi
restitutio” in 1553. Only three of the original five hundred copies survive. Following
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the publication of this text Servetus was burnt at the stake for hereticism, although it 
seems more likely that this was due to his listing of sixty reasons why the pope was 
the Antichrist, rather than his anatomical discoveries [8J. Vesalius’ successor at 
Padua, Realdus Columbus wisely published his anatomical work “De Re Anatomica” 
posthumously in 1559. In it he argued for the existence of the pulmonary circulation, 
the function of the heart valves and described the timing of the pulse in relation to 
systole and diastole, refuting accepted Galenic wisdom.
Despite these significant advances in cardiovascular anatomy, the concept of heart 
failure remained poorly understood, as knowledge of the circulation of the blood 
awaited Harvey’s great work.
1.1.3 The 17th, 18th and 19th Centuries
The death knell of traditionalism was supplied by William Harvey (1578-1657). His 
duties involved teaching anatomy by dissecting the bodies of felons. His lectures 
began the year that Shakespeare died. In 1628, aged fifty, Harvey published 
“Exercitatio anatomica de motu cordis et sanguinus in animalibus” or “The movement 
of the heart and blood in animals” 191. This was based on extensive experimentation 
and dissection: indeed he dissected over one hundred species of animals, including his 
own pet parrot and monkey and even assisted at the dissections of his father, brother 
and sister. Harvey concluded that the heart, rather than the arteries, propelled the 
blood and, in agreement with Colombus, that the apex beat and pulse coincided with
ventricular systole. In this he was aided by the remarkable case of the eldest son of
the Viscount Montgomery who had suffered a fall as a child, and as the wound had 
failed to heal, the heart could be seen t101. Harvey directly denied the existence of 
interventricular pores, and he reasoned that the blood passed through
“the invisible porosities o f  the lungs and the minute cavities o f  their vessels ”
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Capillaries were subsequently visualised and described by Malpighi (1628-1694) 
using the microscope in 1661. Later, Harvey clearly describes angina as a cause of 
“dropsy” or heart failure in a letter to colleague:
“Sir Robert Darcy...about the middle period o f  his life, made frequent complaint o f  a certain 
distressing pain in the chest. The disease going from bad to worse, he by-ctnd-by became 
cachectic and dropsical. . . ”  ^
Boerhave (1668-1738), Professor at Leyden, is credited with first attributing 
“anasarca” to cardiac causes [31, but perhaps the first definition of heart failure was 
produced by Lower in his textbook of 1669 “Tractatus de Cordis” [12)
“...but when the parenchyma o f  the heart has been harmed by various diseases its motion is 
necessarily much altered; fo r  i f  the parenchyma o f  the heart is burdened with too much fat, 
labours under inflammation, abcess or wound, so that it cannot vibrate or contract without 
great trouble or difficulty, it soon gives up its motion, whence the movement o f  the blood also 
to the same degree becomes weak and languid ”
Consequently, by the end of the 17th century, the concept of the hydropic state was 
related to heart disease, and the initial steps towards defining and understanding the 
syndrome of heart failure were made.
The pace of discovery increased: Albertini (1662-1738) described dyspnoea due to 
pulmonary oedema, stressing the importance of cardiac enlargement; Lancisi (1655- 
1720), a Papal physician who studied sudden death described its association with 
cardiac dilatation; whilst Senac (1693-1770) published the most comprehensive 
manual of heart disease in 1749, “Traite sur la structure du coeur, de son action et de 
ses maladies”. In it he wrote that dilation of the cardiac chambers could lead to 
orthopnoea, oedema and cardiac asthma, and that medicine had few remedies for heart 
disease. Perhaps the most outstanding work of this century was Morgagni’s (1682- 
1771) “The Seats and Causes of Diseases Investigated By Anatomy” l131, published in
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1761 and translated into English in 1769. Amongst many other diseases he lucidly 
described anginal syndromes, cardiac rupture, pericardial tamponade and constriction 
and cardiac dilatation associated with “dropsy”:
“serous flu id  in the thorax..then hydrops; afterwards jaundice, dyspnoea, throbbing o f  the
jugular vessels... ”
being credited with coining the term “cor bovinum”.
The first breakthrough in the drug treatment of heart failure occurred in 1785, when 
Withering published the first work of clinical pharmacology I141. Although glycosides 
had been used for many centuries I151, Withering discovered that the active ingredient 
of a herbal remedy for dropsy was the foxglove Digitalis purpurea. Unfortunately, 
much of Withering’s advice was ignored, and digitalis was used rather 
indiscriminately- for example for tuberculosis and “nervous afflictions”. It is thought 
that the latter may have played a role in Van Goch’s vivid colourings, as a portrait of 
his physician Dr. Gachet reveals him holding a foxglove!
Bedside diagnosis was advanced by the popularisation of percussion by Corvisart 
(1755-1821), and the development of the stethoscope by Laennec (1781-1826). 
Further advances in the physiology of heart failure were provided by Potain (1825- 
1901), who correctly elucidated that gallop rhythms were due to reduced ventricular 
compliance or contractility. Cheyne (1777-1836) and Stokes (1804-1878) described 
periodic breathing and Traube (1818-1876) described pulsus paradoxus in patients 
with heart failure. Bright (1789-1858) was the first to differentiate congestion due to 
renal causes from those of cardiac cause. A unifying hypothesis for the patho­
physiology of heart failure was propounded by Hope in 1832 [161. This “back­
pressure” theory considered the symptoms to be caused by increasing pressure behind 
the failing valve or ventricle. Later in the century, the concept of coronary disease as
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a cause of heart failure was gradually accepted. As far back as 1776 Fothergill (1712- 
1780) had described the association of acute cardiac failure with death due to angina, 
but did not comprehend the link. In 1850 Quain (based at the Brompton Hospital) 
described eighty-three cases of “fatty degeneration”, noting the close link with 
coronary “ossification”. In 1874 Fagge (1838-1883) described heart failure associated 
with localised thinned, fibrotic areas of myocardium, and in 1884 von Leyden (1832- 
1910) described chronic diffuse coronary disease leading to “cardiac asthma and 
dropsy”. Thus, by the end of this period, ischaemic heart disease was recognised as a 
cause of heart failure, even though angina and myocardial infarction had not, as yet, 
been differentiated.
Despite these advances, treatment options remained limited. Venesection, purgation 
and the misuse of digitalis were widespread. Pre-load reduction using tourniquets had 
been described by Parry in 1795, and fluid restriction by Hope in 1831. Direct 
drainage of the oedema by incision of the skin, or insertion of Southey’s tubes, 
developed in 1877 by Southey (1835-1899), were popular measures. Brunton (1844- 
1916), who first described the therapeutic use of amyl nitrate for angina in 1867 ll7], 
stated in 1888
“there are several diseases in which it is desirable to relax the blood vessels... in cases o f  the 
failing heart where the enfeebled ventricle is barely able to overcome the resistance o f  the 
arterial walls and force the blood onwards, we require a drug which will produce a prolonged 
fl8Idilatation o f  the vessels ”
Unfortunately, this suggestion for after-load reduction was ignored for the next 
seventy years. Despite such advances, therapeutic nihilism remained common, as 
expressed by Oliver Wendell Holmes in 1860:
“with the exception o f  opium, anaesthetics and wine... i f  the whole materia medica, as now 
used, could be sunk to the bottom o f  the sea, it would be all the better fo r  mankind, - and all 
the worse fo r  the fishes. ”
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1.1.4 The 20th Century: Technology and Therapeutics
Roentgen discovered X-Rays in 1895, the X-Ray of his wife’s hand being reproduced 
in publications across the world. Einthoven’s string galvanometer revolutionised the 
development of electrocardiography, initially being used to facilitate the study of 
arrhythmias [19). In 1912 Herrick proposed his theory of non-fatal coronary 
obstruction [201, and his student published the first ECG of myocardial infarction in the 
dog in 1918. Starling (1866-1927), determined the effects of different loading 
conditions on cardiac function in 1914, enabling the modem concepts of pre and after­
load manipulation to emerge. With the advent of cardiac catheterisation 
haemodynamic measurements could be performed, leading to a greater understanding 
of cardiac function in health and disease I211. Selective coronary angiography was 
introduced by Sones in 1962, finally allowing the definite ante-mortem diagnosis of 
heart failure secondary to coronary disease to be made.
The 20th century also saw great advances in therapeutics. Mercurial diuretics were 
discovered serendipitously in 1919 in Wenckebach’s clinic, when mercury treatments 
for syphilis were noted to cause diuresis in a young girl 1221. Interestingly, over a 
century before, mercury had been used as a diuretic by Stokes (1804-1878). 
Subsequently, thiazides and loop diuretics (introduced in the 1950’s and 1960’s) 
dramatically changed the treatment of acute and chronic heart failure 1231. Despite this, 
the prognosis of patients with heart failure remained poor, with treatments suggested 
including thyroid ablation, inferior vena caval ligation 1245 and even rib resection to 
allow the heart more space 1251. Direct acting vasodilators were introduced in the 
1970’s, large trials demonstrating their ability to produce prolonged symptomatic and 
haemodynamic benefit1261 by changing loading conditions. However, this concept of 
manipulating vascular tone was predated by the use of ganglion-blocking drugs,
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nitrates and phentolamine [27J. Indeed, both Brunton and Osier had suggested the use 
of nitroglycerine for heart failure over a century before. During the 1980’s, the 
angiotensin converting enzyme inhibitors were introduced, and have now been 
become a cornerstone of treatment[281. Over two hundred years after its introduction, 
digoxin has finally been proven to be effective and safe 1291.
1.1.5 Conclusions
For over 5000 years, continuing advances in anatomy, pathology and physiology have 
allowed identification of the heart as the cause of cardiac failure. The introduction of 
digitalis in the 18th century sparked the beginning of therapeutic optimism. Progress 
in clinical examination in the 19th century and the advance of technology, including 
radiology, electrocardiography, cardiac catheterisation and echocardiography in the 
20th century have advanced our understanding of this highly lethal condition. The 
introduction of diuretics, direct acting vasodilators, angiotensin converting enzyme 
inhibitors and surgical techniques such as transplantation and cardiomyoplasty enable 
us to relieve symptoms and decrease mortality in patients with heart failure. Despite 
all these advances, the incidence and prevalence of heart failure are increasing in 
industrialised countries I301, and it continues to carry an ominous prognosis. 
Identification of those who are at greatest risk of death remains elusive, and it was the 
aim of this thesis to enhance risk stratification in chronic heart failure.
1.2 P a th o p h y s io lo g y  o f  H e a r t  F a i lu r e
Heart failure is a complex clinical syndrome that continues to defy simple definition. 
This accounts, in part, for the variety of definitions that have been proposed (Table 1-1). 
These definitions encapsulate how understanding of the heart failure syndrome has 
changed from concentrating on an abnormality of cardiac function to a complex,
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multi-system progressive disorder with adaptive and mal-adaptive compensatory 
responses. The presence of fluid retention or congestion classifies left-ventricular 
systolic dysfunction as decompensated.
Table 1-1: Definitions of chronic heart failure
a condition whereby the heart fails to discharge its contents properly -  Lewis, 1933
the heart fails to maintain an adequate output despite a satisfactory filling pressure -  
Wood, 1952
a pathophysiological state in which an abnormality of cardiac function is responsible 
for the failure of the heart to pump blood at a rate commensurate with the 
requirements of the metabolising tissues 1311
a complex clinical syndrome characterised by abnormalities of ventricular function 
and neurohormonal regulation, which are accompanied by effort intolerance, fluid 
retention and reduced longevity1321
ventricular dysfunction with symptoms 1331
Subjective Symptoms of heart failure
Objective Evidence of important cardiac dysfunction
Retrospective Response to appropriate treatment for heart failure 1341
1.2.1 Symptoms
The link between the severity of cardiac dysfunction and symptoms of breathlessness, 
exercise intolerance and fatigue in chronic heart failure is complex 1351. There is poor 
association between patients’ perception of their symptoms and objective measures of 
the severity of left ventricular dysfunction.
Abnormalities of resting central haemodynamics correlate poorly with functional 
capacity on exercise testing, and acute improvements in haemodynamic indices do not 
result in acute improvements in exercise tolerance [36]. Studies with ambulatory
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pulmonary flotation catheters fail to demonstrate any correlation between exercise 
capacity and peak-exercise left ventricular end-diastolic pressure p?1, although there is 
a close correlation between peak cardiac output and peak VO2 1381. Thus, symptoms of 
breathlessness on exertion are not simply a reflection of resting or exercise induced 
changes in left ventricular filling pressure.
During exercise, ventilation increases more steeply in patients with chronic heart 
failure than in normal controls, and this altered pattern of breathing might lead to the 
sensation of dyspnoea. The slope of the plot of minute ventilation (Ve) V s carbon 
dioxide production (VCO2) is increased in chronic heart failure, representing an 
increased ventilatory drive, increasing gradients correlating with increasing severity of 
heart failure and decreasing exercise capacity l39\ Blood gases remain normal during 
such exercise l401. It is thus unlikely that abnormalities of arterial (or venous) carbon 
dioxide content accounts for the increased ventilatory drive. Hypoxic chemosensitivity 
(measured by the ventilatory response to pure nitrogen inhalation) is increased in 
chronic heart failure l41\ Alterations in diffusing capacity have also been 
demonstrated 142along with decreased pulmonary microvascular permeability 1431, 
possibly related to increased pulmonary vascular resistance.
These alterations provide some, but not all of the reasons underlying the increased 
ventilatory drive and sensation of dyspnoea experienced by patients with chronic heart 
failure.
Patients with heart failure exhibit alterations in the regional distribution of blood flow [44\ 
Decreases in splanchnic and cutaneous flow on exercise precede decreased renal and 
skeletal muscle flow. Patients with heart failure fail to augment skeletal muscle 
blood flow during exercise 1451 and the muscle wasting that occurs in mild/moderate
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heart failure 1461 may account for a proportion of the decreased flow. However, some 
patients with demonstrably normal muscle flow describe symptoms of fatigue 1471. 
Additionally, acute haemodynamic improvements in cardiac output which increase 
muscle flow do not improve exercise capacity or symptoms of fatigue 1481, raising the 
possibility of metabolic abnormalities in exercising muscle. These data support the 
concept of “structural changes” in the microvasculature, rather than vasoconstriction 
alone, as a cause of diminished flow. Biopsy of skeletal muscle from patients with 
chronic heart failure reveals structural abnormalities, with decreased mitochondrial 
size, numbers, enzyme levels and fibre destruction 1491. Studies of muscle metabolism
<3 |
usmg P-magnetic resonance spectroscopy have confirmed that muscle pH and 
phosphocreatine (a high-energy compound) fall more rapidly than in normal subjects 
and endurance in such muscles is decreased 1501. Exercise training can improve 
functional capacity whilst reversing metabolic abnormalities and mitochondrial 
oxidative enzyme deficiencies, without a change in mitochondrial density. Similar 
abnormalities seen in respiratory skeletal muscle may account for the respiratory 
muscle weakness present in chronic heart failure. Respiratory muscle training 
reverses the abnormalities seen on pulmonary function testing, improving symptoms 
of dyspnoea and effort tolerance.
However, it remains unproven whether these changes in skeletal muscle physiology 
provide the non-CC>2 ventilatory stimulus to respiration in chronic heart failure.
1.2.2 Physical Signs
The classical signs of heart failure may be masked by or become absent after 
treatment. Even when physicians agree on their presence, such signs are poorly 
discriminatory in defining underlying cardiac function l51]. Diastolic dysfunction with
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normal systolic function occurs in up to 30% of chronic heart failure patients with 
classical congestive signs 1521. In chronic heart failure, high left ventricular filling 
pressures may cause little in the way of classical signs. Additionally, chest 
radiography may reveal no evidence of pulmonary venous congestion in the presence 
of significantly raised left ventricular filling pressures, leading to inappropriate 
care 1531. Thus, the bedside diagnosis of cardiac dysfunction is fraught with problems. 
Despite this, the presence of clinical and radiological features of congestion are strong 
predictors of mortality in populations, if not in the individual.
1.2.3 Abnormal Cardiac Function and Structure
Left ventricular injury causes a loss of effective contractile mass, leading to a 
complex and interrelated sequence of compensatory cardiac, haemodynamic and 
neuroendocrine responses. The end result of this sequence is: a) cardiac hypertrophy 
in non-damaged myocardium; b) neuroendocrine activation and c) salt and water 
retention.
These compensatory responses are beneficial in the short term, but have long term 
deleterious effects I54], accounting for the inexorable progression of cardiac 
dysfunction. Initially there may be no symptoms, but when these mechanisms fail or 
become unbalanced, the symptoms and signs of heart failure develop.
1.2.3.1 Global cardiac function in heart failure
Injury to the left ventricle causes an acute reduction in stroke volume and, if heart rate 
is constant, a decrease in cardiac output. Preload (left ventricular end diastolic 
volume) increases, returning cardiac output towards normal at the cost of increased 
left ventricular wall stress. Compensatory hypertrophy returns wall stress towards 
normal, and ventricular distensibility increases, so that the ventricle may pump from
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an increased left ventricular end diastolic volume without increasing left ventricular 
end-diastolic pressure. Additionally, ventricular compliance increases, so that for any 
further increase in preload, left ventricular end-diastolic pressure increases less.
The ventricle thus operates on a flattened and depressed function curve, and “preload 
recruitment” allows the maintenance of a normal cardiac output. However, further 
increases in preload are not met by a corresponding increase in cardiac output, and 
preload reserve is eventually exhausted. In this situation, the ventricle becomes 
afterload dependent, increasing afterload decreasing cardiac output, and decreasing 
afterload increasing cardiac output. This forms the physiological basis for vasodilator 
therapy in chronic heart failure.
Global left ventricular systolic dysfunction may relate more to increased wall stress, 
distorted ventricular geometry, interstitial fibrosis and cell loss than myocyte 
contractile dysfunction1551.
1.2.3.2 Functional aspects of cardiac hypertrophy and remodelling
The pattern of compensatory hypertrophy is governed by the type of load placed on 
the heart. Increased afterload (systolic wall stress) leads to the addition of sarcomeres 
in parallel, increasing wall thickness and tending to decrease chamber size. This is 
termed “concentric hypertrophy” and is classically secondary to hypertension or aortic 
stenosis.. Increased preload (diastolic wall stress) leads to the addition of sarcomeres 
in series, increasing chamber size. This is termed “eccentric hypertrophy”, usually 
secondary to valvular regurgitation 1561.
Many stimuli may lead to hypertrophy. Cell stretching causes increases in myocardial 
protein synthesis in proportion to muscle tension. Stretch can modulate ion-channels
Ch a pte r  1: In tr o d u c t io n - 3 5 -
and enzyme levels, changing intracellular concentrations of second messengers. 
Increased expression of proto-oncogenes has also been reported, possibly regulating 
protein synthesis. There is evidence that activation of the sympathetic nervous 
system, in conjunction with the renin-angiotensin system and angiotensin-II, also 
plays a role, possibly explaining some of the beneficial effects of ACE inhibitors in 
regression of left ventricular hypertrophy [5?1.
Cytokines are another group of proteins secreted in response to number of different 
stimuli. There are two major classes that may play a role in heart failure: 
vasoconstrictor cytokines, such as endothelin; and vasodepressor pro inflammatory 
cytokines such as tumour necrosis alpha and interleukin 6. It is hypothesised that 
cytokines exert a deleterious progressive effect by necrosis, perhaps along with 
apoptopic myocyte cell death, progressive myocardial fibrosis and thus myocardial 
dysfunction 1581.
1.2.3.3 Adverse functional consequences of left ventricular
hypertrophy
The hypertrophic response to pathological stresses, including the mixed pattern seen 
in chronic heart failure, carries adverse consequences. The addition of sarcomeres in 
parallel or series decreases wall stress. However, the inter-capillary distance 
increases, collagen content increases, mitochondrial density decreases and coronary 
flow reserve falls. The failing hypertrophied heart is thus more likely to become 
ischaemic. Changes in the amount and activity of the sarcoplasmic reticulum 
Ca2+-ATPase, increases in interstitial collagen content and the appearance of 
abnormal forms of collagen all contribute to impairment of relaxation and cardiac 
function. Angiotensin-II and aldosterone promote pathological hypertrophy, myocyte
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necrosis and interstitial fibrosis, compounding the problem 1591. Animal models of 
heart failure demonstrate species specific alterations in gene expression causing 
iso form switching in myosin, thought to improve myocardial efficiency, at the 
expense of slowing the peak velocity of contraction. Downregulation of a-myosin 
heavy chain has recently been demonstrated in the failing human ventricle. The left 
ventricle enlarges, probably by elongation of myocytes, cell slippage and collagenase 
activity. Irrespective of the aetiology, an increase in left ventricular end systolic 
volume is an ominous sign1601.
1.2.3.4 Myocyte changes in hypertrophy and heart failure
There is consensus that cell elongation with defective transverse growth occurs, so 
that there is an increased myocyte length-to-diameter ratio. These changes could 
account for an increased cell volume, and correlate with left ventricular chamber 
size 1551. However, such changes are unable to account for all of the remodelling seen, 
and cell-cell slippage probably occurs l611.
There is debate over myocyte contractile function in left ventricular systolic 
dysfunction. Recent studies reveal normal contractile function in isolated myocytes 
taken from non-infarcted areas, despite evidence of significant structural 
remodelling [62]. Other groups have confirmed normal maximal contraction 
amplitude, albeit with delayed times to peak contraction and relaxation 1631. However, 
most studies have shown a flattened or reversed force-frequency relationship, 
confirming myocyte dysfunction.
Myocyte cell death may occur by apoptosis or necrosis. Apoptosis causes cell death 
in the absence of replacement fibrosis. In contrast, cell necrosis is characterised by 
an inflammatory reaction, macrophage infiltration and scar formation. Apoptosis or
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programmed cell death has now been demonstrated in human ventricular 
myocardium [64). Stretch can signal apoptosis, as would occur in left ventricular 
dilatation. Apoptosis would occur in the absence of interstitial collagen accumulation, 
and might be responsible for the inexorable left ventricular dilatation seen in 
progressive heart failure. Conclusive evidence regarding the role of apoptosis in the 
progression of heart failure is awaited.
Animal data suggest that although intracellular Ca2+ concentrations may be normal in 
the failing heart, time to peak Ca2+ concentration and rate of decline in Ca2+ 
concentration are slowed, because of a decrease in sarcoplasmic reticulum reuptake 
during diastole. Myofilament Ca2+ sensitivity is decreased and spontaneous 
oscillations in sarcoplasmic reticulum Ca2+ release augment diastolic tone, causing 
asynchronous systolic contraction with a possible role in arrhythmogenesis 1651. 
Similar changes have been found in the human heart 1661. These Ca2+ abnormalities 
may be secondary to changes in the sarcoplasmic reticulum Ca2+-ATPase [6?l, 
compounded by diminished energy reserves and ATP levels. This reduction in 
sarcoplasmic reticulum Ca2+-ATPase has been related to the extent of contractile 
dysfunction. It has been postulated that the inverse force-ffequency relationship seen 
in human papillary muscle preparations from patients with severe heart failure may be 
consequent to these changes: decreased availability of sarcoplasmic reticulum Ca 
consequent to shortened diastole with diminished reuptake. This could explain why 
interventions that increase heart rate reduce cardiac output in chronic heart failure, 
while lowering heart rate appears generally beneficial 1681. Excitation-contraction 
coupling is disturbed further by alterations in cross-bridging kinetics, possibly caused 
by actin/myosin iso form switches secondary to altered gene expression.
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1.2.4 Normal Cardiac Cell Electrophysiology
Myocardial cells have a distinctive action potential profile (see Figure 1-1). From a 
threshold potential, there is rapid depolarisation (phase 0) followed by a rapid 
repolarisation (phase 1), a long plateau (phase 2) and subsequently a more rapid 
repolarisation (phase 3) to the resting membrane potential. Action potential duration 
correlates with the time course of repolarisation of cardiac tissue: lengthening of 
action potential duration correlates with prolongation of repolarisation. A transient 
outward current, It0 contributes to early repolarisation (phase 1) and helps “set” the 
plateau potential. The transient outward current demonstrates regional variation, 
being more marked sub-epicardially, giving rise to the so-called “spike and dome” 
action potential configurations. The situation is complicated by the fact that the 
normal ventricle demonstrates electrophysio logical non-uniformity 1691. Action 
potential duration differs, being longer in the left than right ventricle, longer at the 
base than the apex and longer in the endocardium than epicardium. Recent work has 
demonstrated “M cells” in the mid-myocardial region of the canine ventricle, and 
there is evidence supporting their existence in the human heart. These cells have 
longer action potential durations than normal myocytes which prolong dramatically 
with slower heart rates [701, further adding to nonuniformity.
C h a p t e r  1: In t r o d u c t io n - 3 9 -
+30mV _
-90mV__
Phase 1
Phase 2
Na/Ca
SA
Phase 0 Phase 3
K1
Figure 1-1: The ventricular action potential
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1.2.5 Electrophysiological Consequences of Failure and
Hypertrophy
Animal models of heart failure have produced inconsistent results. This inconsistency 
is attributable to both variation in experimental models and methods (e.g. coronary 
ligation, pressure or pacing induced heart failure) or within species. The 
nonuniformity of electrophysiological characteristics of the normal heart also 
complicates interpretation of the results. Data on electrophysiological properties of 
human tissue are even less complete.
The hallmark of hypertrophy is prolongation of the transmembrane action potential 
duration, generally in the absence of other electrophysiological abnormalities of the 
resting membrane potential, action potential amplitude or upstroke velocity 1711. This 
lengthening of action potential duration is caused by prolonged repolarisation.
1.2.5.1 Abnormalities of calcium current
The major Ca2+ current, Ica-L, conveyed by L-Type ion channels, activates at 
potentials positive to —40 mV, and inactivates slowly (~ 100msec). Its inactivation
9 -1-kmetics are complex and dependent on voltage, time and the intracellular Ca 
concentration, [Ca h . Increased channel density or decreased inactivation kinetics 
would prolong the plateau phase, and hence lengthen repolarisation. Animal models 
have yielded inconsistent results, but in human explanted transplant recipient hearts, 
no change in overall Ica was found. However, dihydropyidine binding receptor 
density was reduced, as was the mRNA encoding this protein. Activation kinetics 
seem to be unaltered, but the voltage dependence of inactivation has shown positive 
shifts, i.e. inactivation requires a more positive membrane potential, so that 
inactivation would be delayed at the normal plateau potential of approximately +10 mV.
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Alterations in [Ca ]i and intracellular pH modify the voltage dependence of 
inactivation of L-Type Ca2+ channels, and both changes occur in the hypertrophied 
cell 1721. Catecholamines may regulate expression of L-Type Ca2+ channel mRNA, 
being decreased by a-agonists and increased by P-agonists t731. Regional 
heterogeneities in sympathetic innervation and p-receptor downregulation could 
amplify spatial dispersion of repolarisation and refractoriness by this means.
1.2.5.2 Abnormalities of Na+/Ca2+ exchange current
The Na+/Ca2+ exchanger provides the principal mechanism of Ca2+ extrusion from the 
myocyte under normal conditions. It generates a small current because of the 3 Na+ to 
1 Ca2+ ratio, but the direction of current is dependent on the membrane potential, and 
the [Ca2+] i . At rest, inward current is generated as the combined equilibrium potential 
(Ens-c# == -30 to -40mV) is more positive than the resting membrane potential. At the 
action potential peak and during early repolarisation, when ENa_c» is negative to the 
membrane potential, a small outward current is produced. During the plateau, one 
would expect the same, but the increase in [Ca2+]i makes ENa.Ca more positive so that 
the exchanger produces a net inward current, i.e. it extrudes lCa2+ for 3 Na+. As a 
result, higher levels of [Ca2+]i increase the net inward current generated by the
I j
Na /Ca exchanger, prolonging action potential duration.
Thus, intracellular Ca2+ concentrations may be normal in the failing heart, but time to 
peak Ca2+ concentration and rate of decline in Ca2+ concentration are slowed. There 
are also spontaneous oscillations in SR Ca2+ release. These Ca2+ abnormalities, which 
may be secondary to changes in the SR Ca2+-ATPase, predispose to Ca2+ overload in 
the failing myocyte, promoting arrhythmogenesis 1741.
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1.2.5.3 Abnormalities of potassium currents
There are regional and interspecies variation in the transient outward current, It0. This 
is thought to represent two separate currents; a K+ current and a more rapidly 
deactivated intracellular Ca2+ dependent Cl' current. Animal and human work 
documents a 30%-40% reduction in It0 density in myocytes from failing, 
hypertrophied hearts with no change in voltage dependence or kinetics of activation, 
inactivation or repriming. This current is of prime importance in “setting” the plateau 
potential, and consequently in determining action potential duration. The density of 
the inward rectifier, Irj, was also reduced by 40% in myocytes from humans with 
“end-stage” heart failure, with no change in the voltage dependence of gating.
The delayed rectifier K+ current, Ik, provides the dominant repolarising current during 
the plateau of the action potential. The importance of this current in human 
ventricular myocytes is unknown.
1.2.5.4 Changes in cell to cell coupling
Interstitial fibrosis and changes in collagen seen in the hypertrophy of 
hypertrophic cardiomyopathy have been correlated with changes in latency and 
cell to cell coupling. Whether this is true o f the hypertrophy present in heart 
failure is unknown, but electron microscopy freeze-fracture analysis has revealed 
reduced numbers of gap junctions, which would slow conduction velocity. 
Disruption of normal gap junction architecture (demonstrated by 
immunlocalisation of connexin 43, the principal gap-junctional protein) occurs 
early in hypertrophy and infarction [7Sl. These changes would be expected to 
influence myocardial conduction and have been correlated with inducibility of 
ventricular arrhythmias in a post myocardial infarction canine modelI76].
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1.2.5.5 Stretch
Myocardial stretch can change transmembrane potentials, which has been termed 
“Contraction-Excitation Feedback” I7?1. Alterations in ventricular geometry, pressure, 
size and function are common to all types of chronic heart failure, irrespective of the 
underlying pathogenesis. These abnormalities magnify wall stress and stretch in a 
nonuniform manner, augmenting spatial dispersion of repolarisation and 
refractoriness.
Summarising animal and human data in the normal myocyte, stretch may
1. shorten action potential duration and repolarisation
2. increase dispersion of repolarisation
3. increase electrical instability
4. cause early afterdepolarisations
These changes are exaggerated in failing hearts. Ionic mechanisms proposed to 
account for these changes include stretch regulated activation of inward currents, or 
inactivation of outward currents. Increases in [Ca2+]i secondary to reduced Ca2+- 
troponin binding or altered sarcoplasmic reticulum Ca2+ release could activate an 
inward current by electrogenic Na+/Ca2+ or Na+/K+ exchange, or may modify a non­
specific “leak” channel. Both mechanisms would prolong action potential duration 
and repolarisation.
1.2.5.6 Ischaemia and acidosis
The failing hypertrophied heart is predisposed to ischaemia, particularly in the sub­
endocardial region, even in the absence of coronary atherosclerosis 1541.
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Neurohormonal activation, autonomic dysfunction and alterations in endothelial 
function favour vasoconstriction, compounding ischaemia, which produces acidosis, 
secondary to lactate accumulation and CO2 production. Acidosis depolarises the 
resting membrane potential, moving it closer to threshold. This is partly offset by a 
more positive threshold membrane potential. Conduction velocity is decreased, 
possibly due to the change in resting membrane potential, changes in voltage 
dependence of the Na+ channel conductance variables, or increased gap junction 
resistance. Ionic changes implicated include
1. Inhibition of the electrogenic Na+/K+ -ATPase
2. Increased [Ca2+] i. Acidosis increases [Ca2+]i. By two mechanisms a) displacement 
from mitochondria and sarcoplasmic buffering sites, and b) activation of Na+/H* 
exchange, which extrudes H+ for Na+, causing an increase in intracellular Na+. 
This decreases Ca2+ extrusion via the Na+/Ca2+ exchanger, activating inward 
current via the Na+/Ca2+ exchanger and a non-specific cation channel.
3. Decreases in K+ currents
4. Accumulation of intercellular K+, which would partially depolarise the membrane.
5. Direct effects of acidosis (via intracellular H+ concentration) on non-specific 
cation conductance and inhibition of the Na+/Ca2+ exchanger.
These changes augment the prolongation of action potential duration seen in 
hypertrophy, and predispose to afterdepolarisations.
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1.2.5.7 Spatial and temporal heterogeneities
The most obvious structural and electrophysiological abnormality common to all types 
of chronic heart failure is the dispersion of change throughout the ventricle. 
Irrespective of aetiology, hypertrophy is nonuniform. Interstitial fibrosis, disruption 
of intercellular connections, regional disparity of sympathetic innervation and 
sensitivity, wall stresses, acidosis and intracellular Ca2+ overload produce variation in 
the density and time course of transmembrane currents. These compound spatial and 
temporal dispersion of action potential conduction, repolarisation, and refractoriness. 
This enhances the arrhythmogenic substrate provided by the isolated myocyte. 
Extrinsic factors such as diuretic induced electrolyte imbalance and antiaarrhythmic 
medication have important electrophysiological effects, which may promote 
arrhythmogenesis.
1.2.6 Arrhythmias Present in Heart Failure
Typical arrrhythmias include atrial and ventricular extrasystoles (in over 70% of 
patients), atrial fibrillation (arguably the most important, occurring in up to 20% of 
patients) and nonsustained polymorphic ventricular tachycardia ,7S|. Sustained 
monomorphic ventricular tachycardia is less common, but more likely in heart failure 
secondary to previous myocardial infarction 1791. This pattern of arrhythmia suggests 
complex functional re-entry and triggered automaticity as mechanisms rather than 
single circuit re-entry 1801 (see Table 1-2).
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Table 1-2: Mechanisms of arrhythmogenesis in chronic heart failure
Mechanism Requirements
Reentry
Altered conduction velocity/ repolarisation
Enhanced Automaticitv
Increased pacemaker current
Increased T-type Ca2+ current
Decreased outward K+ current
Afterdeoolarisations
Early Reduced outward current
Increased inward current
Delayed Transient abnormal inward current
1.2.7 Mechanisms of Arrhythmogenesis
1.2.7.1 Re-entry in chronic heart failure
The essential requirements for re-entry are unidirectional conduction block and a 
specific pathway for impulse propagation. Areas of slow conduction facilitate re­
entry, which is usually dependent on an initiating trigger, such as an extrasystole. 
These requirements may be met by anatomical or functional obstacles. It has been 
demonstrated that re-entry may occur in the absence of anatomical obstacles [81’. 
Functional slowing (or block) of conduction caused by abnormal cellular 
transmembrane properties (including the changes in the resting membrane potential, 
dispersion of repolarisation and heterogeneity of refractoriness discussed above) 
provide a substrate for re-entry. The abnormal prolonged repolarisation and 
heterogeneous recovery of excitation leads to dispersion of repolarisation. This
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increases the susceptibility of the myocardium to ventricular arrhythmias. Cardiac 
muscle is anisotropic, such that conduction is faster in the direction of fibre 
orientation, and slower perpendicular to fibre orientation. It has been shown that 
anisotropic re-entry occurs in the epicardial border zone of infarction, and that in this 
region anisotropy is non-uniform and magnified. Disturbances in ventricular 
geometry and fibre orientation secondary to infarct scar, ventricular remodelling and 
dilatation, intercellular fibrosis and disrupted inter-cellular connections may all 
predispose to magnification of anisotropic conduction. Functional re-entry provided 
by anisotropy need not necessarily occur around an anatomical obstacle (although this 
may facilitate such re-entry), but the requirements for re-entry may be provided by the 
micro-anatomical structure, without abnormal transmembrane cellular current flow.
Thus, the distinction between functional and anatomical mechanisms is blurred in the 
failing, hypertrophied myocardium, and the requirements for re-entry may be provided 
by spatial and temporal dispersion of repolarisation and refractoriness rather than 
anatomical obstacles.
1.2.7.2 Afterdepolarisations
Afterdepolarisations are spontaneous oscillations of membrane potential that occur 
late in the action potential or immediately after repolarisation. They are caused by 
imbalance between outward repolarising currents and inward depolarising currents. 
There are two types
1. Early afterdepolarisations, which interrupt phase 2 or 3 repolarisation, and
2. Delayed afterdepolarisations, which occur after repolarisation is complete
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When large enough, afterdepolarisations may induce a spontaneously propagating 
action potential. This is defined as “triggered activity”. Even if the afterdepolarisations 
fail to reach threshold, they may still retard repolarisation and promote further 
dispersion of refractoriness.
Early afterdepolarisations are prominent at slow heart rates and low extracellular 
potassium concentrations. They have been demonstrated in hypertophied myocytes 
subject to acidosis and high concentrations of catecholamines. Membrane resistance 
is high during the plateau potential, such that even small changes in the net inward 
current may prolong repolarisation and produce early afterdepolarisations.
Delayed afterdepolarisations are prominent at faster heart rates. Increases in diastolic
2+
[Ca ]i induce a transient inward current, Iti, which can cause delayed 
afterdepolarisations. Intracellular diastolic myocyte Ca2+ overload, a feature of 
chronic heart failure, has been described above. In addition, prolonged repolarisation 
reduces Ca2+ extrusion during systole because the electrochemical Na+ gradient is 
lowered at plateau potentials, compounding the problem. The mechanism of Itj is 
unclear, but most evidence favours changes in Na+/Ca2+ exchange induced by calcium 
release from the sarcoplasmic reticulum.
1.2.8 Autonomic Nervous System Dysfunction in Chronic 
Heart Failure
Following myocardial injury there is acute activation of the sympathetic nervous system. 
This is initially an adaptive response serving to maintain cardiac output and arterial 
pressure. Even when left ventricular dysfunction is asymptomatic [82), the sympathetic 
nervous system is activated. However, sustained sympathetic neuronal activation 
activates the renin angiotensin aldosterone system, with deleterious consequences.
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Autonomic nervous system dysfunction may be assessed by a number of different 
methods: plasma markers of neuroendocrine activation; direct sympathetic nerve 
microneurography; noradrenaline spillover techniques; power spectral analysis of 
heart rate or measurement of baroreflex sensitivity.
Direct recordings of muscle sympathetic nerves in humans have demonstrated marked 
activation of the SNS in mild 1831 and severe heart failure 1841. Noradrenaline spillover 
techniques have demonstrated that cardiac sympathetic nerve activity precedes 
changes in renal or muscle sympathetic nerve activity [8S1.
Atrial natriuretic peptide is activated early in heart failure. This has a direct renal 
natriuretic effect; inhibits renin and noradrenaline release; attenuates their 
vasoconstrictor actions and decreases sympathetic outflow by baroreceptor action 1861. 
In animal models of heart failure, ANP is elevated before plasma renin and 
aldosterone, i.e. before the RAAS is activated, and may in fact suppress it. However, 
in humans with severe heart failure, plasma renin and aldosterone are increased 1821. 
Initially, RAAS activation may be beneficial in increasing preload and afterload, but 
in the long-term it is deleterious. Angiotensin-II, a potent systemic vasoconstrictor, 
causes renal efferent arteriolar constriction, favouring proximal tubular sodium 
resorption; stimulates aldosterone release, further augmenting the sodium avid state; 
and increases thirst whilst decreasing water excretion 1871. Centrally, Angiotensin-II 
facilitates sympathetic nerve outflow, while peripherally it facilitates noradrenaline 
release from adrenergic nerves. As heart failure progresses, the effect of atrial 
natriuretic factor is blunted l88], and the beneficial vasodilatory effects of endothelium- 
derived relaxant factor are attenuated l89J. As sympathetic activity causes renin 
release, and angiotensin-II enhances the effects of noradrenaline l90], there is mutual 
neuroendocrine augmentation leading to unopposed vasoconstriction and salt and
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water retention. Angiotensin-II and aldosterone are also implicated in promoting 
pathological hypertrophy, myocyte necrosis and interstitial fibrosis l91].
Chronic sympathetic overactivity leads to desensitisation of the myocardium to 
sympathetic stimulation1921. In human heart failure, Pi receptors are downregulated to 
a greater extent than p2 receptors [93), and p2 receptors are uncoupled from their 
effectors. The end result is decreased cardiac sensitivity to sympathetic stimulation, 
whilst vasoconstriction is unopposed.
Prior work has documented that parasympathetic function (assessed by bedside 
testing [941, heart rate variability techniques 1951 or baroreflex sensitivity ) is 
depressed in chronic heart failure.
1.2.8.1 Aetiology of autonomic dysfunction
Sympathetic nervous system activity is modulated by
1. Baroreceptor inhibition
2. Excitatory afferents (muscle metaboreceptors, peripheral chemoreceptors and 
cardiac sympathetic afferents)
3. Centrally acting neurotransmitters, which can be inhibitory or excitatory.
1.2.8.1.A Baroreceptor abnormalities
Baroreceptors play a central role in autonomic cardiovascular control. Arterial and 
cardiopulmonary baroreceptor function is abnormal in heart failure [97J. The 
mechanism or mechanisms underlying this abnormality could involve any part of the 
reflex arc, including the afferent limb (generation and transmission of neural 
impulses), central processing (in the nucleus tractus solitarius), or the efferent limb. 
Studies using a canine model of low-output heart failure have demonstrated decreased
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baroreceptor gain (change in baroreceptor firing rate per mmHg change in arterial 
pressure), but augmented central integration, allowing normal inhibition of renal 
efferent sympathetic nerve activity [9S1. The same investigators subsequently 
demonstrated abnormalities in the afferent limb of the cardiopulmonary 
mechanoreceptor reflex 1991. In rat models, direct measurements of single-unit 
baroreceptor nerve activity demonstrate a higher threshold pressure for activation, 
diminished afferent baroreceptor gain, and a lower peak baroreceptor discharge rate 11001. 
These data confirm the presence of abnormalities in the afferent limb, but dysfunction 
of central integration and the efferent limb are as yet unproven.
There are 3 proposed models of baroreflex dysfunction:
1. Mechanical: changes in ventricular compliance may be linked to abnormalities of 
the pressure-discharge relationship
2. Humoral: although enalaprilat has been shown to improve baroreflex function in 
dogs with heart failure, most studies document that RAAS activation occurs after 
sympathetic excitation, and so it is difficult to implicate the RAAS in the induction 
of baroreflex dysfunction.
3. Ionic: dog models of heart failure demonstrate augmented carotid baroreceptor 
Na+ - K+ adenosinetriphosphatase activity. This could be reversed with ouabain, 
which augmented baroreflex sensitivity.
Sympathetic nervous system hyperactivity in heart failure is limited to organs usually 
subject to baroreflex restraint. Thus skin sympathetic nerve activity is not increased in 
heart failure 11011. Baroreflex control of forearm blood flow is abnormal 11021, as is 
baroreflex control of muscle sympathetic nerve activity ll03J. There is also evidence 
that abnormal baroreflex control of sympathetic nerve activity precedes more
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generalised neuroendocrine activation 1831. The fact that arterial as well as 
cardiopulmonary baroreceptors are important in the sympathetic overactivity is 
exemplified by normalisation of autonomic dysfunction following cardiac 
transplantation, even though cardiac baroreceptors would be denervated 11041.
1.2.8.1.B Excitatory afferent abnormalities
Abnormalities of skeletal muscle metabolism and afferent nerve activity play a role in 
the symptoms of heart failure 110S1. However, as sympathetic activity precedes 
demonstrable muscle abnormalities, being increased in asymptomatic heart failure, it 
seems unlikely that such abnormalities are the principal force behind the autonomic 
dysfunction seen in heart failure. Chemoreceptor sensitivity is increased in chronic 
heart failure. However, acute administration of oxygen to patients with heart failure 
does not reduce muscle sympathetic nerve activity 11061. Arterial hypoxaemia is 
uncommon in heart failure [40,? so it is unlikely that chemoreceptor abnormalities 
initiate neuroendocrine activation.
1.2.8.1.C Central nervous system dysfunction
A number of potential central mechanisms exist for the sympathetic nervous system 
activation of heart failure:
1. Increased excitatory neurotransmission
2. Increased sympathoexcitatory endogenous brain oubain-like activity
3. Central activation of AT-II
4. Decreased nitric-oxide neuroinhibition
5. Abnormal insulin and/or opiate control of sympathetic outflow.
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There is increased central nervous system turnover of noradrenaline and adrenaline in 
patients with heart failure 11071, associated with increased cardiac noradrenaline 
spillover. Increases in brain ouabain like activity have been described in animal
models of heart failure. The associated elevated resting noradrenaline levels were
normalised by intracerebroventricular administration of digibind, implicating brain 
ouabain-like activity in the sympathoexcitation of heart failure 11081. The overall role 
played by central mechanisms in sympathoexcitation of heart failure remains unclear.
1.2.9 Heart Rate Control
The normal resting heart rate varies between individuals. It is dependent on 
physiological and pathological stresses, age and level of cardiovascular fitness. Heart 
rate is determined by the rate of depolarisation of phase IV of the cells in the sinoatrial 
node. There is a constant, autonomically mediated variation in the sinus node rate, 
which occurs on a beat-to-beat basis. The intrinsic heart rate, in the absence of 
neurohumoral influence (under lull autonomic blockade) is approximately 100 bpm. 
At any one time, heart rate depends on the balance between the opposing effects of the 
sympathetic and parasympathetic nervous systems.
1.2.9.1 Parasympathetic (Vagal) control
The vagus nerve innervates the sinoatrial node, atrioventricular node and possibly the 
ventricles. Experimental stimulation of the vagus nerve slows the sinoatrial discharge 
rate and atrioventricular conduction. The latency of this effect is very short: maximal 
slowing may occur within 400 msec, i.e. within one beat. Paradoxically, at lower 
vagal firing frequencies close to the heart rate vagal activity may entrain the sinoatrial 
cells and cause small increases in heart rate. The physiological importance of this is 
unclear.
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The slowing produced is dependent on the frequency of vagal firing, and the response 
curve best fits a hyperbola: although if the pulse-interval i.e. RR interval is plotted the 
relationship is linear. Thus the response to vagal stimulation is dependent on the 
initial heart rate: prolonging the RR interval by similar amounts will result in greater 
decreases in heart rate from higher initial heart rates.
1.2.9.2 Sympathetic control
Postganglionic sympathetic fibres innervate the whole heart, and sympathetic 
activation increases both rate and force of contraction. There is a latency of about 5 
seconds with a progressive increase in heart rate that reaches a plateau after about 30 
seconds. The effect is non-linear, and right sympathetic stimulation has a greater 
effect on heart rate than left stimulation, which is more concerned with inotropic 
regulation.
1.2.9.3 Baroreceptor control
Arterial baroreflexes were first discovered in 1900 by two Italian physiologists, 
Pagano and Siciliano. They demonstrated that the pressor effects of carotid occlusion 
depended on integrity of nervous structures located near the carotid vessels. 
Subsequent work by Hering and Koch in the 1920s identified the afferent part of the 
reflex as the glossopharyngeal nerve, and described the vasodepressor and 
cardioinhibitory results of carotid stimulation.
Baroreceptors consist of specialised nerve endings in the adventitia of the carotid 
sinus and aorta, which are capable of responding to fluctuations in arterial blood 
pressure. Increased blood pressure distends the walls of the arteries, causing increased 
frequency of baroreceptor afferent firing. After the initial rapid change, if the blood
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pressure stabilises, baroreceptor firing readjusts to a moderately raised level. This 
resetting is both early and rapid, but if elevated blood pressure persists a chronic phase 
may take place over several months. Their discharge provides the central nervous 
system with beat by beat information on the state of the circulation: pressure changes 
as low as 1 mmHg alter baroreceptor discharge rate.
The relationship between distending pressure and heart rate is sigmoidal, and the 
cardiac response may operate at a different range to the vascular response. The net 
change is due to summation of carotid and cardiopulmonary baroreceptors.
The bradycardic response to baroreceptor stimulation is mediated by vagal cholinergic 
mechanisms: the response is abolished by atropine and unaffected by p-blockers 11091. 
Because the bradycardic response is vagally mediated, the latency of the reflex is 
short, from 200 to 475 milliseconds 11101. Thus, baroreceptors are able to modulate the 
sinus rate on a beat to beat basis. However, the tachycardic response to baroreceptor 
deactivation is not exclusively mediated by vagal/cholinergic mechanisms, as it 
requires combined autonomic blockade with atropine and propranolol to abolish it.
1.2.9.4 Assessm ent of autonomic dysfunction
Autonomic nervous system dysfunction may be assessed by a number of different methods: 
plasma markers of neuroendocrine activation; direct sympathetic nerve microneurography; 
noradrenaline spillover techniques; power spectral analysis of heart rate or measurement of 
baroreflex sensitivity. In large populations, direct sympathetic nerve microneurography and 
noradrenaline spillover techniques are impractical.
However, prior work has documented that parasympathetic function, assessed by 
bedside testing 1941, heart rate variability techniques 1951 or baroreflex sensitivity [961, is
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depressed in chronic heart failure. In post-myocardial infarction populations these 
measures correlate poorly with each other, or with the extent of coronary disease or 
severity of left ventricular dysfunction. They provide independent prognostic 
information on cardiac mortality post-myocardial infarction I1H1. At the time of the 
original grant proposal, their prognostic utility in patients with heart failure was not 
known.
1.3 E p id e m io lo g y  o f  C h r o n ic  H e a r t  F a i l u r e
Epidemiological data on heart failure remain scarce, despite the condition being a 
growing and major health burden. There are a number of reasons for this.
1. There is no universally agreed definition of heart failure.
2. The diagnosis of heart failure on clinical grounds alone is often inaccurate |1121, 
particularly in the elderly and obese.
3. Objectively documented cardiac dysfunction need not necessarily be accompanied 
by symptoms of heart failure, although there will often be biochemical evidence of 
neuroendocrine activation 11131.
Thus epidemiological data on heart failure are heterogeneous, accounting for the widely 
disparate figures of incidence, prevalence and frequency of aetiology.
Heart failure in the Framingham community was defined on the basis of a scoring 
system I114l  It was found to be highly prevalent, affecting approximately 1% of people 
aged 50 or over, rising to 10% of those aged over 80. The mean incidence of 4 /1000 
population/annum also rose rapidly with increasing age. At all ages, men were affected 
more frequently than women. Hypertension preceded 75% of cases, with 46% of men 
and 27% of women having co-existent coronary diseasef1151. A large community study of
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the North Glasgow population incorporated echocardiography 11161 and biochemical 
markers of neuroendocrine activation 111?1. The prevalence of definite left-ventricular 
systolic dysfunction (defined as a left-ventricular ejection fraction < or = 30%) was 2.9%. 
In contrast to the Framingham data, only 20% of cases were accompanied by 
hypertension (defined by WHO criteria as blood pressure >160/95 mmHg), and over 80% 
of cases had ischaemic heart disease. Hypertension was defined in the Framingham cohort 
as a blood pressure >140/90 mmHg. Reanalysis of the Glasgow data has shown that 50% 
of heart failure cases would have co-existant hypertension using this definition I118J. The 
consensus from this and other community data 11191 is that the underlying aetiology in 
heart failure has changed, and that the majority of cases have an ischaemic aetiology.
It is also evident that heart failure is increasingly common. Analysis of hospital 
discharges from Scottish hospitals document a 60% increase in the heart failure discharge 
rate from 1980 to 1990, accounting for almost 4% of all general medical discharges 11201. 
The socio-economic burden of this is enormous: it has been estimated at 1-2% of the total 
health care budget, of which two thirds is accounted for by inpatient care. The more 
severe the heart failure, the greater the cost11211.
This increasing trend may represent an increasing community prevalence, presumably due 
to an ageing population and increasing survival from myocardial infarction. It is thus 
clear that heart failure represents a major public health burden in developed countries [1221.
1.4 P r o g n o s is
It has long been recognised that heart failure carries an adverse prognosis:
“When left ventricular failure develops ...the prognosis in untreated cases is poor, patients 
seldom living more than eighteen months. ” PD White: Diseases o f  the Heart, 1953
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Figures from the Framingham cohort estimated the median survival from the onset of 
heart failure as 1.7 years in men, and 3.2 years in women ,123]. Mortality increased 
with increasing age, and there was no evidence of any appreciable improvement in 
prognosis over the four decades of study. Large trials of vasodilator therapy in 
chronic heart failure reveal a mortality of 50% at 6/12 months for severe heart 
failure [124), and 15% per annum for less symptomatic ambulant patients 112S1. Patients 
with mild heart failure and ejection fraction >35% have a more favourable prognosis, 
but still manifest a 1 0 % annual mortality despite treatment with vasodilators 11261.
1.4.1 Classification of Death in Heart Failure
Early death occurs with alarming frequency after the onset of chronic heart failure. 
Death has been classified as that due to progressive pump dysfunction preceded by 
worsening symptoms, or as sudden death, occurring within one hour of the onset of 
symptoms and presumed to be secondary to ventricular arrhythmia 11271. Although 
total cardiac mortality increases with increasing severity of heart failure, the 
proportion of sudden death falls, such that the overall frequency is approximately 
50% l1281. At the time of the original grant proposal for this study, published work 
suggested that sustained ventricular arrhythmias were the commonest cause of sudden 
death in chronic heart failure 11291. However, the limitations of the classification of 
cardiovascular death are now well recognised [1301, and even given strict criteria for 
sudden death, the causes and mechanisms of death in chronic heart failure are diverse. 
The database provided by trials of implantable defibrillators 11311 has confirmed earlier 
work that sudden death need not necessarily be caused by ventricular arrhythmias 11321. 
Even with electrocardiographic monitoring, precise definition of the mode of death is 
difficult11331. Thus, mechanistic assumptions about sudden death are flawed, and the 
underlying assumption that sudden death is equivalent to death caused by ventricular
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arrhythmias is untenable. However, irrespective of the definition used, sudden death 
constitutes the major mortality burden in patients with mild heart failure 11341. The 
causes of non-tachyarrhythmic sudden death that maybe prevalent in patients with 
severe heart failure eg pulmonary emboli11321, are unlikely in this population. As such, 
despite the above caveats, it is likely that a major proportion of sudden deaths in mild heart 
failure are secondary to ventricular arrhythmias.
The accurate elucidation of those patients at greatest risk of sudden death remains 
elusive. This is not entirely surprising, as the cellular mechanisms underlying 
arrhythmias in heart failure are complex (see section 1.2.7). The disorganised 
ventricular activation, abnormal Ca2+ handling, dispersion of repolarisation and/or 
refractoriness and disordered autonomic tone present in chronic heart failure all 
interact to promote arrhythmogenesis.
1.4.2 Prognostic Clinical Variables
1.4.2.1 Age and gender
The incidence and prevalence of chronic heart failure increase with age, and elderly 
patients have a worse prognosis. However, under the age of 75 years there is little 
age-specific difference in mortality in patients with chronic heart failure 11351. Figures 
from the Framingham cohort estimate the median survival from the onset of heart 
failure as 1.7 years in men, and 3.2 years in women 11231. One and five year survival 
rates were 57% and 25% in men, and 64% and 38% in women. The age adjusted 
mortality was also higher in men 11361. However, in the SOLVD registry female 
gender carried an adverse prognosis 11371. Generally, when subject to the scrutiny of 
multivariate analysis, gender carries little prognostic import.
Ch a pter  1: In tr o d u c t io n  - 60  -
1.4.2.2 Symptoms
Irrespective of whether symptoms are assessed crudely or using more objective 
measurements of quality o f life scores and specific activity scales, increasing severity 
of symptoms correlate with a worse prognosis. The most widely used system of 
classification is that of the New York Heart Association, which divides patients into 
four classes based on their reporting of their level of daily activity 11381. Assessment of 
symptoms, particularly variation in grading of moderate heart failure, can be 
problematic I1391. In the present study, symptoms were also assessed objectively using 
a validated disease specific scale, the Minnesota living with heart failure questionnaire 11401.
1.4.2.3 Signs
Despite the poor sensitivity, specificity and reproducibility of clinical signs in chronic 
heart failure, a number of features delineate a worse prognosis. Cardiac cachexia has 
recently been shown to carry independent prognostic information [1411. As in many 
other cardiac disease states, faster heart rates define a poorer outlook, and a group who 
may benefit most from specific therapies 11421. Although some studies have suggested 
that atrial fibrillation carries a worse prognosis 1143), the V-HeFT studies revealed no 
difference in mortality or morbidity with this arrhythmia |144'. The reason for this 
difference is unclear, but may reflect increasing awareness of the dangers of using class 
la and Ic antiarrhythmic therapy for atrial arrhythmias in chronic heart failure 11451. As 
atrial fibrillation precludes assessment of heart rate variability or baroreflex 
sensitivity, and renders QT measurements difficult, patients with atrial fibrillation 
were excluded from the study. Low arterial pressure is an indicator of poor prognosis 
in chronic heart failure |I461, but the increasing use of vasodilator therapy and the 
emerging role of p-blockade as a therapeutic option may confound this physical sign.
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1.4.2.4 Concurrent disease
Hypertension increases morbidity but not mortality [13?l, possibly because of improved 
community treatment of hypertension. New ischaemic events worsen prognosis in 
chronic heart failure. Recurrent cardiac ischaemia, particularly myocardial infarction 
or unstable angina, is associated with an adverse prognosis The 1 year mortality 
rate of patients developing a myocardial infarction was 44.3%, compared to 7.3% of 
those without infarction. Indeed, 34% of all deaths in the SOLVD studies occurred in 
this combined patient group. Diabetes mellitus was a potent predictor of mortality in 
the SOLVD trials and the less stringently selected registry, remaining an independent 
prognostic factor despite treatmentf148*.
1.4.2.5 Aetiology of chronic heart failure
The question of whether an ischaemic aetiology carries a less favourable prognosis is 
vexed by the problem of the potential for misclassiflcation of cardiomyopathy 
aetiology. In the SOLVD data set an ischaemic aetiology did not confer a statistically 
significant adverse prognosis, but over 1 1 % of patients diagnosed as having a 
nonischaemic aetiology were admitted with a myocardial infarction or unstable 
angina. Although some of these events may have been embolic, it suggests a 
significant number of patients were misclassified despite quite stringent entry criteria. 
This data underscores the difficulty of making a clear-cut distinction between 
ischaemic and nonischaemic aetiologies.
1.4.3 Plasma Biochemistry
Serum sodium concentration is inversely related to plasma renin concentration and is a 
powerful predictor of cardiovascular mortality in chronic heart failure |1491. Most 
reports have studied patient populations with severe chronic heart failure referred for
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cardiac transplantation. There are fewer data linking plasma sodium concentration 
with prognosis in milder chronic heart failure. However, the recent UK Heart study 
did confirm the prognostic power of serum sodium in an ambulant population with 
milder chronic heart failure 11501. Hypokalaemia and elevated urea and creatinine have 
also been linked to a poor prognosis ,15!1. Recent data support the view that 
hypokalaemia may be diuretic induced and linked to the development of ventricular 
arrhythmias and sudden death 11521. Generally, the prognostic power of these 
biochemical changes has been less when plasma natriuretic peptides or plasma 
noradrenaline are measured concurrently.
1.4.4 Objective Assessment Of Left Ventricular Systolic 
Dysfunction
Ejection fraction remains the most commonly used measure of left ventricular systolic 
dysfunction. Left ventricular ejection fraction measured by radionuclide 
ventriculography has predicted mortality in many studies of chronic heart failure. 
Although no randomised study has proven that echocardiographic assessment of left 
ventricular ejection fraction can predict prognosis, other echocardiographic variables 
such as left ventricular fractional shortening and internal dimensions carry prognostic 
weight [1531. However, echocardiography was used to measure ejection fraction in 
over 90% of ambulant subjects in a SOLVD registry, and did provide independent 
prognostic information 11541. European guidelines for the diagnosis of heart failure 
suggest that echocardiography should be used routinely to assess left ventricular 
function 1341. Echocardiography is simple, safe, and widely available. M-mode 
echocardiograms can be used to determine left ventricular end systolic and end 
diastolic dimensions. If the ventricle is assumed to be ellipsoid and to have a uniform 
contraction pattern left ventricular volumes and thus ejection fraction can be
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calculated. However, regional wall motion abnormalities are common in heart failure, 
so that a biplane disc summation method is more valid. Recent data suggest that semi- 
quantitative assessment of overall left ventricular systolic function is a valid technique 
that correlates closely with formal echocardiographic or radionuclide measurement of 
left ventricular ejection fraction. This method also allows assessment of systolic 
function when there is insufficient definition of endocardial outline to allow formal 
calculation of ejection fraction|15S|.
1.4.5 Cardiopulmonary Exercise Testing
As oxidative metabolism consumes O2 (VO2) it produces carbon dioxide (VCO2) - the 
metabolic source of CO2. About 80 ml of CO2 are produced for every 1 0 0  ml of O2 
consumed, so that the respiratory gas exchange ratio (R=VC0 2 /V0 2 ) at rest is 
approximately 0.8. Cellular respiration is linked to cardiopulmonary respiration so 
that 02 delivery matches O2 consumption. Normal arterial O2 content is 19ml/ 100ml. 
Some is extracted by respiring tissues, and venous O2 saturation is a function of O2 
delivery (i.e. systemic blood flow) and O2 extraction. Both are linked to O2 
consumption, VO2. At rest, VO2 averages 245 ml/min, while O2 delivery is 950 
ml/min (i.e. 5L/min of blood X 19ml 0 2 /lOOml of blood). Thus systemic O2 
extraction averages 25%.
During strenuous exercise minute ventilation (V e) increases as much as 8 -fold. 
However, less than 50% of total possible ventilatory response (maximal minute 
ventilation X forced vital capacity) is needed for even heavy workloads. Cardiac 
output increases maximally by only 4-5 fold. Cardiac output increases by 2 
mechanisms: a) vagal withdrawal and sympathetic drive increase heart rate, and 
b) increased venous return increases end diastolic volume, which along with increased
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adrenergic drive augments cardiac contraction. Thus during exercise the stroke 
volume increases and end systolic volume decreases, i.e. heart size decreases. Tissue 
O2 extraction increases to a maximum of 75%, but even with this mechanism the 
combined cardiac and tissue reserve poses a limitation to aerobic work, and 
determines maximal aerobic capacity, or maximal oxygen consumption, VO2 max.
In the completely “average” subject
maximal cardiac output = 20L/min 
maximal tissue extraction = 75% 
arteriovenous O2 difference =14ml/100ml=140ml/L 
VO2 max = CO X arteriovenous O2 difference 
VO2 max = 2800ml/min (2 0 X 140) = 40ml/min/kg
These compensations to exercise are abnormal in patients with chronic heart failure. 
Maximal cardiac output is decreased and correlates strongly with VO2 max. In mild 
heart failure, stroke volume increases during light workloads, and then fails to rise 
further. As the severity of chronic heart failure increases, stroke volume becomes 
fixed earlier in exercise, such that cardiac reserve becomes solely dependent on 
increases in heart rate. Additionally, chronic changes in muscle and microvasculature 
described above further limit O2 delivery to metabolising muscle cells.
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The first work on gas exchange in patients with heart failure was undertaken seven 
decades ago by Harrison and colleagues in the 1920s 11561 (see Figure 1-2 & 
Figure 1-3). They demonstrated that the oxygen debt was increased and that VO2 
max was reduced in patients with heart failure. They also recognised that increased 
carbon dioxide production was derived from HCO3' because it buffered metabolic 
acid. It was subsequently recognised that lactate increased during exercise only at 
heavy work rates, thereby implying a lactate or anaerobic threshold.
Later work by Weber and colleagues 11581 demonstrated that cardiopulmonary exercise 
testing provided objective measurement of cardiopulmonary impairment.
1.4.6 Prognostic Power Of Exercise Variables
Simple tests such as the 6 -minute walk test carry independent prognostic information 
in patients with heart failure. Compared with patients walking at least 450m, subjects 
with the lowest level of performance have a 3.7 fold increased mortality [1541. 
Workload achieved on bicycle or treadmill or bicycle ergometer correlates closely 
with VO2 . However both protocol and the patient can influence this association. 
Many studies during the 1970s and 1980s documented the relationship between 
exercise time and survival, but included a heterogeneous group of patients with 
disparate endpoints [1591.
Numerous studies have reported the independent prognostic power of maximal or 
peak oxygen consumption. Two year event free survival rates for patients with 
peak VO2 < 14 ml/kg/min was 48% compared with 84% of patients with a peak 
VO2 > 14 ml/kg/min 11601. Because of this, peak VO2 is the only cardiophysiological 
prognostic factor routinely used as a selection criteria in heart failure patients being 
evaluated for cardiac transplantation [1611. Which value should be used to as a cut-off
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to dichotomise mortality outcome remains unclear 11621, which ignores the fact that 
inability to exercise is in itself prognostic 11631. Indeed, the value of VO2 used to 
dichotomise "good" or "bad" outlook appears unimportant. In one report, there was a 
2 0 % difference in three year mortality between the two groups, irrespective of the cut 
point chosen . However, the lower the value, the lower the survival in each group 11591. 
Whether VO2 should be corrected for age and gender remains unclear. In one survival 
study of 500 patients, subjects whose peak VO2 was < 14ml/kg/min but > 50% of their 
age and gender predicted value had survival rates similar to patients achieving a VO2 
> 14ml/kg/min. In this study the inability to raise systolic pressure to more than 120 
mmHg identified a particularly poor prognostic group (three years survival 55%) 11641.
In a recent prospective study, cardiopulmonary exercise testing was of more 
importance than resting haemodynamic data 11651. Resting data ignore the incremental 
prognostic power of the haemodynamic response to exercise 11661 or improvements in 
haemodynamics with therapy, as even those patients with severe chronic heart failure 
who respond have a good prognosis 11671.
Thus, cardiopulmonary exercise testing provides a non-invasive assessment of global 
cardiovascular function, and has a central role in the assessment of subjects with 
chronic heart failure.
1.4.7 Holter Monitoring and Ventricular Ectopy
Ventricular premature beats are common in patients with heart failure. Ambulatory 
electrocardiographic monitoring reveals single ventricular ectopic activity in over 
70% of patients, and nonsustained ventricular tachycardia in 20% of patients. Many 
factors predispose to ventricular arrhythmias in heart failure: underlying structural 
disease, electrolyte abnormalities, neurohormonal changes and, possibly, therapeutic
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interventions (see section 1.2.5). The frequency of ambulant ectopy is related to the 
severity of underlying cardiac function [168], although this is less clear in non­
ischaemic cardiomyopathy 11691. There is considerable intra-individual day-to-day 
variation [170], which further confuses the situation. The most recent data are 
available from analysis of placebo controlled trials of amiodarone in heart failure. 
In the GESICA study 1171], frequent ventricular ectopy and/or couplets did not 
predict death in the study cohort. However, the presence of nonsustained ventricular 
tachycardia (defined as 3 or more ventricular beats at a rate >100 bpm) identified a 
group at high risk of sudden death. This is at variance with previously published 
data. Most studies have found that frequent ventricular ectopy and nonsustained 
ventricular tachycardia indicate a worse prognosis 11721, but are not strong 
independent predictors of sudden death.
1 .4.8 Signal-averaged Electrocardiography
Late potentials on the body surface recorded by applying signal averaging techniques 
to the surface electrocardiogram are a manifestation of delayed, asynchronous 
ventricular activation11731.
Late potentials are predictive of arrhythmic events and SCD in a post myocardial 
infarction population. The first clinical application of the signal averaged ECG was in 
pre-discharge risk stratification after acute myocardial infarction 11741. The definition 
of a positive late potential was qualitative rather than quantitative, but patients with 
late potentials had a sudden death rate of 1 1 % and ventricular tachycardia rate of 17% 
in short-term follow-up. Based on Simson's original work 117S1, subsequent 
investigators have used a quantitative approach. Comparison of the studies is made 
difficult by different standards for acquisition and identification of a positive late
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potential. However, taken together, they demonstrated that ventricular arrhythmias 
and sudden death were more common in patients with a positive late potential. 
Combining the signal averaged ECG with other non-invasive indices of risk, 
particularly left ventricular ejection fraction, improves predictive accuracy 11761. The 
presence of a positive late potential is poorly related to left ventricular ejection 
fraction [17?1. A combination of low heart rate variability and a positive signal 
averaged ECG increased the risk of any arrhythmic events 18 fold in one study 11781. 
However, the positive predictive value of an abnormal signal averaged ECG in this 
patient population remains low, at only 11 to 17% 11791.
The prognostic utility of a positive late potential in patients with non-ischaemic 
dilated cardiomyopathy or advanced ischaemic heart failure is less clear. The 
frequency of bundle branch block and intraventricular conduction delay in this patient 
population makes analysis more difficult 11801. Late potentials are more common in 
ischaemic cardiomyopathy (40% vs 14%) 11811, and in patients who have manifested 
ventricular arrhythmias [182*. Mancini et al 11831 prospectively studied 114 patients 
referred for cardiac transplant assessment with a diagnosis of non-ischaemic 
cardiomyopathy. Sixty-six patients had a normal signal averaged ECG, 20 patients 
had an abnormal signal averaged ECG, and 28 patients had bundle branch block. 
There was no significant difference in clinical, haemodynamic or exercise variables 
between the three groups. One year event free survival (defined as absence of 
ventricular tachycardia or death) was 95% in patients with a normal signal averaged 
ECG, 8 8 % in patients with bundle branch block but only 39% in those with a positive 
late potential. The signal averaged ECG retained prognostic power in multivariate 
analysis. However, a past history of sustained ventricular arrhythmia or aborted 
sudden death was significantly more common in patients with bundle branch block or
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a positive late potential. In patients without a past history of ventricular arrhythmias 
an abnormal signal averaged ECG did not predict death in patients with non­
ischaemic cardiomyopathy although patients with ischaemic cardiomyopathy and 
positive late potential had decreased survival (73% vs 81% one year mortality) ll84]. 
In a recent report (utilising specific criteria for the diagnosis of an abnormal signal 
averaged electrocardiogram in the presence of bundle branch block), the incidence 
of spontaneous sustained ventricular tachycardia was significantly higher in the 
presence of late potentials. However, a positive signal averaged ECG did not predict 
cardiac mortality I1851.
To date, no study has addressed the utility of combining the signal averaged ECG with 
markers of autonomic dysfunction in patients with chronic heart failure.
1.4.9 Neuroendocrine activation
The pathophysiology and time course of neuroendocrine activation in heart failure has 
been described above (see section 1.2.8.1). Neurohormonal activation has been 
recognised as a potential diagnostic, prognostic and therapeutic target.
1.4.9.1 Plasma noradrenaline
Plasma noradrenaline is elevated in heart failure. The predictive value of elevated 
noradrenaline in symptomatic heart failure 11861 was confirmed in a multivariate 
analysis of V-HeFT II ,187]. Plasma noradrenaline correlated poorly with left 
ventricular ejection fraction, peak oxygen consumption or cardio thoracic ratio, which 
were the most statistically significant prognostic variables in V-HeFT II. Mortality in 
patients with plasma noradrenaline > 900 pg/ml was 60% at 3 years, compared with 
25% in patients with plasma noradrenaline <600 pg/ml. A sub study from the SOLVD 
investigators has extended these findings to patients with asymptomatic left ventricular
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dysfunction |18S|. Plasma noradrenaline levels above the median of 393 pg/ml were 
associated with a relative risk of 2.59 for all cause mortality, 2.55 for cardiovascular 
mortality, 2.55 for hospitalisations heart failure, 1.88 for development of heart failure, 
1.90 for ischaemic events and 2.59 for myocardial infarction. These authors concluded 
that "even modest elevations in PNE levels had significant prognostic importance".
1.4.9.2 Natriuretic peptides
Atrial natriuretic peptide was first demonstrated in 1981, although the amino acid 
structure was identified three years later. In 1988 brain natriuretic peptide was 
discovered, although it was subsequently realised that its main source was the cardiac 
ventricles. The ANP pro hormone is cleaved into two fragments: N-terminal ANP and 
C-terminal ANP, which is the biologically active moiety but is less stable and more 
difficult to measure. Collectively, natriuretic peptides produce natriuresis, 
vasodilatation, antagonise the renin angiotensin aldosterone system and have growth 
suppressing actions 11891. Both peptides increase in response to volume expansion and 
pressure overload, cardinal features of cardiac failure. However, ANP may act as an 
acute response hormone while BNP is only activated after prolonged ventricular 
overload 1190).
Natriuretic peptides correlate with the severity of heart failure but are elevated early in 
left ventricular systolic dysfunction, before the development of symptomatic heart 
failure 1821. Plasma BNP may track less closely with left ventricular ejection fraction 
than ANP 11911. In a random sample of the general population investigated by 
echocardiography, a BNP concentration of 17.9 pg/mL or more gave a sensitivity of 
77% and specificity of 87% in the diagnosis of heart failure 111?1. Similar results were 
found in patients referred with a primary care diagnosis of heart failure 11921. Recent
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data did not confirm these findings 11931. Thus, there is a lack of consensus over the 
relation between plasma concentrations of natriuretic peptides and left ventricular 
function, possibly because of confounding factors such as blood sampling 
conditions and the presence of concomitant drug therapy and renal disease. 
However, elevated plasma ANP levels were associated with increased mortality in 
moderate 11941 and severe 11951 heart failure but failed to predict survival in patients 
with asymptomatic left ventricular dysfunction 11881. Circulating levels of brain 
natriuretic peptide are increased in patients with heart failure in proportion to the 
severity of heart disease 11891. Plasma brain natriuretic peptide provides additional 
independent prognostic information beyond left ventricular ejection fraction in the 
acute post myocardial infarction setting 11961, and has been suggested to provide 
similar data in chronic heart failure [19?1.
None of these studies has addressed other measures of autonomic function in chronic 
heart failure, and the data on brain natriuretic peptide and prognosis remain limited. It 
was hoped that this study would help clarify these matters, so in a subset of patients 
natriuretic peptides were measured.
1.4.10 Heart rate Variability
The clinical relevance of heart rate fluctuations was first recognised in obstetric 
medicine when it was noted that foetal distress was preceded by alterations in beat to 
beat intervals not apparent from analysis of heart rate alone ll9Sl. During the 1970’s 
bedside tests of short term changes in RR intervals were used to detect autonomic 
neuropathy in diabetics. Subsequently Wolf et al demonstrated the association of 
reduced HRV (as reduced sinus arrhythmia) and post myocardial infarction
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prognosis |1991. In 1981, power spectral analysis of RR intervals was introduced to 
quantify underlying periodicities in the data l200l
Normal QRS complexes are identified after filtering of artefact and ectopic beats. 
The QRS is used as a surrogate for the P wave (and hence sinoatrial node) because P 
wave identification is more problematic and prone to error. Heart rate variability 
analysis is performed on this sequence of normal to normal interbeat cycle lengths 
expressed as a function of the beat number. This is known as the NN or RR interval 
tachogram. There are two main approaches to the measurement of heart rate 
variability: analysis in the time domain or frequency domain. Time domain analysis 
addresses the amount of variability present, while frequency domain analysis 
elucidates the underlying rhythms.
1.4.10.1 Time domain analysis
Time domain measures may be based on the interbeat duration between normal 
intervals (NN intervals), or on differences between successive NN intervals.
SDNN is the standard deviation of all NN intervals in 24 hours. SDANN, the 
standard deviation of the 5-minute means, provides an estimate of changes in heart 
rate due to cycles longer than 5 minutes. SDNNI, the mean of the 5-minute standard 
deviations, estimates variability of cycle length shorter than 5 minutes. Variables 
based on differences between adjacent cycle lengths include rMSSD (the root mean 
square successive differences) and pNN50. rMSSD is calculated where each 
difference is squared, summed, the result averaged and the square root obtained. 
pNN50 may be expressed as counts, one count being when the difference between 
adjacent NN intervals exceeds an arbitrary limit (for example >50 msec), and when 
the number of counts is divided by the total number of analysed intervals pNN50 may
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be expressed as a percentage. Both measurements record very short term heart rate 
variability and are thought to reflect alterations in autonomic tone that are 
predominantly vagally mediated, (see Table 1-3).
Table 1-3: Definitions of time domain indices of heart rate variability
Variable Units Definition
SDNN msec Standard deviation of all NN intervals in the 24 hour 
recording
SDANN msec Standard deviation of the mean of all NN intervals for each 5 
minute period of the 24 hour recording (cycles >5 min)
SDNNI msec Mean of the standard deviations of all NN intervals for all 5 
minute periods of the 24 hour recording (cycles <5 min)
pNN50 % Percentage of all NN intervals where the differences 
between adjacent NN intervals > 50 msec
rMSSD msec The square root of the mean of the sums of the squares of 
the differences between adjacent NN intervals
SDNN reflects total 24-hour variation, SDANN reflects long term variability, pNN50 
and rMSSD reflect very short term variability, and SDNNI may be thought of as an 
intermediate measure.
1.4.10.2 Frequency domain analysis
Frequency domain analysis is mathematically more complex, and more sensitive to 
artefact. Frequency domain analysis yields information about the variance in heart 
rate resulting from periodic oscillations of heart rate at various frequencies. Strictly 
speaking, to detect possible rhythmicity in the signal mandates absolute stationarity. 
Such conditions are unknown in biology, particularly over 24-hour time period. 
Shorter time sequences may be recorded under controlled conditions that approximate
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stationarity. Across a remarkably wide range of species it appears that the tachogram 
signal contains well-defined rhythms.
There are three main components in short term recordings:
1. high frequency (centre frequency 0.25 Hz = 15 cycles per minute)
2. low frequency (centre frequency 0.1 Hz = 6  cycles per minute)
3. very low frequency (centre frequency 0.016 Hz = 1 cycles per minute)
Demonstration of very low frequency bands mandates at least 15 minutes of data. A 
further band may be demonstrated in data obtained from 24-hour recordings:
4. ultra low frequency (<0.0033 Hz = <0.1 cycles per minute). (See Table 1-4)
Table 1-4: Definitions of frequency domain indices of heart rate variability
Power Spectrum Frequency range Cycles/Time Time/cycle
High frequency 0 .1 5 -0 .4 0  Hz 9 - 2 4  cycles/min 2.5 sec/cycle 
-  6.6 sec/cycle
Low frequency 0 .0 4 -0 .1 5  Hz 2 . 4 - 9  cycles/min 6.6 sec/cycle 
-  25 sec/cycle
Very low 
frequency
0.0033 -  0.04 Hz 0.2 -  2.4 cycles/min 25 sec/cycle 
-  5 min/cycle
Ultra low 
frequency
1.15x1 O'5- 0.0033 Hz 0.2 cycles/min 
-1 cycle/24 hrs
5 min/cycle 
-  24 hrs/cycle
Total power 1.15 x 10'5- 0.40 Hz 24 cycles/min 
-1 cycle/24 hrs
2.5 sec/cycle 
-  24 hrs/cycle
Abbreviation Hz: hertz
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1.4.10.3 Physiological basis for frequency domain analysis bands
High frequency power (HF) reflects parasympathetic nervous system modulation, 
representing primarily respiratory variation. Low frequency power (LF) reflects 
both parasympathetic and sympathetic modulation, possibly representing 
baroreceptor oscillation 12011. The physiological basis of very low frequency (VLF, 
0.0033 -  0.04 Hz) and ultra low frequency power (ULF, 1.15 x 10' 5 -  0.0033 Hz) 
remains unclear, although it has been suggested that they represent the influence of 
the thermoregulatory, peripheral vasomotor and renin angiotensin systems 1202,2031.
However, it is incorrect to consider high and low frequency components of heart 
rate variability as direct measures of autonomic tone. The data supporting LF 
power as a measure of cardiac sympathetic activity is flawed. There is evidence to 
suggest that low frequency oscillations are strongly modulated by parasympathetic 
activity. Manoeuvres designed to block sympathetic nerve traffic have little effect 
on LF power, whereas low dose cholinergic blocking drugs paradoxically increase 
LF power. Surrogate measures of cardiac sympathetic activity such as muscle 
sympathetic nerve traffic or cardiac noradrenaline spillover have poor correlation 
with LF power. Evidence favouring HF power as a marker for cardiac 
parasympathetic activity is stronger. There is evidence that the high frequency 
component of muscle sympathetic nerve variability is positively and tightly 
correlated with the high frequency component of NN interval variability 12041. In 
an animal model efferent vagal activity correlated strongly with HF power. HF 
power can be abolished by high dose atropine in humans. Changes in HF power 
are strongly influenced by respiratory frequency 12051, being 1 0  fold greater at 
slower breathing frequencies. This differing response to varying respiratory 
frequencies may simply reflect the kinetics of sinoatrial node response to
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acetylcholine 12061. Therefore, there is little evidence that HF and LF power 
correspond to actual levels of nerve traffic. The ratio of low to high frequency 
power (LF/HF) has been suggested as a marker of sympathovagal balance. During 
graded upright tilt, muscle sympathetic nervous traffic and myocardial 
noradrenaline spillover increase, as does the LF/HF ratio. Most of this change is 
due to a progressive reduction in high frequency power rather than an increase in 
absolute low frequency power. Finally, it should be remembered that there is no 
physiological need that the level of sympathetic and parasympathetic nervous 
system activity be balanced, and certainly no physiological evidence that 
fluctuations of sympathetic nerve traffic and parasympathetic nerve traffic 
constantly interact 12071.
1.4.10.4 Stability of heart rate variability measures
Heart rate variability measures increase with time after myocardial infarction 12081. 
There is continued debate whether heart rate variability is altered by chronic, 
uncomplicated coronary disease I209’21°l. There is a paucity of data on the stability 
of heart rate variability over time. In one study of 17 patients with clinically stable 
NYHA II-III chronic heart failure |2n|, 24 hour-Holter measures were obtained at 
baseline and 2 weeks later. Group means and standard deviations were virtually 
identical, and intraclass correlation coefficients for nearly all time and frequency 
domain measures were > 0.8, better than repeat measures of noradrenaline. Thus, 
within group (i.e. NYHA class) and inter-individual measures were stable over this 
short time period. In a community based study of healthy individuals, short term 
measures of heart rate variability were found to be highly reproducible 12121.
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1.4.10.5 Prognostic value of heart rate variability measures
Despite the caveats regarding the underlying pathophysiological significance of 
various heart rate variability measures, there is growing evidence regarding their 
prognostic importance.
Early research on heart rate variability focused on post myocardial infarction 
patients. Using sinus arrhythmia as a marker of heart rate variability, Schneider 
and Costiloe 12131 demonstrated that sinus arrhythmia was depressed in patients 
with acute myocardial infarction. Wolf et al reported that in patients with acute 
myocardial infarction who lacked sinus arrhythmia the in-hospital mortality rate 
was 15.5% compared with 4.1% in patients with retained sinus arrhythmia 11991. 
Later studies showed that decreased heart rate variability correlated with 
established post myocardial infarction risk factors such as Killip class, peak 
creatine kinase and left ventricular ejection fraction 12141. Subsequently, depressed 
heart rate variability has been shown to be a powerful multivariate prognostic 
indicator in patients with acute myocardial infarction. Analyses have included 
established prognostic indicators such as age, NYHA class, clinical evidence of 
pulmonary oedema in the CCU, left ventricular ejection fraction and ventricular 
arrhythmias on 24 hour Holter monitoring. Heart rate variability (measured as 
SDNN) less than 50 milliseconds carried a 5.3 fold increased mortality compared 
with a group with SDNN >100 milliseconds 1215). Although thrombolysis shifts 
“cut points” upward, the independent relative risk of depressed heart rate 
variability is maintained 12161.
That heart rate variability is diminished in chronic failure was demonstrated 
decades ago 1941. Saul et al. 12171 confirmed markedly reduced time and frequency 
domain measures of heart rate variability in patients with severe heart failure when
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compared to controls. Heart rate variability measures correlate with left 
ventricular ejection fraction, although there remains debate regarding the tightness 
of correlation between heart rate variability and established clinical and 
haemodynamic indices of severity I218*2191. However, heart rate variability is 
closely and negatively linked to the degree of a sympathoexcitation measured by 
noradrenaline levels or muscle sympathetic nervous activity 12181.
There is little correlation between depression of heart rate variability and 
surrogates for arrhythmic death such as the extent and severity of ventricular 
arrhythmias 12201. Small retrospective studies have addressed the prognostic utility of 
heart rate variability in dilated cardiomyopathy 1221,2221 0r chronic heart failure 1223-2261 
due to both ischaemic and non-ischaemic aetiologies. Despite different analysis 
techniques and patient characteristics, most have documented that heart rate 
variability measures independently identify patients at greatest risk of 
cardiovascular death. When both time and frequency domain analyses have been 
performed, spectral measures appear to add little prognostic information to that 
provided by simple time domain measurements. In a manner analogous to the 
acute myocardial infarction studies, overall variance (SDNN or total power) 
provides the greatest prognostic information. Most data suggest that depressed 
heart rate variability is correlated with clinical and haemodynamic indices of heart 
failure severity, but that it can still provide independent prognostic information. 
The total number of deaths in these studies is small, and some investigators found 
that none of the conventional time and frequency domain measures were related to 
survival 12241. However, a recent large study has confirmed that patients with low 
values of SDNN constitute a particularly high-risk group 11501.
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1.4.11.1 Techniques of assessing baroreflex function
Various techniques have been used to study arterial baroreflexes. Carotid sinus 
massage has been used for centuries, and was used in primitive medicine to induce 
unconscious. It is still used as a means of terminating supraventricular tachycardia 
and for diagnosis of carotid sinus hypersensitivity. Although the baroreceptor 
stimulation produced by massage is very strong, it is neither precise nor 
reproducible enough for research studies of baroreflex impairment. Electrical 
stimulation of carotid nerves was first performed in 1958, and was subsequently 
used for the treatment of supraventricular tachycardia, hypertension, and angina. 
Electrical nerve stimulation using an implantable device is now an accepted 
procedure for refractory angina. Although reproducible, it is invasive, recruits all 
baroreceptor and chemoreceptor fibres simultaneously and augments ventilation so 
that the cardiovascular effects are non-physiological and represent the sum of 
opposing influences. Surgical denervation of the carotid nerves is obviously non- 
ethical although some earlier workers produced similar results by anaesthetising 
the carotid sinus with local anaesthetic agents. Apart from the possibility of major 
complications, the technique also affects chemoreceptor fibres, and it is difficult to 
assess the completeness of baroreceptor blockade. Occlusion of the common 
carotid arteries inhibits carotid baroreceptors, and has been used in anaesthetised 
and conscious animals. Almost unbelievably, it has been reported in humans! 
Roddie and Shepherd trained subjects to compress their own carotid arteries 
against the cervical column. As has been pointed out, "there are obvious 
limitations to the occlusion method".
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The two ways of assessing baroreflex impairment in current practice are the variable 
pressure neck chamber or the use of vasoactive drugs. The bradycardia caused by 
pressure induced baroreceptor activation may be used to quantify baroreflex function. 
Two methods have been proposed: incremental bolus injections of phenylephrine until 
a satisfactory hypertensive response is seen 12271, or a ramp method of increasing 
infusions until a steady state is achieved 12281. Baroreflex sensitivity may also be 
assessed by off loading the baroreceptors using arterial or venous vasodilators. 
Generally, values obtained by ramp infusions of phenylephrine or vasodilators are less 
than those obtained by bolus injection phenylephrine. The advantages of using 
vasoactive drugs are that the stimulus is physiological, the technique is safe and easy 
to use, and subjects are unaware of the stimulus. That the heart rate responses are 
neural is confirmed by the fact that they are absent in denervated hearts and reduced 
or abolished when the pressure changes are prevented. Limitations of the technique 
include limited reproducibility (which may reflect unavoidable spontaneous central 
modulation of baroreflex control) and simultaneous stimulation of cardiopulmonary 
baroreceptors, although carotid stimulation predominates. However, this latter may be 
seen as an advantage, acting as a global asssessment of baroreflex function.
A number of investigators have attempted to analyse baroreflex sensitivity from 
spontaneous fluctuations in heart rate and systolic arterial pressure 12291. Local 
baroreflex sensitivity is calculated by performing multiple linear regression slopes on 
sequences of intervals that demonstrate 3 successive increases (or decreases) in 
systolic pressure and NN interval. Baroreflex gain is defined as the cross-spectral 
gain of the NN and SAP power spectra where coherence is >0.5. Spectral 12301 and 
linear sequence 12311 methods correlate highly with baroreflex sensitivity calculated 
from phenylephrine slopes in control subjects without evidence of cardiovascular
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disease. However, in post myocardial infarction patients the phenylephrine technique 
allows assessment of baroreflex sensitivity where the non-invasive methods cannot, 
particularly in patients whose baroreflex sensitivity is depressed 12321.
1.4.11.2 Factors modifying baroreflex control
Baroreflex sensitivity is inversely related to age, and declines more rapidly over the 
age of 65 12331. Mental stress and exercise diminish the effects of baroreflex 
stimulation on heart rate, a phenomenon that may be postulated as a link with sudden 
death in these situations. Baroreflex sensitivity increases during sleep, and there is 
evidence to suggest a circadian variation in baroreflex sensitivity. Baroreflex 
sensitivity is decreased in hypertension and a number of cardiac disease states 1941.
The location of the defect altering baroreflex sensitivity in patients with cardiac 
disease is unclear. The abnormality may be localised to the afferent limb, involve 
abnormal central integration, or involve defects in the efferent limb. All three areas 
may be involved. Single-unit baroreceptor activity measured from vascularly isolated 
carotid sinus from dogs with pacing induced heart failure provides insight into the 
potential abnormalities. The threshold pressure for baroreceptor activation was 
higher; there was a decreased baroreceptor gain (i.e. change in baroreceptor discharge 
rate to change in arterial pressure); and the peak baroreceptor discharge rate was 
decreased compared to controls. Digoxin partly normalised these abnormalities, 
suggesting that augmented Na+K+ATPase could be implicated in baroreceptor 
dysfunction 12341. However, in a different study, central integration of the afferent 
impulses appeared to be preserved. Central gain (defined as the ratio of efferent renal 
sympathetic nerve activity to afferent aortic depressor nerve activity) appeared 
unimpaired or even increased. However, it should be noted that baroreceptor
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modulation of efferent sympathetic nerve activity may be normal when baroreceptor 
control of heart rate is abnormal12351.
1.4.11.3 Prognostic role of baroreceptor function
Baroreflex sensitivity provides prognostic information in cardiac disease. Interest was 
first stimulated by a seminal paper using a myocardial infarction model in dogs 12361. 
Myocardial infarction depressed vagal reflexes, and those dogs demonstrating the 
greatest depression of baroreflex sensitivity were most likely to develop ventricular 
fibrillation during a further episode of myocardial ischaemia. Conversely, those 
animals with preserved baroreflex sensitivity were less likely to develop ventricular 
fibrillation under similar circumstances.
Clinical studies of baroreflex sensitivity in myocardial infarction have addressed 2 
major issues: the time course of recovery and its prognostic value. There is an acute 
depression of baroreflex sensitivity following myocardial infarction, and in most 
studies values returned towards normal within one to three months 12371.
In an pilot study of 78 post infarct patients, depressed baroreflex sensitivity provided 
independent prognostic information: annual mortality was 3% in patients with 
baroreflex sensitivity > 3 msec/mm Hg, but rose to 50% in those with baroreflex 
sensitivity <3 msec/mmHg 12381. In this small study baroreflex sensitivity did not 
correlate with left ventricular ejection fraction, and in those patients with depressed 
left ventricular ejection fraction mortality was increased if there was co-existent 
depression of baroreflex sensitivity. Subsequently, depressed baroreflex sensitivity 
post myocardial infarction was also associated with inducibility of sustained 
ventricular tachycardia at electrophysiological study 12391, and the development of 
future arrhythmic events 12401. A recent large multicentre study has confirmed these
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findings 12411. Depressed heart rate variability or baroreflex sensitivity carried a 
significant multivariate risk of cardiac mortality (hazard ratios 3.2 and 2.8 
respectively).
At the time of the grant proposal for this study, evidence linking baroreflex sensitivity 
with prognosis in patients remote from myocardial infarction was scarce. In a case- 
control study of patients remote from myocardial infarction with and without 
ventricular arrhythmias no difference was found in any frequency domain measure of 
heart rate variability. However patients with ventricular arrhythmias had a 
significantly lower baroreflex sensitivity (4.2 ± 0.5 vs 8.0 ± 1.1 msec/mm Hg) 12421. A 
small study (n=35) of patients with mild moderate heart failure demonstrated that a 
low baroreflex sensitivity (assessed by neck suction) correlated with a poor prognosis. 
However, in a multivariate model including haemodynamic indices and plasma 
noradrenaline baroreflex sensitivity did not provide independent prognostic 
information 12431. More recent data is discussed in Chapter 4 (see section 
4.3.2.6 Baroreflex sensitivity)
1.4.12 QT Dispersion
1.4.12.1 Genesis of the T wave
The history of the QT interval began in 1856 went two German physiologists 
ingeniously attached a frog sciatic nerve to the surface of the ventricle and observed 
contraction of the gastrocnemius muscle immediately preceding systole. Occasionally 
they observed a second twitch at the beginning of diastole, and thus were the first to 
demonstrate that there were two major voltage deflections during each ventricular 
beat. Subsequently, Burden-Sanderson and Page used a capillary electrometer to 
obtain continuous records of potential changes in the frog heart, demonstrating a
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biphasic deflection. They elegantly obtained monophasic action potentials using 
heated electrodes, and demonstrated that the duration of electrical excitation in the 
tissue did indeed last 1.5 seconds, and that spatial variation in action potential duration 
was responsible for the negativity of the T wave (see Figure 1-4). Other investigators 
confirmed these findings and it was felt that the shape of T wave reflected action 
potential duration differences between the base and apex of the ventricle 12441. Recent 
data suggests that the T wave is secondary to electrophysiological heterogeneity 
across the ventricular wall, with major distinctions in action potential characteristics 
between epicardium and endocardium 12451.
1.4.12.2 QT dispersion: clinical and methodological aspects
There was little clinical interest in the QT interval until 3 reports linking 
prolongation of the QT interval with sudden death 1246-2481. Subsequent 
investigators correlated a prolonged QT interval with risk of cardiovascular death 
in a normal healthy population, ischaemic heart disease, post myocardial 
infarction, diabetic neuropathy and patients presenting with ventricular 
arrhythmias despite structurally normal hearts 12491. Two major limitations in the 
use the QT interval heart are determining the end of the T wave and correcting the QT 
interval for heart rate.
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Figure 1-4: The first recorded monophasic action potential (after re f239)
a) monophasic action potential
b) \ surface electrocardiograms
c) >
This record demonstrated that the duration of the cardiac action potential was long, 
about 1.5 seconds in the frog, and could thus acount for the negative voltage 
deflection of the T wave. See section 1.4.12.1 for details.
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That spatial variation in the QT interval of the 12 lead electrocardiogram could 
provide important information regarding arrhythmia risk was first suggested in 1990 
in a seminal report by Day et al 12501. This variation had been commented on 
previously, although its significance was unrecognised 1251 ]. The surface 
electrocardiographic QT interval reflects complex and interrelated aspects of cellular 
electrophysiology, cardiac geometry, torso shape, thoracic impedance and signal 
processing 12521. There are 2 assumptions: the end of the surface electrocardiographic 
QT interval is a surrogate for the end of ventricular repolarisation, and that spatial 
variation in surface electrocardiographic QT intervals measure the known underlying 
heterogeneity of ventricular repolarisation 12531. This latter assumption is supported by 
little evidence. In an isolated heart study, total T wave area and T peak to T end 
interval correlated more significantly with monophasic action potential duration than 
did QT interval 12541. However, monophasic action potentials measured during cardiac 
surgery correlated strongly with surface QT dispersion for both sinus and paced beats 12551.
There is still no accepted standard for QT dispersion measurement. QT dispersion has 
been measured by photocopy magnification, using digitising pads, and by automated 
or computer interactive techniques. The problem of the definition of the end of the T 
wave remains more important than the method used 12521. Manual measurements of 
QT intervals are affected by paper speed and amplifier gain 12561, but automated 
measurements fair no better 12571. Intra-observer variability has been documented at 
about 8  milliseconds [2581, but inter-observer reproducibility is worse 12591. 
Fundamental electrocardiographic theories should also be taken into account: 
information contained in limb leads is redundant in that if any of 2  of the 6  of 
recorded, the other 4 may be calculated. Additionally complete information regarding 
electrical activity is contained only in the vectorcardiogram. If the last 40
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milliseconds of ventricular repolarisation is negative in lead I, and equally positive in 
lead II, then there would be no electrical activity in lead III creating a spurious QT 
dispersion of 40 milliseconds 12601. Therefore, QT dispersion measured in the frontal 
plane derived from only 2  leads is unlikely to provide information on local electrical 
repolarisation.
There is now a growing literature devoted to the prognostic utility of QT dispersion. 
It is a marker of arrhythmia risk post myocardial infarction I2611, in congenital long QT 
syndromes 12501, in patients with documented ventricular arrhythmias 12621, and in 
hypertrophic cardiomyopathy 12631 (see Table 1-5). Subsequent reports suggested that 
QT dispersion could be used for prognostic assessment in patient populations at high 
risk of cardiovascular death such as peripheral vascular disease 12641 and non-insulin- 
dependent diabetes mellitus 12651. However, a recent large study using the best 
available methodology (previously validated against monophasic action potential 
duration 12541) failed to demonstrate prognostic significance of any measured QT 
variable post myocardial infarction 12661.
1.4.12.3 QT dispersion in chronic heart failure
The prognostic utility of QT dispersion in chronic heart failure remains unclear. There 
are data supporting I267'2691 and refuting its use [270’271l (see Table 1-6).
In the first reported study, Barr et al. characterised 44 patients suffering from severe 
chronic heart failure. Left ventricular ejection fraction was lower, and plasma 
neurohormones higher in patients who died of progressive heart failure (n = 1 2 ), but 
only QT dispersion was significantly different between survivors and those who died 
suddenly (n = 7). Exclusion criteria were not stated, although no patient was on 
antiarrhythmic drug therapy. The small number of events and flawed statistical
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methodology dilutes the significance of these findings.. Subsequently, in 163 patients 
with left ventricular dysfunction (126 ischaemic) prolonged QTc had a 94% 
sensitivity and 92% specificity in identifying subsequent sudden death, and was the 
most important multivariate predictor of survival 12691. Exclusion criteria included 
atrial fibrillation and antiarrhythmic drug treatment, but not bundle branch block. 
There were 24 sudden deaths, 10 patients experienced ventricular tachycardia, and 19 
died from pump failure. The cut-off value for JTc dispersion was 85 milliseconds, 
giving a 74% positive and 98% negative predictive accuracy in identifying patients at 
risk of sudden death or ventricular tachyarrhythmia. Over a quarter of patients at 
study entrance had JTc dispersion > 85 msec, and 76% of these died suddenly or 
experienced a ventricular tachyarrhythmia. In comparison, a study of 80 more 
severely ill patients awaiting transplantation (including ischaemic and non-ischaemic 
aetiologies) reported that a QT dispersion > 140 milliseconds carried a 4.1 relative risk 
increase in all cause mortality, but did not predict sudden death. There were 14 
cardiovascular deaths in total. However, 17% of patients were in atrial fibrillation, 
31% were receiving antiarrhythmic therapy and 50% had bundle branch block. Data 
from patients with idiopathic dilated cardiomyopathy have been even less 
rewarding 1270,271 These 2 reports documented that QT dispersion was increased in 
DCM, and that there was a greater increase in patients with bundle branch block and 
those who had subsequent arrhythmias. However, the large overlap between values 
precluded clinically or statistically significant differences.
These data would suggest that the pathophysiological significance, confounding effect 
of bundle branch block and prognostic role of QT dispersion in patients with chronic 
heart failure remain unclear.
>
CT*
SfCB<
£* X  
S' Q
f
I
*§
c t *o’0ES
&*.
1
PSS'v:
E*
CT
<z> O CB S3
GO <  
DO H 
CO ,
I <
S  s5 r^6  o' o P
£f 3
§ p
S* tS « o £?9r B:
§“
aCT*
o
?c 
0  —t
3’
03
Sporton
G
lancy
Higham
Pye
Buja
Linker
Day
1—»VOvo
00
1997
1995
1995
1994
1993
1992
1990
nfaCOCD
npco0
0pco0
0pcoCD
OpCOCD
OpCOcd
0pCO0
OpCOa>
OO
a
0
03
0
0
a
0
0
a
OO5.
0
0
a
0
03
0
0
3ftO ft0 ft0 ft0 ftO ft0 ft0 •t0
VF 
survivors
fH MI deaths
MI vs U
A
V
T
HCM 
+/- V
F
Long 
QT 
vs control
Long 
QT 
vs Sotalol
50 OO
163 vyi
57 26 vo 0
BBB/A
F
BBB/A
F
none
unclear
BBB/A
F
unclear
unclear
unclear
M
anual (50)
M
anual (50)
Interactive (25)
M
anual (50)
M
anual (*4)
M
anual (25/50)
M
anual (*4)
M
anual (50)
44 44 94 38 32 43 45 60
Ui
82 94 66 77 i—*
u>
i—*
0 0
3A
0
*3AO g
'TOAO
3AO
*3AO
3Ap
3A
0
0 OO OI—* O OO 0 00
01—1
>c
-<
0
0
*<■u
0
0
000
0
9 * to
2"
0"o
0
mxo
0
o’3
0
I-*7oQ.
VO
D O 
H  O
O
D D
« w Q. q0
0
0
Table 
1-5: Associative studies of 
QT 
dispersion
>CT*
sro3v:o s- o CT'$ B
C L  ca
E o
Bi 5^  iB. g.s  ^
p I.o
c t *CD
H
ao
S
CDClO
a
§
ls
c t *v;
T3Si
t
«p
<03
CA
s
ao
CT
Bi
5 '
cw
CL
* s
sCL
s
CO
CT*CD
Z
abel
N
aas
Pinsky
Fu Grim
m
D
arbar
Fei
B
arr
A
uthor
S OsoO O
S O
S O
O O
S Oso- o
S Oso
- o
so
S Oos
soso
O s
i— »so
S O
O S
S O
S O- t L
(D
f l )■n
►d
300
8
&
►d
300
8C/3cH-
► d
300
8CA*—
►d
300
8CAr-K
" d
300
8CAr-K
►d
300
8
a
h d
300
8
a
► d
300
8CAr-t-
H
» <■o
©
o * o ‘ o' o' o' S’ o' o'
M
I
N
ID
D
M
C
H
F-both
C
H
F-both
CH
F-D
CM
PV
D
CH
F-D
CM
CH
F-both
D
isease
280
182
80 p— »O Su >
107
49 135
44 Subjects
(n
)
30 not given
1— k
4 ^
59 t—at o h—kt o h—k■ o H-kV O
Events
(n
)
Not stated
Not stated
none
none
A
F/D
rugs
CAD
BBB/A
F
none
Exclusion
HH
BCD»-t
8<—►
£p
B
sp
B
P
sp
BP
I
I 1I
s
1
£
pg
M
ethod
I
c o
3
T o
c /»
73O) C /3o C /3© T o0 3 T 3c /» T ocy>
O n 78 
(cut pt)
85 54 60 56 62 53 Alive
Q
Td
65
h o
95*
76 86 67 soO O
*
C
ardiovascul
Q
Td
s
not given
p<0.005
Ap
oo S3CA
p<0.002 3CA
ds
Ap
ooo
&>
Q .
CDft)
r+
3 "
!?
a *
►»*■
Os
I
8
&03*<*.
a
S :
S
tO
I
a
o
a
n
ato
Z
I
Iri
§
SO
t o
Ch a pte r  1: In t r o d u c t io n - 9 3 -
1.4.13 Summary
For over 5000 years, continuing advances in anatomy, pathology and physiology have 
allowed identification of the heart as the cause of cardiac failure. It is now recognised 
that heart failure is a common clinical disorder characterised by abnormal ventricular 
function associated with neuroendocrine dysregulation, autonomic dysfunction and 
symptoms of breathlessness, fatigue and effort intolerance. It is highly prevalent, 
affecting 1% of the population over age 50, rising to 10% of those aged over 80. Over 
the last decade it has become increasingly common, and in conjunction with the 
ageing population is a major public health burden in developed countries. Symptoms 
are related more to ventilatory and skeletal muscle abnormalities than to central 
haemodynamics, and clinical signs may be masked by treatment. Thus the clinical 
history and examination are poorly discriminatory in defining the severity of 
underlying cardiac dysfunction. Cardiac injury leads to a loss of effective myocyte 
mass, with compensatory salt and water retention, neuroendocrine activation and 
cardiac hypertrophy. These processes cause “remodelling”, and if unopposed, 
progressive left ventricular dilatation. Abnormalities of calcium handling and 
ventricular repolarisation associated with hypertrophy combine with autonomic 
dysfunction to predispose the failing heart to ventricular arrhythmias, an important 
cause of death in heart failure.
The socio-economic burden of chronic heart failure is enormous: it has been estimated 
at 1-2 % of the total health care budget, of which two thirds is accounted for by 
inpatient care. The more severe the heart failure, the greater the cost. Thus, chronic 
heart failure is a common, growing and major public health care burden l1211. 
Identifying high-risk patients suitable for aggressive intervention, optimisation of
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treatment and prevention of death is of great importance. Despite extensive study by 
many investigators, identification of those patients who are most likely to deteriorate 
and die remains difficult. Whilst many features are predictive of prognosis in 
populations, their clinical utility in an individual setting is less clear. Clinical, 
exercise, echocardiographic and haemodynamic variables are known to carry 
prognostic information, but accurate identification of those most likely to die remains 
difficult.
The aim of this work was to determine the prognostic significance of abnormalities of 
ventricular repolarisation, autonomic dysfunction and neuroendocrine activation in 
chronic heart failure.
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2 METHODOLOGY
2.1 R ecruitm en t  and  S cr een in g
Patients were recruited from medical/cardiology wards, outpatient departments and 
echo clinics of Glasgow Royal Infirmary and the Western Infirnary.
Patients were screened:
if they had been admitted with undiagnosed breathlessness or with a diagnosis 
of heart failure,
if they had a previously documented admission with a diagnosis of heart failure, 
if they had been referred for assessment of breathlessness/heart failure or 
if they were found to have documented left ventricular systolic dysfunction at 
angiography, radionuclide ventriculography or echocardiography.
One experienced observer screened all patients. Because of the limited reliability of 
physical signs in the diagnosis of heart failure l272'27S|, the following features were 
used as a guideline for the diagnosis of heart failure [34)
Symptoms of heart failure: breathlessness, fatigue or exercise intolerance 
Clinical signs of heart failure: a third heart sound, basal crepitations, elevated 
jugular venous pressure, peripheral oedema and alteration of signs induced by 
diuretic therapy
Radiological: cardiomegaly, pulmonary venous congestion/pulmonary oedema 
Objective evidence of left ventricular systolic dysfunction determined by 
echocardiography or radionuclide ventriculography (LVEF <40%).
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The major inclusion criteria were currently or previously documented objective 
evidence of left ventricular systolic dysfunction with stable chronic heart failure. 
Stable chronic heart failure was defined as heart failure outside the context of recent 
myocardial infarction with no change in symptoms, signs or diuretic dosage for four 
weeks before the study protocol.
The following exclusion criteria were applied: 
age greater than 75 years
uncontrolled hypertension (defined as >170/100 mmHg) 
atrial fibrillation 
permanent pacemaker
recent myocardial infarction or unstable angina (< 6  months)
previously documented ventricular tachycardia or ventricular fibrillation
outside the context of acute myocardial infarction
chronic renal failure (defined as serum creatinine > 2 0 0  pmol/1)
longstanding diabetes mellitus
any co-morbid disease likely to lead to significant mortality within two years.
Age over 75 years, hypertension, longstanding diabetes, chronic renal failure and 
autonomic impairment are associated with blunted cardiovascular reflexes, disturbing 
the assessment of baroreflex sensitivity and heart rate variability. Chronic atrial 
fibrillation precludes measurement of heart rate variability or baroreflex sensitivity.
2.2 E th ic a l  C o n s id e r a t io n s
The study received ethical approval from the Ethics Committees of Glasgow Royal 
Infirmary and the Western Infirmary.
C h a pter  2: M eth o d o lo g y  - 97 -
The same physician (A M-D) recruited all patients. After initial contact and a verbal 
explanation, patients were invited to attend for study. If they agreed, contact 
information was obtained, and an appointment arranged by telephone or letter. This 
was then confirmed in writing, and on attendance for the study protocol informed 
consent was obtained (see Appendix A). Patients could decline or withdraw from any 
part of the study protocol at any point. Informed consent included provision to review 
hospital and community medical records in the future.
2.3 C l in ic a l  A s s e s s m e n t
Following screening, a full explanation of the study was given to all eligible patients. 
In those who offered to take part, the same observer obtained informed consent. If 
subjects were outpatients with stable heart failure (see above) they were studied as 
soon as practicable. Patients recruited from wards were studied at earliest 4 weeks 
from the index admission. All patients continued their normal medication before the 
and during the study period.
2.3.1 Symptoms
Patients were stratified by New York Heart Association functional class based on 
responses to standardised questionairres. All subjects completed a questionnaire 
giving demographic details, current medication, a history of physician diagnosed 
myocardial infarction, angina, or diabetes mellitus and their smoking status (current, 
never or ex). They also completed 2 general health questionnaires: the Nottingham 
Health Profile and the SF36, in addition to a disease specific questionnaire: the 
Minnesota "Living with Heart Failure" questionnaire 12761 (see Appendix B) which has 
previously been validated as an accurate and reproducible tool. This consists of 21 
questions, each of which assesses the patient’s perception of how his or her emotional
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or physical state is impaired by heart failure. The answer to each question ranges 
from 0 (no impairment) to 5 (severe impairment). Questions 2 (needing to rest during 
the day), 3 (walking and climbing stairs), 4 (housework), 5 (going away from home), 
6  (disturbance in sleep pattern), 7 (doing things with others), 1 2  (dyspnoea) and 
13 (fatigue) focus primarily on physical limitation. These were combined to give a 
score for physical limitation. Other questions focus primarily on emotional limitation.
2.4 E l e c tr o c a r d io g r a ph y
2.4.1 Resting 12 Lead ECG
Patients were studied in the resting, supine, post-absorptive state. A 12 lead ECG was 
recorded on a Siemens Megacart R (Siemens Elema), computer analysed and the 
analysis confirmed by one experienced observer. Rate, rhythm and evidence of 
previous myocardial infarction, left ventricular hypertrophy, conduction defects or 
ST/T wave changes were documented. Left atrial strain was determined by computer 
algorithm and manually checked ( P wave >0.12 seconds, bifid P wave in lead I/II, ± 
negative terminal P wave in lead VI).
2.4.2 QT Measurements
The Siemens Megacart R records all 12 leads simultaneously, so removing 
temporal variation errors in QT dispersion measurement. There is no accepted 
standard methodology for QT dispersion measurement, although some authors 
have examined the intra and inter-observer errors associated with various paper 
speeds and gain settings 12561. For these reasons, a pragmatic decision was taken to 
analyse all ECG tracings at standard paper speeds of 25mm/sec and gain of 
lOmm/mV -  a technique which had been reported to provide prognostic 
information in patients with heart failure 12671.
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The hard-copy ECG format chosen for analysis allowed 3 successive complexes to be 
analysed in each lead. The following points were digitised on each lead:
P wave onset 
QRS onset 
QRS end 
T wave peak 
T wave end
In leads where the T wave was not clearly visualised, no measurement was made. No 
ECG was analysed if less than 8  leads were analysable.
The following T wave morphologies were recognised 12771:
Inverted T waves 
Biphasic T waves 
Humped T waves 
U waves
In the presence of these T wave morphologies, the nadir of the T-U wave or the return 
of the T wave to the isoelectric line was chosen to represent the end of the T wave. 
Measurements were performed on all 12 leads, and QT dispersion calculated from all 
available leads, and then on a separate analysis on only the chest leads. This has been 
suggested to be less dependent on intra/inter-observer variability whilst providing 
similar information.
The data were manually analysed using a high resolution digitising pad (Drawing 
Board 3, Calcomp Corporation) and a software package made available by the 
Department of Academic Cardiology, Freeman Hospital, Newcastle upon Tyne. This
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software had been extensively validated in prior studies 12781. Subsequent data 
manipulation and analysis was performed in Microsoft Excel.
Table 2-1: QT measurement definitions
QT measure Definition
QTend QT measured to end of T wave
QTpeak QT measured to peak of T wave
QTend max maximum QT measured to end of T wave
QTend min minimum QT measured to end of T wave
QTpeak max maximum QT measured to peak of T wave
QTpeak min minimum QT measured to peak of T wave
QTend dispersion maximum QTend minus minimum QTend
QTpeak dispersion maximum QTpeak minus minimum QTpeak
Coefficient variation standard deviation of QT variable/mean of QT variable
2.4.3 Signal-Averaged Electrocardiography
A signal averaged ECG was acquired according to the Joint Task Force Committee 
standards 12791. The patient’s skin was cleaned thoroughly with alcohol and abraded to 
provide excellent contact. A Frank orthogonal 3 lead XYZ lead set was used for 
acquisition. Two to three hundred successive QRS complexes were recorded. The 
signals were amplified, band pass filtered (low band pass 40 Hz, high band pass 250 
Hz), and AD converted. A QRS template was chosen, each successive beat compared 
and aligned with this template, and sequential beats averaged. As noise is random, 
signals that repeat on a beat to beat basis will remain, while noise averages to zero. 
Acquisition was terminated when a predetermined noise level was reached. Each lead
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was further amplified and filtered, and the vector magnitude calculated from the 
filtered XYZ leads using the formula (X2 + Y2 + Z2)1/2. The QRS onset and offset 
were then identified, allowing determination of QRS duration (QRSd). Two further 
measurements are obtained by analysis of the last 40 milliseconds of the QRS 
complex. These were the root mean square voltage of the terminal 40 milliseconds 
(RMS 40), and the duration of low amplitude signal under 40 pV (LAS40). A late 
potential appears as low-level "tail”: a low RMS 40 and long LAS40 describe a low- 
level "tail”. The abnormalities described in the above section on basic 
electrophysiology all contribute to delayed ventricular conduction which may 
manifest as a late potential and positive signal averaged ECG. Thus the signal 
averaged ECG noninvasively assesses conduction delay in sinus rhythm.
Criteria for the definition of a late potential are outlined below (Table 2-2). Bundle 
branch block and intraventricular conduction delay are common in the ECG’s of 
patients with heart failure, and alter the predictive value of a late potential defined by 
normal criteria. Patients with bundle branch block were prospectively analysed using 
the criteria below 11801.
Table 2-2: Definition of a positive Signal-Averaged ECG
Filtered QRSd RMS40 LAS40
(msec) (pV) (msec)
Normal conduction >114 < 2 0 >38
Bundle branch block >145 <17 >55
RMS40 : root mean square voltage of the terminal 40 msec of the filtered QRS;
LAS40 : the duration of low amplitude signal under 40 pV.
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2.5 C a r d io p u lm o n a r y  E x e r c is e  T e s t in g
2.5.1 Test Protocol
All exercise test were performed using the same equipment and were supervised 
by the same physician and one of two technicians. Testing was carried out in an 
air conditioned exercise laboratory under standardised conditions.
Patients able to exercise underwent symptom limited, maximal cardiopulmonary 
treadmill exercise testing using a standardised exponential workload protocol 12801. 
This is suitable for heart failure patients, and has a validated normal range from 
2000 randomly chosen age and sex stratified subjects from the North Glasgow 
population. Most subjects were familiar with treadmill exercise testing, but a 
short demonstration was given before the test. Patients were allowed to 
familiarise themselves with treadmill walking and breathing through the 
mouthpiece of the gas analysis system. Before commencing the test, they were 
instructed in the use of standardised hand signs to allow communication once the 
mouthpiece of the gas-exchange analyser was in place.
Patients were allowed one minute to acclimatise. Heart rate and 12 lead 
electrocardiograms were monitored continuously using a Siemens Megacart R 
with a dedicated exercise ECG module, and hard-copy 12 lead ECG’s recorded 
during the last 10 seconds of each stage, and at 1 minute and 3 minutes of the 
recovery stage. Blood pressure was measured manually every 3 minutes, and 
immediately after cessation of exercise. Gas exchange data were collected 
continuously at rest and during exercise using an automated breath by breath 
system (Medical Graphics Corporation, St Paul, Minnesota). A clamp was 
placed on the nose, and the patient breathed through a mouthpiece connected to a
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non rebreathing valve. Expired airflow, O2 and CO2 were respectively measured 
using a pneumotach, a zirconia cell O2 analyser and an infrared CO2 analyser, all 
connected to a dedicated PC. The gas exchange analyser was calibrated before 
every session with precise reference gases corrected for barometric pressure, 
ambient temperature and humidity. Rapidly responding O2 and CO2 analysers 
linked to a portable computer allowed O2 and CO2 to be monitored on a breath by 
breath basis. By also measuring respiratory air flow, VO2, VCO2, VE, were 
estimated noninvasively. Electrocardiographic and gas exchange data were 
acquired for three minutes post exercise.
Patients were encouraged to exercise for as long as possible. The attending 
physician could also stop the test. The reason for the termination of the test was 
recorded in a standardised fashion (fatigue, dyspnoea and/or pain).
2.5.2 Test Analysis
Resting and end exercise heart rate, systolic and diastolic blood pressures, and 
ST segment changes (at 80 milliseconds post J point) were collected for 
subsequent analysis. Gas exchange data were stored on a dedicated computer.
Maximal oxygen consumption (VO2 max) was defined as the mean of the last 30 
seconds of exercise data. The anaerobic threshold was determined by “V slope 
analysis” I2811. Both values were calculated automatically using the 
Cardiokinetics software package.
Further analyses were performed “off-line”. The breath by breath gas exchange 
data file was exported as 1 0  second averages, and subsequent data manipulation 
performed in Microsoft Excel. The slope of the regression line (VE/VC0 2  slope) 
of minute ventilation (VE) vs carbon dioxide production (VCO2) was also
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determined l39), as discussed in the introduction (see Chapter 1 section 1.4.6 
Prognostic Power Of Exercise Variables). This value is proven to be less 
effort dependent than peak VO2.
2.6 A m b u la to r y  ECG  M o n ito r in g
2.6.1 Acquisition
Twenty-four hour ambulatory ECG's were obtained on all patients during normal, 
unrestricted out of hospital activity using new Oxford MR 45 recorders (Oxford 
Medical, UK), whose use was confined to this study cohort. The sampling rate 
was 125 per second, giving a temporal resolution of 8  milliseconds. Channel 1 
and 2 recorded the ECG, channel 3 provided beat classification from real-time 
analysis, and channel 4 was a quartz generated timing track, reducing tape speed 
errors to <0.5%. These recorders were suitable for heart rate variability analysis. 
A separate, new, demagnetised tape was used for each patient. The patients’ skin 
was appropriately prepared to ensure electrode stability, to minimise impedance, 
and to decrease noise and artefact. A standard 2 channel lead set up was used, 
and an automatic ECG check performed before commencing each tape. If  either 
channel was unsatisfactory, then the appropriate electrodes were removed, the 
skin recleaned, and new electrodes applied. If, despite these measures, 
unsatisfactory ECG signals were obtained, new electrodes were applied at 
different positions. These measures ensured high-quality, low noise recordings.
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2.6.2 Arrhythmia Analysis
Twenty-four hour ambulatory ECG’s were replayed through the Oxford Xcel 
arrhythmia analyser. Initial automated computer analysis classified beats by QRS 
template morphology, and the trigger section of the analysis detects individual QRS 
complexes. Manual editing was then performed by two technicians experienced in 
24-hour arrhythmia analysis to further refine data accuracy. Ectopic beats, arrhythmic 
events, missing data and artefact were appropriately classified.
Arrhythmia analysis provided the following parameters: 
mean, maximum, and minimum heart rate 
bradycardic arrhythmia events
supraventricular ectopic and supraventricular arrhythmia counts 
ventricular ectopic counts: these were subdivided into single VE’s, couplets, 
and nonsustained ventricular tachycardia defined as > 3 consecutive 
ventricular beats at a rate > 1 0 0  beats per minute
2.6.3 Heart Rate Variability Analysis
Ambulatory ECG’s <22 hours duration and/or with < 90% of the recording suitable 
for analysis were excluded from heart rate the ability analysis. From the edited 
ambulatory electrocardiograms, the remaining normal-normal RR intervals were 
stored as a tachogram for heart rate variability measurement. Time and frequency 
domain measures of heart rate variability (see Table 2-3 and Table 2-4) were 
calculated in accordance with accepted standards 12821, using the Oxford Xcel 
analysis package.
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Table 2-3: Definitions of time domain measures of heart rate variability
Variable Units Definition
SDNN msec Standard deviation of all NN intervals in the 24 hour 
recording
SDANN msec Standard deviation of the mean of all NN intervals for each 5 
minute period of the 24 hour recording (cycles>5 min)
SDNNI msec Mean of the standard deviations of all NN intervals for all 5 
minute periods of the 24 hour recording (cycles<5 min)
pNN50 % Percentage of all NN intervals where the differences 
between adjacent NN intervals > 50 ms
rMSSD msec The square root of the mean of the sums of the squares of 
the differences between adjacent NN intervals
Abbreviation: mssec- milliseconds
Table 2-4: Definitions offrequency domain indices of heart rate variability
Power Spectrum Frequency range Cycles/Time Time/cycle
High frequency 0 .1 5 -0 .4 0  Hz 9 - 2 4  cycles/min 2.5 sec/cycle 
-  6.6 sec/cycle
Low frequency 0 .0 4 -0 .1 5  Hz 2 .4 - 9  cycles/min 6.6 sec/cycle 
-  25 sec/cycle
Very low 
frequency
0.0033 -  0.04 Hz 0 .2 -2 .4  
cycles/min
25 sec/cycle 
-  5 min/cycle
Ultra low 
frequency
1.15x10'5- 0.0033 Hz 0.2 cycles/min 
-1 cycle/24 hrs
5 min/cycle 
-  24 hrs/cycle
Total power 1.15 x 10'5- 0.40 Hz 24 cycles/min 
-1 cycle/24 hrs
2.5 sec/cycle 
-  24 hrs/cycle
Abbreviation Hz = hertz
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Standard two-dimensional, colour and doppler echocardiography (Accuson 128) was 
performed with subjects recumbent at 40 degrees, in the left lateral position. Images 
were stored on videotape and analysed on line using the pre-installed Accuson 
software package.
2.7.1 Left Ventricular Ejection Fraction
Left ventricular volumes were obtained using a disc summation method (Simpson’s 
rule) from the apical 4-chamber and 2-chamber views. The endocardium was traced 
in systole (smallest left ventricular dimension) and diastole (ECG R wave onset), in 
triplicate, avoiding post-extrasystolic beats 12831. Left ventricular volumes were 
calculated using the mean of the 3 values by the internal software of the Accuson 128. 
Left ventricular ejection fraction was automatically calculated from these volumes as
[LV end diastolic volume - LV end systolic volume] ^  ^
LV end systolic volume
In subjects with poor endocardial definition (defined as less than less than 80% of the 
endocardium being visible), a semi-quantitative assessment of left ventricular ejection 
fraction was made 11551. If echo quality precluded analysis of ejection fraction, the 
results of recent radionuclide ventriculography were used.
2.7.2 Structural Abnormalities
Echocardiograms were also analysed for significant structural heart disease: atrial or 
ventricular septal defect, valvular disease, ventricular hypertrophy and/or pericardial 
disease.
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2.7.3 Colour-Doppler Echocardiography
Patients with documented valvular heart disease were excluded from the study. 
Standard Doppler assessment of valvular flow was performed. Pulsed wave-Doppler 
waveform through the mitral valve and continuous wave Doppler waveform through 
the aortic valve were determined, and semi-quantitative assessment of valvular 
regurgitation performed by visual inspection of regurgitant jet width and length.
2.8 Ba r o r e fl ex  S ensitivity Testin g
An indwelling cannula was placed in an antecubital fossa vein. Continuous 
electrocardiographic monitoring was performed with a single channel V lead. To 
avoid the hazards of intra-arterial pressure monitoring, beat to beat arterial pressure 
was measured non-invasively using a Finapres 2300 (Ohmeda, Englewood, USA). 
The Finapres method is based on dynamic unloading of the finger arterial walls using 
an inflatable finger cuff with built-in photo-electric plethysmograph. By keeping 
finger volume constant, the arteries will not change in size. Thus, at constant volume 
(i.e. determined by the photoplethysmogram) instantaneous cuff pressure equals 
instantaneous arterial pressure. A rapid pneumatic servo system and a dynamic servo 
set point adjuster ensure accuracy. From the finger pressure waveform, systolic, 
diastolic and mean arterial pressures were output on a beat by beat basis. This 
methodology had been extensively validated in published studies l284,285!. After an 
initial start-up period for calibration, a representative pressure waveform was 
obtained. If no satisfactory arterial pressure waveform was obtained, a different sized 
cuff was used or, if necessary, the patient’s hand was warmed. Patients were 
instructed to keep the hand and arm immobile during the testing procedure. The servo 
set point adjuster was switched off immediately before each test. The analogue
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outputs of the ECG and Finapres were AD converted (sampling rate 200 Hz) and the 
digitised signals monitored real-time using a PC and commercially available software 
package (CAFTS, Medikro Oy, Finland). At the end of each study, files were 
analysed and stored.
After 20 minutes of rest in a semi-recumbent position, a “trial run” was performed 
after explanation of the testing procedure and equipment. If this was satisfactory, 15 
minutes of simultaneous ECG and BP data were recorded during controlled 
respiration. Tidal volume was not fixed, but patients were instructed to breathe in 
time with an electronic metronome at 12 breaths per minute. Data from this rest 
period were analysed to determine baroreflex gain and short term measures of heart 
rate variability. After this rest study, baroreflex challenges were performed.
Baroreflex gain was measured by means of the spectral analysis of simultaneous RR 
and systolic blood pressure variabilities 12301. Cross spectral analysis was performed 
on both high and low frequency bands and values analysed only if the weighted 
coherence between systolic pressure and RR interval was greater than 0.5 12861.
Baroreflex challenges were performed using a bolus phenylephrine injection 12271. An 
intravenous bolus of 25 to 400pg of phenylephrine hydrochloride was followed by 10 
mis saline flush, to induce a 20 to 30 mmHg increase in systolic arterial pressure. The 
software allowed online analysis of baroreflex slopes where systolic pressure was 
plotted against the succeeding RR interval. The slope of the linear regression line of 
this plot was taken as baroreflex sensitivity if there was a significant correlation 
coefficient. Three tests were averaged to provide mean baroreflex sensitivity.
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2.9.1 Natriuretic Peptides
Venesection was performed in a standardised fashion after 20 minutes of supine rest. 
Venous blood was withdrawn by syringe and needle into pre-prepared chilled tubes 
containing EDTA and trasylol (50IU/ml). Care was taken to prevent painful or 
prolonged venepuncture that might artefactually raise plasma noradrenaline. Samples 
were centrifuged at 3,000 rpm for 10 minutes at 4 °C, and the supernatant plasma 
stored at -70 °C. Subsequent analyses were performed at a laboratory experienced in 
neurohumoral measurement. The plasma was acidified with trifluoroacetic acid, and 
natriuretic peptides extracted by gel chromatography. Recoveries were 87% and 82% 
for N-ANP and BNP respectively.
N-ANP was measured, after dilution (1:100), by radioimmunoassay using an antibody 
from Peninsula Laboratories (RAS 9129) raised against the 1 to 30 N-terminal 
fragment. This antiserum has no detectable cross reaction with either C terminal ANP 
or BNP and has an IC50 of 18pg/tube in the assay. The within-assay and between- 
assay coefficients of variation for this assay were 15% (n=16) and 16% (n=48) 
respectively 12871.
BNP was measured in the extract (1:4) using a radioimmunoassay kit for human BNP 
obtained from Peninsula Laboratories (RIK 9086). This has an I C 5 0  of 20pg/tube. 
The within-assay and between-assay coefficients of variation were 18% (n=16) and 
(n=46) 15% respectively.
The range of a sample of controls for plasma ANP was less than 50 ng/ml, and the 
mean for plasma BNP was 12 ± 9 pg/ml (unpublished internal reference ranges).
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2.9.2 Plasma Noradrenaline
Noradrenaline was measured by HPLC and electrochemical detection after prior 
extraction from plasma 12881. The coefficient of variation for the method is <10% and 
recovery is corrected by including an internal standard. The range of a sample of controls 
for this laboratory is less than 5 nmol/1 (unpublished internal reference range).
2.10 C l a s s i f i c a t io n  o f  E n d p o in ts
Specified mortality endpoints were:
Cardiovascular death: defined as death due to myocardial infarction, progressive 
heart failure, stroke, attempted resuscitation from ventricular arrhythmia or urgent 
cardiac transplantation.
Progressive heart failure death: defined as death occurring in the context of 
increasing symptoms/signs of heart failure, with no recent (>4 weeks) antecedent 
ischaemic event.
Sudden death: a pragmatic classification of sudden death was chosen. Patients who 
died of a documented ventricular arrhythmia, or who did not survive a community 
resuscitation attempt were classed as sudden death. Patients who died at home with 
no recent (>4 weeks) documented change in cardiac status were also classed as sudden 
death, unless an obvious alternative aetiology was documented. If patients died of an 
arrhythmia while in a decompensated state, this was classed as a progressive heart 
failure death. If they had been treated and had become stable, death was classified as 
sudden.
The limitations of classification of death are well documented and are discussed in 
Chapter 1.4.1 Classification of Death in Heart Failure.
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Patients did not undergo routine follow-up. However, appropriate information was 
extracted annually from review of their hospital and/or GP case records. Follow-up 
was closed on the first of September 1998. Vital status was determined in all cases 
from information from the death section of the General Register Office of Scotland.
2.12 S tatistical  A nalysis
A power calculation was performed at the time of the original proposal. It was 
estimated that a cohort of 300 patients followed up for 2 years with an annual 
mortality of 15% would provide 55 cardiovascular deaths. Patient recruitment was 
truncated early (as the principal investigator took up another appointment). However, 
follow-up was extended, and subsequent analysis demonstrated that the original power 
of the study was retained.
Statistical analyses were performed using SPSS for Windows Version 8 . Results are 
given as mean ± SD, except where indicated as median and inter-quartile range. 
Spearman’s rank correlation procedure was used to compare non-normally distributed 
variables, and Pearson’s correlation coefficient if variables were normally distributed 
or could be transformed to a normal distribution. The statistical association of co- 
variates with mortality was determined by Kaplan-Meier curves and the log-rank test. 
A multivariate Cox proportional hazards analysis was performed to determine the 
incremental prognostic power of investigational variables. To simplify this model, 
NYHA status was grouped as class II or below, or HI and above. Maximal oxygen 
consumption was dichotomised at 14ml/kg/min (as in previous studies), with patients 
unable to exercise being assigned a value of <14ml/kg/min. Autonomic variables
Ch a pte r  2: M eth o d o lo g y  - 1 1 3 -
were dichotomised above and below the median values. Two types of Cox analyses 
were performed:
1. The incremental prognostic utility of each investigational variable was determined 
singly after adjustment by multivariate analysis of readily available parameters: 
age, aetiology of heart failure, NYHA class, peakV0 2 , left ventricular ejection 
fraction and presence of intraventricular conduction defect/bundle branch block on 
the 12 lead ECG.
2. In the second model, all investigational co-variates were analysed together using a 
forward conditional stepwise model after adjustment for baseline co-variates.
Analyses of cause specific mortality should be interpreted with caution. There are 
potential confounding problems with definitions of and smaller numbers of events. 
Additionally, there is the conceptual difficulty that one event may interact with or alter 
the probability of another occurring. For example, it might be assumed that patients 
who succumb to sudden death have died before they can develop progressive heart 
failure, and so their data cannot contribute to analyses of progressive heart failure death.
Cox proportional hazards analysis uses the hazard function to estimate the risk of 
death cocurring. This is an estimate of the potential for death per unit time at any 
given instant. “Proportional hazards” implies that the hazard ratio for a co-variate (eg 
previous myocardial infarction) remains constant over time, and is not altered by 
censored data. Log minus log plots were analysed for each co-variate to ensure that 
assumptions of constant proportionality were not violated.
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3 RESULTS
3.1 C linical and  De m o g r a ph ic  C h a r a c ter istic s
Table 3-1: Clinical and demographic characteristics
Patient Demographics
Age, years* 61.6 54.2-67.5
NYHA class 2.7 0 .8
Cause of CHF (n) Ischaemic 163
Non-ischaemic 36
Therapy (%) ACE Inhibitor 89
Diuretics 6 6
Digoxin 27
Other vasodilators 41
p blockers 2 0
LVEF(%) 23 9
Peak V02 (ml/kg/min) 16.9 4.9
IVCD/BBB (n) Present 64
Absent 135
NYHA -  New York Heart association functional class; IVCD -  intraventricular conduction 
defect; BBB -  bundle branch block.
Values given as mean ± SD, except where indicated *, median ± IQR
3.1.1 Clinical Demographics
The mean age of the study population was 60.0 years (SD 10.3 years). There were 148 
(74.4%) men and 51 (25.6%) women. Age did not differ significantly between sexes 
(men, mean 59.3 SD 10.3 vs women 61.9 SD 10.1). Median duration of heart failure 
was 16 months, IQR 8-48 months. Ischaemic heart disease was the commonest cause of 
chronic heart failure: 163 patients had an ischaemic aetiology (81.9%), and 153 (76.8 %)
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had documented prior myocardial infarctioa One hundred and four patiens had 
undergone previous coronary angiography, and 58 had been revascularised with 
coronary bypass grafting. Risk factors for coronary disease were common: 94 (47.2%) 
patients had hypercholesterolaemia (defined as random cholesterol >5.5 mmol/1), 6 8  
(34.2%) had a past history of hypertension but only 21 (10.0%) were diabetic. This 
latter finding reflects selection criteria as longstanding diabetics were excluded. Only 
38 (19.1%) patients were current smokers, but 109 (55%) were ex-smokers.
3.1.2 Symptoms and Questionnaire Data
Mean NYHA status was 2.7 (SD 0.8). Twelve (6 %) patients were in NYHA class I, 
6 8  (34%) in NYHA class II, 89 (45%) in NYHA class III and 30 (15%) in NYHA 
class IV. For the purposes of multivariate analysis, patients were grouped as being 
in functional class 1 (NYHA classes I and II, 80 patients) or functional class 2 
(NYHA classes III and IV, 119 patients).
Mean Minnesota Living with Heart Failure Questionnaire (MLHFQ) Physical Score 
was 19.1 (SD 11.0) of a possible score value of 40. The score differed significantly 
between all NYHA classes and functional status (p<0.001 ANOVA): see Table 3-2). 
Substituting MHFQ physical score in place of NYHA class produced almost identical 
survival analysis results.
Table 3-2: Minnesota heart failure questionnaire score by NYHA Status
NYHA Class Mean MHFQ Score SD
1 2 2.5
II 11 6.8
III 23 7.7
IV 33 5.5
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3.2 L e f t  V e n t r i c u l a r  E je c t io n  F r a c t i o n
An objective assessment of left ventricular function was available in all 
patients. Left ventricular ejection fraction was determined by radionuclide 
ventriculography in 57 patients whose echocardiograms demonstrated poor or 
moderate definition of endocardial outline. Mean left ventricular ejection 
fraction was 23.4% (SD 8.7%). Mean left ventricular ejection fraction was 
statistically different between groups classified as having mild, moderate, 
severe or very severe left ventricular impairment at “eyeball” assessment 
(p<0.001 ANOVA, see Table 3-3 and Figure 3-1).
Left ventricular ejection fraction correlated poorly with age (Pearson 
correlation coefficient r = -0.16, p = 0.90). There was no significant difference 
in left ventricular ejection fraction between ischaemic/non-ischaemic 
aetiologies (mean 22.9%, SD 8.1% vs 25.2%, SD 10.2%); or between male and 
female gender (mean 22.9%, SD 8.4% vs 24.6%, SD 9.3%). There was a trend 
toward lower left ventricular ejection fraction in higher NYHA class. Left 
ventricular ejection fraction was significantly lower in patients with prolonged 
compared with normal QRS duration (mean 20.4%, SD 8.3% vs 24.7%, SD 8.5%, 
p<0.001 unpaired T test).
For description of box & whisker plot see section 3.8 Correlative Statistics
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Figure 3-1: Left ventricular ejection fraction by “eyeball” assessment
Table 3-3: Left ventricular ejection fraction and subjective assessment
Subjective LV impairment Mean LVEF (%) SD
Mild 34.5 5.8
Moderate 26.6 4.5
Severe 17.9 3.8
Very Severe 12.9 3.1
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3.3 E l e c t r o c a r d i o g r a p h y
3.3.1 Resting 12 Lead Electrocardiography and Measures
of Ventricular Repolarisation
One hundred and ninety five subjects were in sinus rhythm. Four subjects were found to be in 
atrial fibrillation at the time of study. Their data are not included in heart rate variability, 
baroreflex sensitivity, QT dispersion or signal averaged ECG analysis. The following data are 
expressed as mean ± SD in msec: PR interval 169 ±30.1, QRS duration 114 ± 27.9, QT interval 
407 ± 43.3, corrected QT interval 428 ± 30.6. Normal atrial activity was present in 164 and 30 
had electrocardiographic features of left atrial strain. First degree heart block was present in 28 
patients, left axis deviation in 56, right axis deviation in 6 and a normal frontal plane axis in 137. 
The QRS duration was normal in 135 subjects, and prolonged in 64 subjects (non-specific 
intraventricular conduction delay in 30, LBBB in 22 and RBBB in 12). One hundred and 
nineteen subjects had ECG evidence of prior Q wave myocardial infarction (76 anterior, 43 
inferior). ST/T wave changes were common. Of 119 patients without IYCD or LVH, 40 
patients had anterior or anterolateral ST/T changes, 30 lateral changes and 37 inferior or 
infero lateral changes. The remaining 12 patients had ECG evidence of Q wave infarction Only 
one patient had a completely normal ECG.
Measures of QT interval and QT dispersion are reported by presence or absence of IVCD 
(Table 3-4). One hundred and fifty ECG’s were suitable for QT dispersion analysis: no QT 
dispersion measures were analysed for the 4 subjects in atrial fibrillation, or if more than 3 leads 
were unsuitable for T wave analysis. QT interval and corrected QT interval were significantly 
longer in the IVCD group (pO.OOl). In contrast, QTE Dispersion, corrected QTE dispersion 
and QTE CV were significantly longer in the normal conduction group (p<0.05, unpaired T 
test). The normal conduction group contained 19 records with electrocardiographic LVH.
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Table 3-4: Measures o f ventricular repolarisation and presence/absence IVCD
Normal IVCD P
Mean
(msec)
SD
(msec)
Mean
(msec)
SD
(msec)
QTend 396 38 430 46 <0.05
Corrected QTend 419 24 447 34 <0.05
QTend Dispersion 111 44 91 30 <0.05
QTend CV 8.6 3.3 6.9 2.3 <0.05
QTpeak Dispersion 66 29 59 28 NS
QTpeak CV 6.8 2.8 6.5 2.7 NS
Corrected QTend Dispersion 118 45 95 29 <0.05
Corrected QTend CV 9.2 3.5 7.2 2.5 <0.05
Corrected QTpeak Dispersion 69 30 70 27 NS
Corrected QTpeak CV 7.2 3.0 6.8 2.7 NS
QTend= QT measured to end of T wave; QTpeak= QT measured to peak of T wave; QTend CV = standard 
deviation of QT^ /mean of QT^; Q T ^  CV= standard deviation of QTpe* /mean of Q T ^
3.3.2 Signal A veraged Electrocardiography
Signal averaged electrocardiography was performed in all patients. The noise level 
was too high for reliable analysis in 2 subjects and these subjects were excluded from 
further analysis. Prospectively defined abnormal ranges were used in the presence of 
IVCD (see section 1.4.8 Signal-averaged Electrocardiography and Table 2-2). 
Results are presented by presence or absence of conduction defect. The presence of a 
late potential was defined in 3 ways: all 3 criteria abnormal, any 2 criteria abnormal or 
QRS duration prolongation and any one other criteria abnormal (see Table 3-5). A 
representative positive Signal-Averaged ECG is presented in Figure 3-2.
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Figure 3-2: A positive Signal-Averaged ECG
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Table 3-5: Signal averaged ECG and conduction defect
-121-
Normal
conduction
IVCD) Combined
(n = 133) (n = 64 (n = 197)
QRSd prolonged and any 
1 other criteria abnormal
28 23 51
Any 2 criteria abnormal 44 25 69
All 3 criteria abnormal 21 16 37
QRSd -  QRS duration
No measure of QT dispersion differed significantly between groups with positive or 
negative signal averaged ECG.
3.4 Ex e r c ise  Va r ia b l es
Twenty six patients did not undergo exercise testing, 20 because of patient preference 
or inability to exercise and 6 because of limiting osteoarthritis. Five patients could not 
tolerate the noseclip and mouthpiece necessary for gas exchange analysis. Thus, 173 
patients underwent exercise testing, and expired gas analysis was available on 168 of 
these. Breathlessness and/or fatigue were the commonest limiting symptoms 
(163/173, 94.2%). Eight subjects experienced chest pain as a limiting symptom, but 
none demonstrated significant ST change on exercise. Exercise variables are shown 
below (see Table 3-6).
All patients demonstrated significant impairment of functional capacity compared 
with age matched normal values.
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Table 3-6: Cardiopulmonary exercise test variables
Variable Mean (SD)
Exercise time (seconds) 436 (218)
A Heart rate (bpm) 48 (20)
A Systolic arterial pressure (mmHg) 27 (17)
PeakV 02 (mls/kg/min) 16.8 (4.9)
Peak RER 1.03 (0.11)
3.5 Ho l t e r  A n a l y s e s :
C a rdiac  R hythm  and  He a r t  Rate  Variability
One tape was damaged and was not analysable. Median tape duration was 23 hours 
and 30 minutes: only 4 tapes had less than 20 hours of data. Four patients were found 
to be in chronic atrial fibrillation, and 2 patients had evidence of sustained 
(>30seconds) paroxysmal atrial arrhythmias. Ventricular and supraventricular 
arrhythmia analysis for the entire study cohort is presented in Table 3-7. Ventricular 
arrhythmias were common, and over 25% of the study cohort demonstrated 
nonsustained ventricular tachycardia.
Heart rate variability was analysed only if more than 80% of the 24 hour recording 
was artefact and arrhythmia free. One hundred and seventy-three tapes were included 
in analysis (1 tape was damaged, 4 patients were in atrial fibrillation, and the 
remainder had frequent ectopy). Time and frequency domain measures of heart rate 
variability are presented respectively in Table 3-8 and Table 3-9. Short term time 
domain measures of heart rate variability and all frequency domain measures of heart
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rate variability were significantly skewed and required log transformation for normality. 
Time and frequency domain measures of heart rate variability were highly correlated (see 
Table 3-10). Time and frequency domain measures of heart rate variability were 
depressed compared to published normal controls of similar age 1951.
Correlations between measures of heart rate variability, age, left ventricular ejection 
fraction, NYHA status and other autonomic variables are shown in Table 3-12.
Table 3-7: Ventricular and supraventricular arrhythmia analysis
V e n t r ic u l a r  A rrhythm ia
Variable Variable present Median (IQR)
Tape duration (hrs) 198 24 (23.5-24.0)
Total VE/24 hours 197 264 (53-1512)
VE/hour 197 11 (2-63)
VE/1000 beats 197 3(1-13)
Ventricular couplets 127 8 (2-60)
NSVT 57 2(1-5)
VT 9 1 (1-5)
S u p r a v e n t r ic u l a r  A rrhythm ia
Variable Variable present Median (IQR)
Total SVE/24 hours 192 68 (27-225)
NSSVT/24 hours 68 4(2-15)
SVT/24 hours 2 12 (6-23)
VE = ventricular ectopic beat;
NSVT = nonsustained ventricular tachycardia (>3 beats<10 beats, rate>120 bpm);
VT = ventricular tachycardia (>10 beats, rate>120 bpm);
SVE = supraventricular ectopic beat;
NSSVT = nonsustained supraventricular tachycardia (>3 beats<10 beats, rate>120 bpm); 
SVT = supraventricular tachycardia (>10 beats, rate>120 bpm).
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Table 3-8: Heart Rate Variability: time domain analysis
Units Mean (SD) Median IQR
SDNN msec 120 (41) 119 89-144
Triangular Index msec 30(10) 30 23-38
SDANN msec 108 (38) 106 80-131
SDNN Index msec 45(18) 43 31-54
r-MSSD msec 30 (19) 26 19-36
pNN50 % 6.4 (7.2) 4 1.4-8.9
Ln rMSSD 1.4 (0.2) 1 1.3-1.6
Ln pNN50 0.5 (0.6) 1 0 .2-1.0
Ln: natural logarithm transform
Table 3-9: Heart Rate Variability: frequency domain analysis
Units Mean (SD) Median IQR
Total power msec2 2607 (2051) 2122 1105-3269
ULF power msec2 383 (502) 244 131-447
VLF power msec2 1592(1230) 1342 685-1998
LF power msec2 431 (469) 290 127-532
HF power msec2 199 (224) 133 68-248
Ln Total Power 7.6 (0.8) 7.7 7.0-8.1
Ln ULF Power 5.5 (1.0) 5.5 4.9-6.1
Ln VLF Power 7.1 (0.9) 7.2 6 .5-7.6
Ln LF Power 5.6 (1.1) 5.7 4.8-6.3
Ln HF Power 4.9 (1.0) 4.9 4.2-5.5
Ln: natural logarithm transform
pearson 
correlator! coefficient, all values p<0.05
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3.6 P lasm a  Ne u r o h o r m o n es
Due to a freezer breakdown, 29 noradrenaline samples, 47 natriuretic peptide and the 47 
corresponding spare samples were thawed and unsuitable for analysis. Comparison of cases 
available for analysis against those where samples were missing revealed no significant 
difference in age, left ventricular ejection fraction, baroreflex sensitivity, or heart rate 
variability indices. The frequency distributions of plasma adrenaline, BNP and ANP were 
markedly skewed and are presented along with their natural logarithmic transforms:
Table 3-11: Plasma noradrenaline and natriuretic peptides
Variable Mean (SD) Median IQR
Atrial natriuretic peptide (ng/ml) 5.4 (4.2) 4.2 2.2-7.1
Brain natriuretic peptide (pg/ml) 87.3 (48.3) 48.3 24.1-93.1
Plasma noradrenaline (nmol/l) 4.79 (3.9) 3.9 2.9-5.7
Ln atrial natriuretic peptide 1.38(1.43) 1.4 0.79-1.96
Ln brain natriuretic peptide 3.89 (3.88) 3.9 3.18-4.53
Ln plasma noradrenaline 1.42(1.37) 1.4 1.06-1.74
Correlations between plasma neurohormones, age, left ventricular ejection fraction, 
NYHA status and other autonomic variables are shown in Table 3-12.
3.7 Ba r o r e fl ex  Me a su r e m e n ts
Phenylephrine baroreflex challenges were available on all patients in sinus rhythm. 
Subjects demonstrated 2 types of heart rate response to the phenylephrine challenge: a 
normal response with heart rate slowing (n=151) or a delayed, absent or paradoxical heart 
rate response (n=44). Mean baroreflex sensitivity for the entire cohort was 6.7 (SD 6.1)
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milliseconds/mmHg. This high mean is because absent or paradoxical responses were 
dichotomised as below the median for survival analysis, but not quantitatively determined.
Correlations between plasma baroreflex sensitivity measurements, age, left ventricular 
ejection fraction, NYHA status and other autonomic variables are given and discussed 
in the section below.
3.8 C o r r e l a t i v e  S t a t i s t i c s
Plasma neurohormones, baroreflex sensitivity and short term time domain and all 
frequency domain measures of heart rate variability were log transformed, because of 
their skewed distribution. Correlations between age, left ventricular ejection fraction, 
peak VO2 and autonomic variables are shown in Table 3-12. For simplicity, only 
time domain measures of heart rate variability are shown, as frequency domain 
measures duplicated the time domain results.
Age was weakly, but significantly and negatively correlated with peak VO2, plasma 
neurohormones, baroreflex sensitivity and SDNN-I (Table 3-12). There were weak 
but significant correlations between all autonomic variables, but the correlation 
coefficients would suggest that they could still provide independent prognostic 
information. Baroreflex sensitivity was most strongly correlated with log transforms 
of plasma BNP and ANP (r = -0.47 and -0.52) and with peak VO2 (r = 0.48). Perhaps 
surprisingly, baroreflex sensitivity correlated only weakly (albeit significantly) with 
short term “parasympathetic” measures of heart rate variability (log transform rMSSD 
and pNN50 r = 0.20 and 0.24 respectively). This was also true for the respective 
frequency domain measure (log transform HF power r =0.30, p<0.01).
: pearson 
correlation 
significant 
at p<0.01; * 
pearson 
correlation 
significant 
at p<0.05 Ln: natural log 
transform
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Peak V 02 was strongly and inversely related to NYHA class (p<0.0001 by ANOVA). 
Long term indices of heart rate variability (triangular index, SDNN and SDANN) 
were also strongly and inversely related to NYHA class (p<0.05 by ANOVA). Short 
term indices of heart rate variability were not significantly related to NYHA Class. 
Plasma BNP and baroreflex sensitivity were significantly different between NYHA 
Class I and IV (p<0.05 by ANOVA) (see Figure 3-3 to Figure 3-6).
Explanation of Box & Whisker Plots
The blue line series shows parametric statistics:
I*—  —  Parametric percentile range-----------------
1 ^ -------------------------------------1
t — Mean
H H Confidence interval of mean
The blue diamond shows the mean and the 95% confidence interval around the mean. 
The blue notched lines show the 95% parametric percentile range.
The notched box and whiskers show non-parametric statistics:
|« N earest ob serva tion s within 1.5 IQ R s M
1+ Non-parametric percentile range---------------- H
................. + o
M edian
C onfidence interval o f median  
►I Interquartile range, upper/lower quartile
The notched box shows the median, lower and upper quartiles, and confidence interval 
around the median. The dotted-line connects the nearest observations within 1.5 inter­
quartile ranges (IQRs) of the lower and upper quartiles.
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Figure 3-4: Triangular Index and NYHA Class
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Figure 3-6: BRS by NYHA Class
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3.9 S u r v iv a l  A n a ly s is
All data are expressed as mean ± SD, except where indicated as median and IQR. 
Follow up was complete on all patients. Median duration of follow-up was 1086 days, 
IQR 734-1259 days. In survivors, median follow-up was 1173 days, IQR 1031-1289 
days. There were 54 (27%) deaths in total, and 47 (24%) cardiovascular deaths. Six 
patients died of cancer, and one of multi-organ failure following an appendicectomy. 
For statistical purposes, follow-up of these patients was censored at the time of death, 
and the data included in the survival analyses. There were 23 (12%) progressive heart 
failure deaths and 24 (12%) sudden deaths. Median time to cardiovascular death was 
376 days, IQR 203-734 days. Median time to progressive heart failure death was 
342 days, IQR 200-583 days and to sudden death was 483 days, IQR 247-877 
days (Mann whitney p = 0.2, NS). The proportion of sudden death (6 of 8 total) in 
NYHA class I/LI patients was not statistically different to that in NYHA class IH/IV 
patients (18 of 29, p= 0.27, Fisher exact test).
To simplify univariate and multivariate analysis, continuous variables were 
categorised by prospectively defined cut-points. Continuous variables were 
dichotomised above and below median values. NYHA status was grouped as Class 
I/II vs III/IV. Because of concerns over the use of 2 different methodologies to 
determine LVEF, ejection fraction was dichotomised at the cohort median value (22), 
and with the RNVG and Echo determined LVEF groups dichotomised at their 
respective group medians. In only 6 patients did the dichotomisations conflict (of the 
43 patients where data was available from both methods). Whether LVEF was 
dichotomised at the total cohort median value, the RNVG group median, Echo group 
median or by eyeball assessment made no difference to the results of survival analysis.
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To ensure further statistical validity, analyses were repeated with the continuous 
variables entered as continuous co-variates, dichotomised at the median value, 
categorised into tertiles and categorised into quartiles. All analyses produced similar 
results, and, in particular, made no difference to the multivariate analysis of 
cardiovascular death, progressive heart failure or sudden death. The absence of data 
(eg because of freezer breakdown for plasma BNP, non-analysable QT dispersion, 
non-analysable echocardiogram) was not statistically associated with survival.
3.9.1 Univariate Analysis
Kaplan-Meier survival curves were constructed for all variables according to the level 
of categorisation described above, and comparison between groups was assessed using 
the Log Rank test.
Survival of the entire cohort is presented in Figure 3-7. Cumulative mortality at 
follow-up of 1, 2 and 3 years was respectively 12, 18 and 24%. Established clinical 
parameters (aetiology of heart failure, NYHA class, left ventricular ejection fraction 
and peak oxygen consumption) predicted cardiovascular death significantly (log rank 
test p<0.01 in all). Therapy was associated with survival: p-blocker use was 
favourable, whereas digoxin, diuretic and amiodarone therapy was associated with an 
iicreased mortality. However, duration of chronic heart failure and prior 
revascularisation did not affect survival. Plasma neurohormones, baroreflex 
sensitivity, and time and frequency domain measures of heart rate variability 
(Triangular Index, SDNN, SDNN-I) predicted cardiovascular death (log rank test 
I<0.01). Intraventricular conduction defects/bundle branch block and a positive 
signal averaged ECG also predicted death (log rank test p<0.01). However, none of 
tie electrocardiographic measure of ventricular repolarisation was statitically
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associated with prognosis. This was true if analyses were repeated excluding patients 
with intraventricular conduction defect, or if different dichotomisation values were
chosen. These results are summarised in Figure 3-8 to Figure 3-29.
The association of established and investigational variables with prognosis was studied by 
Cox regression analysis. Total cardiovascular mortality, death due to progressive heart 
failure and sudden death was analysed and hazards ratios were calculated for each 
investigational co-variate (see Table 3-13). Recognised prognostic clinical, 
echocardiographic and exercise variables predicted cardiovascular death significantly in 
the study cohort. Aetiology was “synonymous” with cardiovascular mortality: 45 of 47 
deaths occurred in the ischaemic group. Because there were so few patients with non- 
ischaemic aetiology, and even fewer events in this group, further statistical analysis would 
not provide discriminant information. As such, following statistical advice, aetiology of 
heart failure was excluded from further statistical analyses.
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Figure 3-7: Survival for entire study cohort.
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Figure 3-9: Survival and severity o f heart failure: NYHA Class
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Figure 3-11: Survival and drug therapy: Digoxin use
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Figure 3-13: Survival and drug therapy: Amiodarone use
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3-14: Survival and severity o f pump dysfunction: LV ejection fraction
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Figure 3-15: Survival and severity o f exercise intolerance: Peak VO2
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3-16: Survival and presence/absence o f conduction defects: IVCD
Survival: S A E C G
0
9
SAECG-
8
7
SAECG+Log Rank 8.91
p=0.0028
6
5
1200 16000 400 800
Follow-up (days)
Figure 3-17: Survival and presence/absence o f late potentials: SAECG
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-18: Survival and neurohormones: Plasma Noradrenaline
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Figure 3-19: Survival and neurohormones: Plasma Atrial Natriuretic Peptide
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3-20: Survival and neurohormones: Plasma Brain Natriuretic Peptide
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Figure 3-21: Survival and time domain heart rate variability: Triangular Index
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3-22: Survival and time domain heart rale variability: SDNN
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Figure 3-23: Survival and time domain heart rale variability: SDNN-lndex
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Survival: Total power
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3-24: Survival and frequency domain heart rate variability: Total power
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Figure 3-25: Survival andfrequency domain heart rate variability: ULF power
C
um
ul
at
iv
e 
Su
rv
iv
al
 
 ^
C
um
ul
at
iv
e 
Su
rv
iv
al
C h a p t e r  3: R e s u l t s - 1 4 4 -
Survival: VLF Power
0
.9
>1380 msec2
8
<1380 msec27
6 Log Rank 5.18
p= 0.0228
5
0 400 800 1200 1600
Follow-up (days )
3-26: Survival and frequency domain heart rate variability: VLF power
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Figure 3-27: Survival andfrequency domain heart rate variability : LF power
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3-28: Survival andfrequency domain heart rate variability: LF:HFpower
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Figure 3-29: Survival and baroreflex sensitivity
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3.9.1.1 Univariate Analysis: Cardiovascular death
Established clinical, echocardiographic and electrocardiographic variables predicted 
cardiovascular death in this patient cohort (see Table 3-13). Functional class 
significantly predicted cardiovascular death (hazards ratio for class III/IV 3.9 
compared with class I/II). A similar hazards ratio was seen for patients unable to 
exercise due to cardiac limitation or with peak VO2 <14 mls/kg/min. Interestingly, the 
presence of intraventricular conduction delay carried important prognostic information 
and was more powerful than the signal averaged ECG (hazards ratio 3.5 vs 2.4).
Treatment with diuretics, digoxin or amiodarone significantly worsened prognosis, p- 
blockade was associated with a better prognosis.
Holter variables predicted cardiovascular death significantly: higher average heart 
rates and the presence of non-sustained ventricular tachycardia carried respective 
hazards ratios of 2.0 and 2.5.
Autonomic dysfunction identified patients with a poorer prognosis. Higher levels of 
plasma neurohormones, and lower values of baroreflex sensitivity or heart rate 
variability conferred increased risk. In particular, patients with supramedian levels of 
plasma noradrenaline or plasma BNP had a five-fold increase in risk of death. These 
variables were the strongest univariate predictors of mortality: depressed baroreflex 
sensitivity or heart rate variability (triangular index) carried a lower, but still 
statistically and clinically significant risk (3.3 and 2.8 respectively).
These results were replicated when analysis was repeated with variables dichotomised 
at the median, the tertile or at the quartile values.
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3.9.1.2 Univariate Analysis: Progressive heart failure death
Functional status significantly predicted death due to progressive heart failure: 
patients with higher NYHA status had an 8 fold increased risk of death. Inability to 
exercise or a peak V02 <14 mls/kg/min conferred a similar hazard (see Table 3-13).
The presence of intraventricular conduction delay identified patients at high risk of death, 
reflecting both lower left ventricular ejection fraction and ventricular dyssynchrony.
Signal averaged electrocardiography and/or the presence of non-sustained ventricular 
tahycardia did not predict progressive heart failure death.
Elevated plasma neurohormones were very strong predictors of death due to 
progressive heart failure (hazards ratios categorised at median values: plasma 
noradrenaline 23.1, plasma BNP 10.0). With the exception of SDNN-lndex, 
depressed spectral domain measures of heart rate variability performed better than the 
respective time domain measures in predicting progressive heart failure death.
3.9.1.3 Univariate Analysis: Sudden death
Generally, variables predictive of progressive heart failure death either did not identify 
patients at risk of sudden death (NYHA status/peak V02), or, in the case of plasma 
neurohormones, demonstrated reduced prognostic power (see Table 3-13).
Current smoking carried a 4 fold increased risk of sudden death.
A positive signal averaged ECG, the presence of non-sustained ventricular tachycardia 
and depressed baroreflex sensitivity conferred more than threefold increased risk of 
sudden death.
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3.9.2 Multivariate Analysis
The association of variables with prognosis was studied by Cox regression analysis. 
To establish the incremental prognostic utility of investigational variables over 
parameters easily obtained in clinical practice, a 2 block Cox regression was 
performed. Age, NYHA status (grouped as I/H or IH/IV), presence or absence of 
intraventricular conduction defect, left ventricular ejection fraction (dichotomised 
above and below median), and peak VO2 (dichotomised at 14 ml/kg/min) were 
classed as baseline variables. The first block of the Cox regression was the forced 
entry of baseline co-variates. Each of the investigational co-variates was then added 
singly to this base model to form the second block of the Cox analysis. Those 
investigational variables demonstrating statistical significance in this model were then 
added concurrently in the second block, and these co-variates were analysed using a 
forward stepwise model. These analyses were repeated for cardiovascular death, 
progressive heart failure death and sudden death.
Because not all variables were available in all patients (particularly plasma markers of 
neuroendocrine activation), the numbers given as deaths out of total at risk in each 
table varies slightly and are therefore not additive.
3.9.2.1 Multivariate Analysis: Cardiovascular death
After adjustment for baseline variables (age, NYHA status, presence/absence of 
IYCD, left ventricular ejection fraction and peak oxygen consumption), only a 
positive SAECG, markers of autonomic dysfunction and plasma markers of 
neuroendocrine activation retained prognostic power (see T a b le  3 -1 4 ). When 
investigational variables were analysed concurrently, depressed heart rate variability 
and baroreflex sensitivity failed to predict all cause cardiovascular mortality.
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However, plasma markers of neuroendocrine activation significantly predicted 
cardiovascular death: only 4 of 64 subjects with a plasma BNP <48 pg/ml died, 
compared with 23 of 60 with a plasma BNP > 48 pg/ml, a 5 fold increase in risk. 
Elevated plasma noradrenaline also predicted cardiovascular death significantly, 
supramedian values were associated with a hazards ratio of 2.9. Perhaps 
surprisingly, a positive SAECG provided similar prognostic power, but the utility of 
this measure would be more limited, as a smaller proportion of patients had a 
positive SAECG (31 of 124, 25%).
3.9.2.2 Multivariate Analysis: Progressive heart failure death
Examining investigational co-variates singly after adjustment for baseline variables, 
plasma noradrenaline and plasma BNP strongly and significantly predicted death from 
progressive heart failure (see Table 3-15). Patients with supramedian levels of plasma 
noradrenaline or plasma BNP had respective increases of 17 fold and 10 fold in their 
risk of progressive heart failure death. The only other investigational co-variate 
retaining prognostic power was total power obtained by frequency domain analysis of 
heart rate variability, with depressed values conferring a 5 fold increased risk of death. 
However, no other measure of heart rate variability predicted progressive heart failure 
death, and this isolated finding must be accepted with caution.
Adjusting for all these investigational variables concurrently in addition to the 
baseline model, only plasma noradrenaline predicted death from progressive heart 
failure. Only 1 of 66 patients with a plasma noradrenaline below the median value of 
3.9 nmol/1 died of progressive heart failure during the study period, while 13 of 66 
patients with elevated plasma noradrenaline succumbed (hazards ratio 12.4). This was 
highly statistically significant.
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3.9.2.3 Multivariate Analysis: Sudden death
When subject to the scrutiny of multivariate analysis, a positive SAECG, the presence 
of non-sustained ventricular tachycardia during Holter monitoring and depressed 
baroreflex sensitivity predicted sudden death significantly (see Table 3-16). 
Prognostic significance was retained even when the variables were analysed 
concurrently, rather than singly. A positive SAECG carried a 3.4 fold increased risk of 
sudden death. The presence of non-sustained ventricular tachycardia was also a potent 
predictor of sudden death: of 54 patients with non-sustained ventricular tachycardia, 
10 succumbed to sudden death. Only 5 of 87 (6%) patients with preserved baroreflex 
sensitivity died, while 15 of 95 (16%) patients with depressed baroreflex sensitivity 
succumbed, a 4.1 fold increased risk of sudden death.
3.10 S ummary
Measures of abnormal ventricular depolarisation (expressed as a positive SAECG), 
the presence of non-sustained ventricular tachycardia during Holter monitoring, 
increased plasma markers of neuroendocrine activation, depressed baroreflex 
sensitivity and depressed heart rate variability all identified a cohort of patients with 
chronic heart failure who have a particularly poor prognosis. However, after 
adjustment for baseline variables of age, NYHA status, the presence of 
intraventricular conduction defects, left ventricular ejection fraction and exercise 
tolerance (peak oxygen consumption), plasma markers of neuroendocrine activation 
remained strongly significant predictors of all cause cardiovascular mortality and 
death due to progressive heart failure. These co-variates failed to predict sudden 
death, whereas a positive SAECG, the presence of non-sustained ventricular 
tachycardia and depressed baroreflex sensitivity were all associated with a high risk of 
sudden death.
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Table 3-14: Multivariate association of investigational variables with cardiovascular 
mortality.
Mortality : Cardiovascular  Death
Adjusted model (age, NYHA, IVCD, LVEF, peak V02): Single additional variable 
Variable  Deaths/Total Ha za rds  Ratio  (95% Cl) Wald p  value
SAECG
Negative
Positive
21/138
20/49
1
2.2 1 .1 -4 .2 5.8 0.0162
N oradrenaline (nmoi/l)
<3.92
>3.92
8/79
28/80
1
3.4 1 .4 -8 .2 8.0 0.0045
Plasm a BNP (pg/ml)
<48.2
>48.2
6/72
26/70
1
4.1 1 .5 -1 1 .4 7.9 0.0050
BRS (msec/mmHg)
<5.95
>5.95
10/87
30/95
1
2.4 1 .1 -5 .3 4.6 0.0318
NSVT
Absent
Present
23/130
18/57
1
2.9 1 .5 -5 .5 9.9 0.0017
Triangular index (msec)
>30
<30
9/88
26/84 2.3 1 .0 -5 .1 4.0 0.0460
Adjusted model (age, NYHA, IVCD, LVEF, peak V02): Stepwise additional variables 
Variable Deaths/Total Hazards Ratio  (95% Cl) W ald p  value
SAECG
Negative
Positive
16/93
11/31
1
2.6 1 .1 -6 .0 5.4 0.0206
Noradrenaline (nmol/l)
<3.92
>3.92
6/62
21/62
1
2.9 1 .0 -8 .3 4.0 0.0449
Plasm a BNP (pg/ml)
<48.2
>48.2
4/64
23/60
1
5.0 1 .3 -1 8 .6 6.1 0.0137
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Table 3-15: Multivariate association of investigational variables with progressive 
heart failure death.
Mortality : P ro g r essiv e  Heart  Failure Death
Adjusted model (age, NYHA, IVCD, LVEF, peak V02): Single additional variable 
Variable  Deaths/Total  Haza rds  Ratio  (95% Cl) Wald  p  value
N oradrenaline (nmol/l)
<3.92
>3.92
0/79 1
16/80 17.0 2 .1 -1 3 8 .4  7.3 0.0068
Plasm a BNP (pg/ml)
<48.2
>48.2
1/72 1
14/70 10.1 1 .2 -8 3 .4  4.8 0.0281
Total power (m sec2) 
>2156 
<2156
2/88 1
16/88 4.7 1 .0 -2 2 .1  4.0 0.0446
Adjusted model (age, NYHA, IVCD, LVEF, peak V02): Stepwise additional variables
Variable Deaths/Total  Hazards  Ratio  (95% Cl) Wald P VALUE
Noradrenaline (nmol/l)
<3.92
>3.92
1/66 1
13/66 12.4 1 2 .0 -1 0 4 .3  5.6 0.0183
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Table 3-16: Multivariate association of investigational variables with sudden death.
Mortality : S udden death
Adjusted model (age, NYHA, IVCD, LVEF, peak V02): Single additional variable 
Variable  Deaths/Total  Ha za rds  Ratio  (95% Cl) Wald  p  value
SAECG
Negative
Positive
9/138
12/49
1
2.9 1 .2 -7 .2 5.4 0.0205
BRS (ms/mmHg)
<5.95 5/87 1
>5.95 15/95 4.3 1 .2 -1 5 .8 5.3 0.0210
NSVT
Absent 11/130 1
Present 10/57 3.3 1 .3 -8 .3 6.5 0.0106
Adjusted model (age, NYHA, IVCD, LVEF, peak V02): Stepwise additional variables
Variable Deaths/Total Hazards Ratio  (95% Cl) Wald P VALUE
SAECG
Negative
Positive
9/135
11/47
1
3.4 1 .3 -9 .5 6.1 0.0136
BRS (ms/mmHg)
<5.95 5/87 1
>5.95 15/95 4.1 1 .1 -1 4 .9 4.6 0.0328
NSVT
Absent 10/128 1
Present 10/54 2.9 1 .1 -7 .4 4.7 0.0310
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4 DISCUSSION
4.1 S ta tem en t  o f  prin c ipa l  findings
In a prospective cohort study of chronic heart failure, I have demonstrated that the 
presence of intraventricular conduction delay, a positive signal averaged ECG, the 
presence of non-sustained ventricular tachycardia and abnormal autonomic function 
can identify patients at high risk of death. These variables carry prognostic 
information that is additive to and independent of established risk indicators.
1. Abnormal ventricular depolarisation manifest as intraventricular conduction delay 
on a resting ECG, or the presence of late potentials on the signal averaged ECG 
both identify a high risk group.
2. Autonomic dysfunction, evaluated by plasma markers of neuroendocrine 
activation or baroreflex sensitivity and/or heart rate variability, is also associated 
with a poor prognosis.
3. Abnormalities of ventricular depolarisation, ventricular arrhythmias and abnormal 
cardiovascular reflexes, delineated by late potentials on the signal averaged ECG, 
non-sustained ventricular tachycardia during Holter monitoring and low baroreflex 
sensitivity identify a cohort likely to die a sudden death.
4. No electrocardiographic parameter of ventricular repolarisation predicted death 
significantly.
1 conclude that non-invasive testing aids risk stratification in this common and highly 
lethal condition.
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4.2 S t r e n g t h s  a n d  l im i ta t io n s  o f  T he  S tu d y
4.2.1 General Limitations
The exclusion of those patients with atrial fibrillation, longstanding diabetes and aged 
over 75 precludes extrapolation of these results to such patient cohorts. Invasive 
haemodynamic measurements were not performed. However, recent data suggest that 
invasive risk models (utilising measurement of pulmonary capillary wedge pressure) do 
not add discriminant information above comprehensive non-invasive risk assessment|16Sl. 
Additionally, such measurements are logistically complex, and difficult to justify in 
patients with milder chronic heart failure. For pragmatic reasons, tests were performed 
only once in each patient. Whether repeated analyses at regular time intervals would 
allow earlier identification of patients at risk is conjectural As discussed previously (see
1.4.2.2 Symptoms) new ischaemic events and recurrent admissions with heart failure 
worsen prognosis. There are no follow-up data on such events. The problems of defining 
cause of death in chronic heart failure (outlined in section 1.4.1 Classification of Death 
in Heart Failure) are recognised and discussed below.
4.2.2 Patient Cohort
This was a prospective study of a well-characterised patient cohort. Recruitment, 
methodology and endpoints were all pre-defined. Categorisation of variables for 
survival analysis was performed using median values, or pre-specified cut points 
based on published literature. The study design was simple and deliberately inclusive: 
subjects maintained normal medication, no invasive haemodynamic measurements 
were made, and follow-up was maintained through normal hospital after-care, as 
opposed to specialist clinics.
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There are a number of questions that may be asked of any study regarding its more 
widespread application:
Was the cohort too selected for results to be more widely applicable? Patients with more 
severe heart failure have symptoms and signs at rest that are easy to identify, have an 
annual mortality of 40% despite optimal therapy, but constitute a minority of chronic 
heart failure patients [172\ Although the current study was hospital based, all patients were 
clinically stable ambulant outpatients with mild to moderate heart failure -  an important 
proportion of the chronic heart failure population. Despite optimal treatment, this group 
has an annual mortality of 10% [1261. Determining which of these patients is most at risk 
of early death is difficult, but important. It is a strength of this study that it was not an 
analysis of a highly selected group referred for cardiac transplantation. In keeping with 
criticisms of other studies, patients were younger than those seen in epidemiological 
studies and clinical practice, but comparable to those recruited into recent large trials of 
vasodilator therapy 12891. Most patients had chronic heart failure caused by ischaemic 
heart disease, the commonest aetiology in most recent epidemiological studies 11161. 
Patients with longstanding diabetes mellitus, pre-existant chronic renal failure or atrial 
fibrillation were excluded. Diabetes mellitus and chronic renal failure are themselves 
associated with autonomic dysfunction, and are potent predictors of mortality 11481. Thus, 
the current results cannot be extrapolated to such a patient population. Small studies have 
suggested that atrial fibrillation confers a worse prognosis [1431, but the presence of atrial 
fibrillation did not influence morbidity or mortality in the V-HeFT studies [l44\ Atrial 
fibrillation precludes baroreflex sensitivity or heart rate variability analysis, and patients 
with chronic atrial fibrillation were therefore excluded from this study. It is not possible 
to state whether the prognostic importance of plasma neurohormones would be affected 
by the presence of atrial fibrillation.
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Could drug effects be implicated in survival, or have affected investigational 
variables? Although drug therapy was associated with differing prognosis at 
univariate analysis, after adjustment for baseline variables drug treatments were not 
significantly related to survival. Long term treatment with angiotensin converting 
enzyme inhibitors I2901, digoxin 12911 or p-blockers 12921 is associated with restoration of 
autonomic balance, assessed by augmentation of “parasympathetic” measures of heart 
rate variability, and diminished levels of plasma noradrenaline. Angiotensin 
converting enzyme inhibitors have also been demonstrated to augment 
cardiopulmonary and arterial baroreflex control of sympathetic nerve activity in 
chronic heart failure 12931, leading to a persistent reduction in central sympathetic 
outflow. This may have affected some of the investigational variables. However, in 
keeping with previously published similar studies, a pragmatic decision was made to 
continue medication during the study investigations. The principal study aim was risk 
assessment of patients with optimally treated chronic heart failure, rather than the 
patho-physiological assessment of autonomic dysfunction in chronic heart failure.
Why should the mortality in the current study be relatively low? All subjects were 
outpatients, and patients with recent myocardial infarction or acute coronary 
ischaemic events were excluded. Although the majority of the study cohort had an 
ischaemic aetiology, none had limiting angina, and only 8 patients experienced 
limiting angina on cardiopulmonary exercise testing. Patients were studied only if 
clinically stable for 4 weeks: frequent heart failure admissions were an exclusion 
criterion. Thus, the cohort studied was a non-transplant population of clinically stable 
ambulant outpatients with chronic heart failure free from limiting angina. It is in such 
a group that prognostication using conventional techniques is most difficult, 
emphasising the need for novel risk indicators.
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4.2.3 Methodology
NYHA status was assessed by standard questionnaires: a reproducible and valid tool, 
which is less subject to observer bias than normal clinical assessment. 
Echocardiographic assessment of left ventricular function may be problematic: standard 
M mode fractional shortening and cube root left ventricular ejection fraction ignore the 
complex regional wall motion abnormalities which characterise ischaemic heart failure. 
The Simpson’s biplane disc summation method overcomes these flaws, but necessitates 
clear endocardial outline. The advent of new technologies such as tissue harmonic 
imaging can only add to the applicability of this technique. An overall “semi- 
quantitative” estimation of left ventricular function was available on all patients. This 
assessment by an experienced echocardiographer collated wall motion abnormalities, 
left ventricular size, and global left ventricular function. It does not require clear 
endocardial definition or complex technology, and would be widely applicable in 
clinical practice. It has been demonstrated to be valid and robust means of estimating 
left ventricular ejection fraction11551. This assessment provided similar statistical power 
to measurement of ejection fraction. Where echocardiographic image quality precluded 
biplane Simpson’s methodology, left ventricular ejection fraction was determined by 
radionuclide ventriculography. These two methods are not directly comparable, but 
caveats regarding their combined use are addressed in section 3.9 Survival Analysis. 
That the survival analyses were unaffected whether formal measurement of left 
ventricular ejection fraction or “eyeball” assessment were used in the Cox model makes 
it unlikely that differences between the techniques would have confounded the results.
Signal averaged electrocardiography was performed in accordance with published 
guidelines 12791. However, in the presence of intraventricular conduction delay pre­
determined abnormal criteria were applied from published literature 11801. There is no
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standard accepted methodology for QT dispersion measurement, so QT dispersion 
was determined using a method previously validated in chronic heart failure 12671. 
Heart rate variability analysis was performed as per accepted guidelines 12821. New 
Holter monitors used solely for this study ensured that tape errors were minimised. 
Time domain measures of heart rate variability were determined using two separate 
ectopic filtering algorithms and software programs. The results for all time domain 
measures produced by these two algorithms were strongly correlated (r>0.9, p<0.001), 
and survival analyses identified no differences between the methodologies. This 
demonstrates the robustness of the results. Frequency domain analysis was performed 
with commercial software. As expected 12941, there were strong correlations between 
time and frequency domain measures, supporting the validity of these results. 
However, from theoretical considerations underlying the mathematics of spectral 
analysis, total spectral power should be equal to the time domain variance. Therefore, 
a plot of total power vs the square of SDNN should be a straight line with a regression 
slope of 1. In this data set the regression coefficient was 0.72. The potential reasons 
include analysis of the raw rather than resampled tachogram, problems with 
interpolation algorithms used to reconstruct sequence defects caused by ectopy, and 
the inherent non-stationarity of the 24-hour RR interval time series. Whether 
reanalysis using resampled tachograms and different spectral windowing would 
change these data has not been addressed, but remains an area for future attention. 
However, frequency domain analyses added little to time domain measures, 
supporting the routine use of time rather than frequency domain data.
At the time of planning of this work, little prospective data were available as to the 
best technique for assessing baroreflex sensitivity. Of the available methodologies 
there is general agreement that the bolus phenylephrine technique is superior (see
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section 1.4.11.1 Techniques of assessing baroreflex function). It is the technique 
most widely applied for risk stratification I241’295l. Calculation of linear sequence, 
spectral and complex demodulation measures did not form part of the main body of 
this thesis, but at preliminary analysis they fail to add to the prognostic model.
4.2.4 Follow-up and Endpoint Analysis
The logistics of the study precluded follow-up in a dedicated clinic. Consequently, I 
have not included data on time to first hospital admission or frequency of readmission 
with heart failure. As discussed (see section 1.4.1 Classification of Death in Heart 
Failure), the classification of cardiovascular death is fraught with problems and 
mechanistic assumptions regarding the aetiology of sudden death are flawed. To 
overcome this problem, a pragmatic definition of sudden death was used i.e. death 
occurring without evidence of a recent change in symptoms. This definition does not 
allow differentiation between primary arrhythmic death, or death secondary to 
arrhythmia in the setting of acute myocardial infarction. From the potential victim’s 
standpoint, this is of academic interest. The data suggesting a high incidence of 
bradyarrhythmic death in chronic heart failure is based on a highly selected subset of 
patients 11321. The applicability of these data to the wider population of ambulant 
patients with milder heart failure has not been demonstrated. The three variables that 
predicted sudden death viz. a positive SAECG, non-sustained ventricular tachycardia 
and depressed baroreflex sensitivity may model the substrate, trigger 12961 and 
abnormal cardioprotective reflexes 12971 necessary for the development of sustained 
ventricular tachyarrhythmias . One may postulate that these variables identify a 
group most likely to die during a primary ventricular tachyarrhythmia or most likely 
to develop a life-threatening ventricular tachyarrhythmia during myocardial
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ischaemia or infarction. This assumption is supported by published data. Recent 
reports suggest that baroreflexes are important in maintaining systolic arterial pressure 
during episodes of ventricular tachycardia. Depressed baroreflexes correlate with 
lower systolic arterial pressures during episodes of induced or simulated ventricular 
tachycardia 1298,2991. A positive signal averaged ECG has been correlated with 
inducibility of ventricular tachycardia during programmed electrical stimulation 13001, 
and with recurrence of ventricular arrhythmias following myocardial infarction 11781. 
Animal models have demonstrated the development of ventricular tachyarrhythmias 
during acute myocardial ischaemia in dogs with depressed baroreflexes but not in 
dogs with preserved baroreflexes 12361. Depressed baroreflexes predict recurrent 
ventricular tachyarrhythmias post myocardial infarction 124G1, and predict “electrical
storms” in patients with implantable defibrillators 13011. Variables predicting sudden
death also predicted all cause cardiovascular mortality, making it unlikely that these 
were spurious results.
4.3 R elation  To  O th er  S tu dies
4.3.1 Established Prognostic variables
Elderly patients have a worse prognosis, but under the age of 75 years there may be 
little difference in mortality I135). Age was a univariate but not multivariate predictor 
of mortality in the study cohort. However, because the data on the effect of age are 
mixed, it was decided to include age in the multivariate Cox regression. Gender was 
not found to predict prognosis in the study cohort, concurring with previous studies 
using multivariate analysis.
In contrast to the findings of the SOLVD trial and registry ll4Sl, diabetes mellitus did 
not predict death in this study cohort. However, the small numbers of patients with
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diabetes preclude further comment. In large studies, whether an ischaemic aetiology 
confers a poorer prognosis is vexed by the problem of the potential for 
misclassification of cardiomyopathy aetiology. In the study cohort, cause was 
synonymous with outcome. However, patients with non-ischaemic cardiomyopathy 
were significantly younger and less “sick”. The statistical relevance of aetiology as a 
prognostic predictor must be interpreted with caution because of these caveats and 
because the number of patients with a non-ischaemic aetiology was small.
A number of clinical signs may delineate a worse prognosis. In agreement with 
previously published data I165J, more rapid heart rates defined a poorer outlook -  but 
only with univariate analysis (hazards ratio 2.0 p=0.03). A low, resting systolic 
arterial pressure dichotomised at 100 mmHg was a univariate (log rank 9.1, p<0.002), 
but not multivariate predictor of mortality, as indicated by previous data [146,1651. 
However, resting SAP dichotomised at the median value of 115 mmHg did not predict 
death. It is possible that frequent use of vasodilator therapy and emerging role of P- 
blockade as a therapeutic option 13021 may confound this physical sign.
In agreement with a large body of work reporting the independent prognostic power of 
peak oxygen consumption |1591, peak VO2 was found to be a strong prognostic 
indicator -  irrespective of which value was used for dichotomisation.
Many factors predispose to ventricular arrhythmia in heart failure (see section 1.2.6 
Arrhythmias Present in Heart Failure): underlying structural disease, electrolyte 
abnormalities, neurohormonal changes and, possibly, therapeutic interventions I1511. 
The frequency of ambulant ectopy is related to the severity of underlying cardiac 
function ,1681, although this is less clear in non-ischaemic cardiomyopathy [1691. Most 
studies have found that frequent ventricular ectopy and nonsustained ventricular
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tachycardia indicate a worse prognosis 11721. In the GESICA study of amiodarone in 
chronic heart failure, 300 of 516 patients with chronic heart failure had 24-hour Holter 
tapes available for study |3031. At multivariate analysis nonsustained ventricular 
tachycardia and couplets retained independent significance (RR 1.75 and 1.81 
respectively). For sudden death, relative risks were higher (nonsustained ventricular 
tachycardia 2.43, couplets 3.37)l1711. Frequent ventricular ectopy and/or couplets did 
not predict death in the current study cohort. However, nonsustained ventricular 
tachycardia (defined by the criteria used in the Gesica trial i.e. >3 ventricular 
premature beats at > lOObpm occurring at least once on the 24 hour tape) was a 
univariate and multivariate risk predictor. Nonsustained ventricular tachycardia was 
seen in 52 patients. The hazards ratio for all cause mortality was 2.5 (1.9-3.1) and 2.8 
(2.0 -3.6) for sudden death. Combining couplets and/or nonsustained ventricular 
tachycardia did not add prognostic power. However, in keeping with results from the 
Gesica study, nonsustained ventricular tachycardia was seen in only 26.1% of the 
study group, limiting its usefulness as a prognostic indicator.
4.3.2 Investigational Variables
4.3.2.1 Assessment of autonomic dysfunction
Autonomic nervous system dysfunction may be assessed by a number of different 
methods (see section 1.2.9.4 Assessment o f autonomic dysfunction). A number of 
different authors have investigated the prognostic utility of various markers of 
autonomic dysfunction in heart failure, but no study yet published has simultaneously 
compared the prognostic utility of plasma markers of neuroendocrine activation, heart 
rate variability, baroreflex abnormalities and the signal averaged ECG in patients with 
heart failure.
Ch a pter  4: D isc u ssio n  - 167 -
4.3.2.2 Signal-averaged Electrocardiography
As discussed previously (see section 1.4.8 Signal-averaged Electrocardiography) 
late potentials are predictive of arrhythmic events and sudden death in a post 
myocardial infarction population but are poorly correlated with the severity of left 
ventricular dysfunction 117?1. However, the positive predictive value of late potentials 
is low in this patient population 11791.
The prognostic utility of late potentials in patients with non-ischaemic dilated 
cardiomyopathy or ischaemic heart failure remote from myocardial infarction is less 
clear. The frequency and prognostic importance of bundle branch block and 
intraventricular conduction delay in the chronic heart failure population makes 
analysis even more difficult[1801. Only one other published study other than the current 
analysis has prospectively utilised specific criteria for the diagnosis of an abnormal 
signal averaged electrocardiogram in the presence of bundle branch block 11851. The 
investigators followed 151 patients with chronic heart failure for a mean of 27 months. 
Late potentials were present in 49 patients. The incidence of late potentials was not 
different in patients with or without bundle branch block. A past history of ventricular 
arrhythmias was significantly more common in patients with a positive signal 
averaged ECG (8.2% vs 1.9%). A positive signal averaged ECG did not predict total, 
cardiac or sudden mortality. However, during follow up the incidence of spontaneous 
sustained ventricular tachycardia was significantly higher in the presence of late 
potentials. Why should this study of a similar patient cohort reveal different results? 
Age, mean NYHA and left ventricular ejection fraction were similar to the present 
study. However, in the study by Galinier et.al atrial fibrillation was present in 13% of 
patients, 45% were receiving chronic amiodarone therapy, and there were only 13 
sudden deaths. In the current cohort, only 4 patients were in sustained atrial
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fibrillation, only 10% of patients were taking amiodarone, and there were a greater 
number of sudden deaths. These reasons may account for the disparate results 
between these 2 studies.
4.3.2.3 QT Dispersion
The surface electrocardiographic QT interval reflects complex and interrelated aspects 
of cellular electrophysiology, cardiac geometry, torso shape, thoracic impedance and 
signal processing 12521. There are two assumptions on which QT dispersion is based: 
that the end of the surface electrocardiographic QT interval is a surrogate for the end 
of ventricular repolarisation, and that spatial variation in surface electrocardiographic 
QT intervals measures the known underlying heterogeneity of ventricular 
repolarisation. As discussed previously (see section 1.4.12.2 QT dispersion: clinical 
and methodological aspects) both assumptions are supported by debatable evidence. 
Monophasic action potentials measured during cardiac surgery correlated strongly 
with surface QT dispersion for both sinus and paced beats 12551. However, in an 
isolated heart study, total T wave area and T peak to T end interval correlated more 
significantly with monophasic action potential duration than did QT interval 12541. 
There are many methodological problems. There is still no accepted standard 
methodology for QT dispersion measurement. The problem of the definition of the 
end of the T wave seems more important than the method used 12521. Inter-observer 
reproducibility is poor, with low voltage and morphologically abnormal T waves 
contributing significantly to inter-observer variability 12591. Fundamental 
electrocardiographic theories should also be taken into account: information contained 
in limb leads is redundant in that if any of 2 of the 6 of recorded, the other 4 may be 
calculated. Additionally complete information regarding electrical activity is
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contained only in the vectorcardiogram. If the last 40 milliseconds of ventricular 
repolarisation is negative in lead I, and equally positive in lead II, then there would be no 
electrical activity in lead HI creating a spurious QT dispersion of 40 milliseconds 12601. 
Therefore, QT dispersion measured in the frontal plane derived from only 2 leads is 
unlikely to provide information on local electrical repolarisation.
Continuing the uncertainty regarding underlying pathophysiology and methodology, 
the prognostic utility of QTd in heart failure remains unclear, with studies 
supporting I267_269J or refuting its importance [270’2711 (see section 1.4.12.3 QT 
dispersion in chronic heart failure). Previous investigators have retrospectively 
studied small numbers of widely differing populations, using different methodologies, 
excluding or including (or not mentioning) patients with atrial fibrillation and bundle 
branch block.
There is thus a plethora of literature on the prognostic utility of QT dispersion, much of 
the data being retrospective, case-controlled studies of limited statistical power. Recent 
work using the best available methodology (previously validated against monophasic 
action potential duration [254)) failed to demonstrate prognostic significance of any 
measured QT variable post myocardial infarction 12661. Data from the UK-HEART 
study also confirms that QT dispersion offers no prognostic information in chronic heart 
failure in a prospective well designed study 13041. These data corroborate the present 
findings that QT dispersion is not associated with mortality in chronic heart failure.
4.3.2.4 Plasma markers of neuroendocrine activation
Elevated plasma noradrenaline carries prognostic information in symptomatic 11871 and 
asymptomatic 11881 chronic heart failure. These data are confirmed in the current study 
cohort. There is less data on the prognostic importance of natriuretic peptides in
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chronic heart failure. Natriuretic peptides correlate with the severity of heart failure 
and are elevated early in left ventricular systolic dysfunction, before the development 
of symptomatic heart failure 1821. However, plasma BNP tracks less closely with left 
ventricular ejection fraction than ANP 1191). Elevated plasma ANP levels have been 
associated with increased mortality in moderate 11941 and severe 11951 heart failure. 
Plasma ANP was a significant univariate, but not multivariate predictor of mortality in 
the study cohort. Plasma BNP provides additional independent prognostic 
information beyond left ventricular ejection fraction in the acute post myocardial 
infarction setting 11961, and it has been suggested to provide similar information in 
chronic heart failure 11971. A recent substudy from the Australia-New Zealand heart 
failure group investigated the role of plasma neurohormones, including plasma BNP 13051. 
Supramedian levels of plasma BNP were associated with a mortality rate 3 fold 
greater than that of inframedian levels. There are few other prospective data on the 
prognostic utility of plasma BNP in chronic heart failure. The available data on 
plasma BNP and prognosis in chronic heart failure supports the current finding of its 
prognostic importance. However, no other study has investigated the role of heart rate 
variability, baroreflex sensitivity and plasma markers of neuroendocrine activation in 
patients with chronic heart failure. Despite being subject to this multivariate scrutiny, 
plasma BNP remained highly predictive of total cardiovascular and progressive heart 
failure mortality.
4.3.2.5 Heart rate variability
A body of work has established that depressed heart rate variability is a powerful 
multivariate prognostic indicator in patients after acute myocardial infarction. Heart 
rate variability (measured as SDNN) less than 50 milliseconds carried a 5.3 fold
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increased mortality compared with a group with SDNN >100 milliseconds ,21S1. 
Longer term frequency domain measures derived from 24 hour data or from 
recordings 2 to 15 minutes long have similar prognostic utility but do not add to the 
simple time domain measures 13061. Although thrombolysis shifts “cut points” upward, 
the independent relative risk of depressed heart rate variability is maintained 12161.
It has been known for decades that heart rate variability is diminished in chronic heart 
failure 1941. Small studies have addressed the prognostic utility of heart rate variability 
in dilated cardiomyopathy I221,222! 0r chronic heart failure I223’225’226! due to both 
ischaemic and non-ischaemic aetiologies. Despite different analysis techniques and 
patient characteristics, most reports have documented that heart rate variability 
independently identifies patients at greatest risk of cardiovascular death. When both 
time and frequency domain analyses have been performed, spectral measures appear 
to add little prognostic information to that provided by simple time domain 
measurements. The total number of deaths in these studies is small, and some 
investigators found that none of the conventional time and frequency domain 
measures were related to survival 12241.
A recent large study (UK-Heart 11501) has demonstrated that patients with low values 
of SDNN constitute a particularly high-risk group. Values of SDNN<100 msec 
carried a hazard ratio of 1.8 for cardiovascular death after adjusting for baseline 
variables. There are caveats to this study: the characterisation of patients was limited, 
left ventricular ejection fraction was calculated from M-mode measurements and no 
other autonomic variables were determined. M-mode echo techniques can 
artefactually overestimate ejection fraction in patients with previous anterior 
myocardial infarction, who would otherwise be expected to have the lowest value of 
SDNN and a poor prognosis. This could have overestimated the prognostic power of
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depressed SDNN. However, my data confirm that reduced heart rate variability is an 
independent predictor of all cause cardiac and progressive heart failure death, but fails 
to predict sudden death.
4.3.2.6 Baroreflex sensitivity
There is an acute depression of baroreflex sensitivity following myocardial infarction, 
but values return towards normal within one to three months 12081. The largest 
prospective post myocardial infarct study (ATRAMI), compared the prognostic power 
of baroreflex sensitivity with heart rate variability 1241]. Low values of either heart rate 
variability (SDNN <70 msec) or baroreflex sensitivity (<3 msec/mm Hg) carried a 
significant multivariate risk of cardiovascular mortality (3.2 and 2.8 respectively). 
The one year mortality was 15% when both variables were low compared to 1% if 
both were preserved. Baroreflex sensitivity but not heart rate variability maintained 
its multivariate prognostic power even when left ventricular ejection fraction was 
<35%: the relative risk of dying in young patients (<65 years) with low LVEF (<35%) 
and low baroreflex sensitivity (<3.0 msec/mm Hg) was 11.5. These figures are even 
more impressive when one considers that the study population was relatively low risk.
There are fewer data linking baroreflex sensitivity with prognosis in patients with 
chronic heart failure remote from myocardial infarction. The largest study 
investigated the prognostic role of baroreflex sensitivity in 282 patients with chronic 
stable heart failure 12951 but did not include plasma markers of neuroendocrine 
activation. Baroreflex sensitivity was found to be significantly associated with 
symptoms of heart failure, but only weakly related to left ventricular ejection fraction, 
cardiac index, and pulmonary capillary wedge pressure. At multivariate analysis, 
baroreflex sensitivity was an independent predictor of death, and was more
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informative in patients with ischaemic rather than idiopathic cardiomyopathy. When 
haemodynamic indices were added to the multivariate model, baroreflex sensitivity did 
not provide independent prognostic information. However, haemodynamic indices 
require instrumentation and are time-consuming to measure. Additionally, the patients 
studied by Mortara et al were a pre-transplant population with severe heart failure. 
Thus, these data relate to a more selected cohort, and are less widely applicable.
4.4 Im plicatio ns  o f  th e  stu d y
The socio-economic impact of chronic heart failure is enormous: it has been estimated 
at 1-2% of the total health care budget, of which two thirds is accounted for by 
inpatient care l1211. The more severe the heart failure, the greater the cost. Thus, 
chronic heart failure is a common, growing and major public health care burden.
Identifying high-risk patients suitable for aggressive intervention, optimisation of 
treatment and prevention of death is of great importance. Despite extensive study by 
many investigators, identification of individuals who are most likely to deteriorate and 
die remains difficult. Identification of those most likely to die unexpectedly is even 
more problematic. Answers to these questions were the principal aim of this thesis.
I have demonstrated that autonomic dysfunction, neuroendocrine activation and/or 
abnormal ventricular depolarisation identify patients with chronic heart failure at high 
risk of death. Plasma BNP may be measured from a single venous blood sample, and 
has been proven to be stable at room temperature over 72 hours. It is inexpensive, and 
requires no specialised equipment at the bedside. Direct assay kits are now available 
which both simplify and lessen the cost of its measurement. This finding is 
particularly important, because of the possibility for its widespread application. 
Obviously, identification of those at greatest risk is only the initial step towards
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preventing death in this condition. However, optimising therapy in those with severe 
heart failure has been shown to improve symptoms and outcome. The present study 
suggests that plasma BNP may be a simple, inexpensive, and widely applicable means 
of selecting such patients. Linking the prognostic importance of depressed baroreflex 
sensitivity in the study cohort with recent data on “electrical storms” in patients with 
implantable cardioverter-defibrillators l3011, it is attractive to speculate that these 
markers might be used to identify patients who would derive greatest benefit from 
such devices.
4.5 F u t u r e  R e s e a r c h
The opportunities for future research relate to larger scale studies of the prognostic 
value of BNP. These in due course may lead to the use of BNP as a means of 
targeting or monitoring therapy in high-risk patients with heart failure.
Invasive electrophysiological testing has proved disappointing for risk stratification in 
chronic heart failure. Although certain patients who have inducible ventricular 
arrhythmias benefit from implantable cardioverter-defibrillator therapy l3071, these data 
have been criticised and the technical demands of the technique limit its widespread 
application. Perhaps as a result, the role of non-invasive assessment of arrhythmia risk 
has expanded. The utility of non-sustained ventricular tachycardia, baroreflex sensitivity 
and the signal averaged ECG in prediction of sudden death could be clarified by 
examination of subjects who already have implantable cardioverter-defibrillators. 
Validated prognostic models based on nonsustained ventricular tachycardia, the signal 
averaged ECG and markers of autonomic dysfunction could then be applied to identify 
high risk patients without manifest ventricular arrhythmias who would benefit from these 
devices. At least one such trial (SCD-Heft, a randomised comparison of implantable
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cardioverter-defibrillator use in patients with chronic heart failure at high risk of sudden 
death) is already recruiting. SCD-Heft is using depressed heart rate variability as a risk 
marker for appropriate patient selection. The results from this thesis are now being 
incorporated into the protocol of a similar study.
4.6 S ummary
In this well-characterised cohort of patients with chronic heart failure, the presence of 
intraventricular conduction delay, a positive signal averaged ECG or autonomic 
dysfunction carried a poorer prognosis. The most powerful variable predicting 
cardiovascular mortality was neuroendocrine activation assessed by plasma BNP. The 
presence of nonsustained ventricular tachycardia on Holter monitoring, an abnormal 
signal averaged ECG or depressed baroreflex sensitivity identified patients at risk of 
sudden death -  a unique finding which requires further investigation and clarification. 
This information was additive to and independent of other powerful prognostic 
variables including NYHA class, age, left ventricular ejection fraction and 
presence/absence of intraventricular conduction delay on the surface ECG.
Appendix A  - 1 7 6 -
Appendix A
Consent Form
Patient Summary: Predicting Problems in Heart Failure
We would like to ask you to participate in this study.
Heart failure is a common condition caused by damage to the pump of the heart, 
leading to symptoms of breathlessness, fatigue and limitation of exercise capacity. We 
are interested in predicting which patients will benefit from which particular 
treatments.
To do this, we shall first ask you to come to Glasgow Royal Infirmary where you 
will have a special heart tracing, or ECG, which takes about 15 minutes. This is 
entirely painless. Following this, we will measure your heart rate response to an 
increase in blood pressure that requires a small injection into a vein in the arm. The 
drug injected is called “Phenylephrine”, a standard medical preparation. The injection 
is painless, but some people may experience a mild feeling of flushing, headache or 
palpitation which passes quickly. The whole procedure would be performed by an 
experienced doctor, and would take about one hour. Lastly, you will be asked to wear 
a 24-hour heart rhythm recorder, very much like a personal stereo cassette.
The following afternoon you would be asked to attend the Clinical Research 
Initiative (the CRI) based at the Western Infirmary in Glasgow. Here you would 
have an ultrasound scan of your heart. This is a completely painless procedure that 
builds up moving pictures of your heart from sound waves (the same type of scan that 
is used to show the baby in a pregnant woman’s abdomen). The next examination we 
would ask you to undertake is a treadmill walking test. A treadmill is like a moving 
walkway, which slowly increases in speed in stages. You would be asked to exercise 
until you felt you needed to stop. We would not ask you to go on exercising longer 
than you felt able, and although different people are able to exercise for different 
durations the average time is about 5 minutes. This test would allow us to measure 
your fitness. Finally, we hope that you would allow us to take a sample of blood from 
a vein in your arm to measure a substance made by the heart. Giving the blood is in no
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way dangerous. An experienced doctor will oversee the whole series of tests, but your 
treatment will continue to be supervised by your own hospital doctors and GP.
In order to decide whether the tests are useful in predicting your progress, we request 
your permission to review your hospital and GP case records which are relevant to the 
project. This access will be restricted to the doctors who are involved in the study.
It should be noted that your participation in this study may not be of direct benefit to 
you, but could help in the development of treatments for the benefit of future patients.
If you do not wish to participate in this study, or wish to withdraw at any time after 
commencing the study, your care will in no way be affected.
If you wish to take part in this study, your General Practitioner will be advised of your 
participation and the clinical management that you will undergo.
If you are, or are likely to become, pregnant, you should not participate in the study.
CONSENT
I ,______________________________  of __________________________
give my consent to the research procedures described above, the nature, purpose 
and possible consequences of which have been explained to me by
S ign____________________________ Date
Witness
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Appendix B
Minnesota Living With Heart Failure Questionnaire
We would be grateful if you would complete and return the following questionnaire. 
These questions concern how your heart problem has prevented you from living as 
you wanted in the last month. If the item does not apply to you or is not due to your 
heart problem, circle 0 (No), and go to the next item. If an item does apply to you, 
then circle the number rating how much it prevented you living as you wanted.
Did your heart problem prevent you from No Very 
living as you wanted during the last month little
Very
much
1. Causing swelling in your ankles, legs, etc 0
2. Making you sit or lie down to rest during 0 
the day
3. Making your walking about or climbing 0 
stairs difficult
4. Making your working around the house 0 
or garden difficult
5. Making your going away from home 0 
difficult
6. Making your sleeping well at night 0 
difficult
7. Making your relating to or doing things 0 
with friends or family difficult
8. Making your working to earn a living 0 
difficult
9. Making your recreation, hobbies, sports 0 
etc difficult
Did your heart problem prevent you from No Very Very
living as you wanted during the last month little much
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10. Making your sexual activities difficult 0
11. Making you eat less of the foods that 0 
you like
12. Making you short of breath 0
13. Making you tired, fatigued or low on 0 
energy
14. Making you stay in hospital 0
15. Costing you money for medicines 0
16. Giving you side effects from medicines 0
17. Making you feel a burden to family or 0 
friends
18. Making you feel a loss of self-control in 0 
your life
19. Making you worry 0
20.Making it difficult for you to concentrate 0 
or remember things
21. Making you feel depressed 0
PATIENT DETAILS
SURNAME: DOB:
STUDY NO:
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Appendix C
HEALTH QUESTIONNAIRE
We would be grateful if you could complete this questionnaire and bring it with you 
when you attend the examination, if you have any questions, please ask when you 
come to the examination. We are there to help you, and will check through the record 
with you.
Listed below are some problems people might have in their daily lives. Read the list carefully 
Circle YES for any problem that applies to you at the moment
Circle NO for any problem that does not apply to you.
PLEASE ANSWER EVERY QUESTION.
Remember, if you are not sure whether to answer YES or NO to a problem, 
circle whichever answer you think is more true at the moment.
1. Ifm tired all the time. Yes No
2. I have pain at night. Yes No
3. Things are getting me down. Yes No
4. I have unbearable pain. Yes No
5. I take tablets to help me sleep Yes No
6. I’ve forgotten what it's like to enjoy myself. Yes No
7. I'm feeling on edge. Yes No
8. I find it painful to change position. Yes No
9. I feel lonely. Yes No
10. I can only walk about indoors. Yes No
11. I find it hard to bend. Yes No
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Remember, if you are not sure whether to answer YES or NO to a problem, 
circle whichever answer you think is more true at the moment.
12. Everything is an effort.
13.
14.
15.
16.
17.
18.
19.
20. 
21 . 
22.
23.
24.
25.
26. 
27.
I'm waking up in the early hours of the morning. 
I'm unable to walk at all.
I'm finding it hard to make contact with people. 
The days seem to drag.
I have trouble getting up and down stairs or steps. 
I find it hard to reach for things.
I'm in pain when I walk.
I lose my temper easily these days.
I feel there is nobody I am close to.
I lie awake for most of the night.
I feel as if I'm losing control.
I'm in pain when I'm standing.
I find it hard to dress myself.
I soon run out of energy.
I find it hard to stand for long
(e.g. at the kitchen sink, waiting for a bus).
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
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Remember, if you are not sure whether to answer YES or NO to a problem, 
circle whichever answer you think is more true at the moment.
28. I'm in constant pain. Yes No
29. It takes me a long time to get to sleep. Yes No
30. I feel I am a burden to people. Yes No
31. Worry is keeping me awake at night. Yes No
32. I feel that life is not worth living. Yes No
33. I sleep badly at night. Yes No
34. I'm finding it hard to get on with people Yes No
35. I need help to walk about outside Yes No
(e.g. a walking aid or some one to support me)
36. I'm in pain when going up and down stairs or steps. Yes No
37. I wake up feeling depressed. Yes No
38. I'm in pain when I'm sitting. Yes No
Now please go back to page 1 and make sure that you have answered YES or NO 
to every question, on all three pages of the questionnaire.
THANK YOU FOR YOUR HELP
Please bring this questionnaire with you to your next appointment.
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Appendix D
PERSONAL HEALTH RECORD
(All information is confidential)
Please answer the questions in this record as far as you are able and bring it with you 
when you attend the examination. Please answer every question, as far as you can, 
(except those you are told to skip) and circle the answer which applies to you. We 
cannot use those questions that you leave completely blank. If the answer in your case 
is 'No' or 'I don't know' you still need to show this on the paper. If you need any help, 
or have any questions, please ask when you come to the examination. We will check 
through the record with you.
Personal history
1. (a) Please circle the appropriate box Male Female
(b) Date of birth: day month year
(c) How many years have you lived in this town or within 10 miles of this 
town? ____________ years
(d) Where were you bom?
Town/place
County
Country
2. Please circle the number showing your present marital status 
1 married 2 widowed
3 cohabiting 4 divorced
5 single 6 separated
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3. (a) What is the highest level of education you have completed?
1 university degree
2 other professional or technical qualification/diploma after leaving school
3 secondary school
4 primary school
(b) How many years altogether have you gone to school or studied full­
time from the age of 5 years? ______ years
4. (a) Please circle the appropriate number about your employment situation.
1 in a full-time job
2 in a part-time job
3 unemployed, seeking work
if unemployed and seeking work, for how long have you been 
unemployed?
Years___________ Months____________
4 unemployed because sick or disabled
5 housewife/homemaker
6 wholly retired from employment
7 full-time student
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4. (b) Please give full and precise details of your occupation (if
unemployed now, give details of last job).
Your occupation
Description of your work
Husband/wife's occupation
Description of his/her work
4. (c) What is your employment status? (if unemployed now, give details of
last job.)
1 employee not supervising other employees
2 employee supervising other employees
3 self-employed not employing others
4 self-employed employing others
5. (a) How do you and your household occupy your accommodation?
1 as an owner-occupier (including purchase by mortgage)
2 by renting, or rent-free, or by lease from a local authority (council or
New Town) or from a housing association
3 by renting or rent-free, from a private landlord or in some other way
5. (b) If you are owner-occupier, is your house one which you previously
rented from a local authority Yes No
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Family history
6. Did your mother or father have heart disease before they were 60 years old?
Yes No Don’t know
7. How many brothers and sisters did you have in your family (not counting
yourself)?__________ brothers and sisters
8. Did any of your brothers and sisters have heart disease before they were 60 
years old?
Yes No
9. How many children have you had (including any who died at birth or in 
childhood)?
___________children
Medical history
10. Have you ever been told by a doctor that you have, or have had any of the 
following? Circle Yes or No for each condition.
Angina Yes No
Heart attack (coronary thrombosis, myocardial infarction) Yes No
High blood pressure Yes No
Stroke Yes No
Diabetes Yes No
High cholesterol Yes No
Appendix D
11. Are you now taking any medication for high blood pressure? 
Yes No
If yes, please write the names of the medicines you are taking:
12. Are you now taking any medication for high cholesterol?
Yes No
If yes, please write the name of the medicine you are taking:
13. Are you now taking aspirin regularly?
Yes No
If no, go to question 14.
If yes, is it for your heart? Yes No
Don't know
If it is for your heart, why did you start taking it? 
the doctor told you to take it 
you decided for yourself other reason 
please give details
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14. (a) Are you regularly taking any other medication at present?
Yes No
If yes, write the name of the medicine(s) and what you are taking them for (if 
you know). Please include all pills, bottles, tablets, inhalers (puffers), 
injections, etc.
14. (b) Are you regularly taking any vitamins, minerals or food supplements at
present?
Yes No
If yes, give the type of supplement, brand name and how often you take each one. 
Type Brand (and strength) Frequency
Men miss out the next page and go to question 18
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WOMEN ONLY
14. (a) Are you pregnant now?
Yes No
If no, have you ever been pregnant?
Yes No
(b) How old were you when you had your first pregnancy? years old
16. (a) Have you ever been on the contraceptive pill?
Yes If yes, for how many years?_____ years.
No If no, go to question 17.
(b) Are you on the contraceptive pill now?
Yes No
If no, how long ago did you stop?________years   months ago
17. (a) Are you still having periods (menstruating)?
Yes, as usual
Yes, but irregularly
No If no, how old were you when you stopped.? years old
Was this because of a hysterectomy (surgical removal of the womb)?
Yes No
(b) Have you ever taken hormone replacement therapy (HRT)?
Yes No
If yes, for how many years? years
If no, go to question 18.
(c) Are you on hormone replacement therapy (HRT) now?
Yes No If no, how long ago did you stop taking it?
 years months
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Chest Pain
18. (a) Have you ever had any pain or discomfort in your chest?
Yes No If no, go to question 20
(b) Do you get this pain or discomfort when you walk uphill or hurry?
Yes No
(c) Do you get it when you walk at an ordinary pace on the level?
Yes No
(d) When you get any pain or discomfort in your chest, what do you do? 
Stop
Slow down
Continue at the same pace
(e) Does it go away when you stand still?
Yes No If no, go to question 18(g)
(f) How soon?
10 minutes or less 
more than 10 minutes
(g) Where do you get this pain or discomfort? Mark the place(s) with X on 
the diagram.
19. Have you ever had a severe pain across the front of your chest lasting for half 
an hour or more?
Yes No
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Leg problems
20. (a) Do you get a pain or discomfort in your leg(s) when you walk?
Yes No If no, go to question 22
I am unable to walk If unable to walk, go to question 22.
21. (a) Does this pain ever begin when you are standing still or sitting?
Yes No
(b) Do you get it if you walk uphill or hurry?
Yes No
(c) Do you get it when you walk at an ordinary pace on the level?
Yes No
(d) What happens to it if you stand still?
Usually continues more than 1 0 minutes 
Usually disappears in 10 minutes or less
(e) Where do you get this pain or discomfort?
Mark the place(s) with X on the diagram below.
Front
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Cough
22. (a) Do you usually cough first thing in the morning in the winter?
Yes No
(b) Do you usually cough during the day, or at night, in the winter?
Yes No
(c) Do you cough like this on most days for as much as three months each year?
Yes No does not apply
Phlegm
23. (a) Do you usually bring up any phlegm from your chest first thing in the
morning in the winter?
Yes No
(b) Do you usually bring up any phlegm from your chest during the day, or
at night, in the winter?
Yes No
(c) Do you bring up phlegm like this on most days for as much as three 
months each year?
Yes No does not apply
Breathlessness
24. (a) Do you get short of breath when hurrying on level ground or walking
up a slight hill?
Yes No
b) Do you get short of breath walking with other people of your own age on
level ground?
Yes No
(c) Do you have to stop for breath when walking at your own pace on level ground?
Yes No
(d) Do you get short of breath when washing or dressing?
Yes No
(e) Are you ever wakened from sleep by breathlessness?
Yes No
Appendix D
Cigarette smoking
25. (a) Do you smoke cigarettes now?
Yes, regularly
No If no, go to question 26.
Occasionally (usually less than one a day)
(b) On average, about how many cigarettes do you smoke a day? 
__________cigarettes a day
(c) On average, on how many days a week do you smoke cigarettes? 
__________days a week
(d) How old were you when you began to smoke cigarettes?
__________years old
26. Did you ever smoke cigarettes?
Yes, regularly
No, never
Occasionally (usually less than one a day)
Cigar smoking
27. (a) Have you ever smoked cigars?
No If no, go to question 28.
Used to, but not now If used to, go to question 28.
Yes, now smoke occasionally (usually less than one a day)
Yes, now smoke regularly
193 -
(b) About how many cigars do you smoke a week? cigars a week
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Pipe smoking
28. (a) Have you ever smoked a pipe?
No If no, go to question 29.
Used to, but not now If used to, go to question 29.
Yes, now smoke a pipe occasionally (usually less than one a day)
Yes, now smoke a pipe regularly
(b) About how many ounces of tobacco do you smoke a week?
 ozs a week
Physical activity
29. Which of the following four activity classes best describes your present activity
outside of your job? Please consider going to and from work, sporting activity 
and other physical effort during your leisure time, like gardening or dancing, 
(please circle one box only.)
1 No physical activity weekly
2 Only light physical activity in most weeks
3 Vigorous physical activity at least 20 minutes once or twice a week
(Vigorous activity causes breathlessness, a rapid heart rate and sweating)
4 Vigorous physical activity for at least 20 minutes three or more times a week
Thankyou for completing this questionnaire. 
Please bring it with you to your next appointment.
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